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Summary  
RIG-I is a pattern recognition receptor that is responsible for the initiation of an antiviral 
response to a variety of virus infections. Cytoplasmic nucleic acid derived from virus replication 
is detected by RIG-I resulting in the initiation of a signalling cascade that ultimately leads to 
the activation of transcription factors, namely IRF3 and NFkB. Activation of these transcription 
factors leads to the production and secretion of type I and III interferons (IFN), which act in an 
auto- and paracrine manner to induce the expression of a large array of IFN stimulated genes 
(ISGs). In concert, these ISGs promote an antiviral state of the cell, limiting viral replication 
and spread. Much is known about the individual steps and proteins involved in the RIG-I 
signalling pathway, however, much less is understood about its regulation and dynamics. 
Upon virus entry into a cell, the initial response phase is critical to the outcome and determines 
if the infection is cleared or established. Understanding the dynamics of these processes will 
be key to comprehend and possibly predict the outcome of a viral infection. The main goal of 
this thesis, therefore, was to identify novel regulators and to kinetically characterize the rapid 
induction of the cellular antiviral signalling cascade. 
 As for the identification of previously unrecognized regulators of the RIG-I pathway, 
we have performed an siRNA-based high-throughput screen of over 600 known and putative 
E3 ubiquitin ligase genes. Post-translational ubiquitination has been shown to constitute a 
major regulatory process in innate immune signalling. From our screening approach, we were 
able to identify several genes that significantly impacted IRF3 activation upon silencing during 
viral infection. 
 The main part of this thesis deals with the temporal characterisation of RIG-I-initiated 
antiviral signalling. For that purpose, we developed an approach which permitted the 
completely synchronous stimulation of cells with virus-like double-stranded RNA. In contrast 
to authentic infections or classical liposome-based transfections, this method allows for a very 
high degree of time-resolution in measuring the flow of the signal along the cascade. 
Quantitative, time-resolved activation measurements of critical proteins in the RIG-I pathway 
showed that RIG-I signalling is rapid and, in contrary to previous reports, strictly deterministic 
with very little variability from cell to cell. Furthermore, we extensively characterized the 
transcriptional program triggered by RIG-I in a time-resolved manner by full-genomic 
transcriptional profiling. We found that the panel of genes upregulated directly by the primary 
IRF3 response is surprisingly large and congruent with the ISGs classically known to be 
induced only by IFN signalling, with only very few genes exhibiting a strict dependence on 
IFN/JAK/STAT signalling.  
 This work represents the first detailed molecular characterization of the kinetics of host 
cellular processes triggered in the first few minutes after virus infection. The comprehensive 
quantitative and time-resolved data generated can serve as a solid basis for a mathematical 
model that combines viral replication dynamics and host antiviral responses. Such a model 
will be an unprecedented and powerful tool to study the principles governing the outcome of 
viral infection and to help understanding how certain viruses manage to overcome host 
immunity and cause fulminant disease or even establish life-long persistence. 
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Zusammenfassung 
RIG-I ist ein pattern recognition receptor (dt. etwa Mustererkennungsrezeptor) der für die 
Initiierung eines antiviralen Zustandes in der Zelle nach Virus-Infektion verantwortlich ist. Er 
erkennt und bindet bei der Virus-Replikation entstehende Nukleinsäuren im Cytoplasma, wird 
aktiviert und stößt eine Signalkaskade an, die letztendlich zur Aktivierung der 
Transkriptionsfaktoren IRF3 und NFkB führt. Dies wiederum resultiert in der Produktion und 
Sekretion von Typ I und III-Interferonen (IFN), die dann auto- und parakrin wirken und die 
Expression eines breiten Panels an IFN-stimulierten Genen (ISGs) hervorrufen. Zusammen 
schaffen diese ISGs einen stark antiviralen Zustand in der Zelle und limitieren somit die Virus-
Replikation und die Ausbreitung der Infektion. Obwohl die einzelnen Schritte und involvierten 
Proteine des RIG-I-Signalweges bereits gut erforscht sind, fehlen noch wichtige Erkenntnisse 
über deren Regulation und Dynamiken. Die initiale Phase einer Infektion ist ausschlaggebend 
für deren weiteren Verlauf und entscheidet ob sich der Virus vermehren kann oder ob er 
ausgelöscht wird. Eine Auflösung dieser sehr frühen Dynamiken ist somit unerlässlich für ein 
besseres Verständnis von Virus-Infektionen und kann die Vorhersage des Verlaufs einer 
solchen Infektion ermöglichen. Das Hauptziel dieser Arbeit war es folglich bisher unbekannte 
Regulatoren dieser antiviralen Signalkaskade zu identifizieren und ihre rapide Aktivierung in 
hoher Zeitauflösung zu dokumentieren. Zur Identifizierung neuer Regulatoren des RIG-I-
Signalweges führten wir einen siRNA-basierten Hochdurchsatz-Screen mit mehr als 600 
bekannten und vermuteten E3-Ubiquitin-Ligasen durch, da post-translationale Ubiquitinierung 
als weit verbreitetes Mittel zur Regulierung der Immunantwort gilt. Auf diese Weise konnten 
wir mehrere Gene identifizieren die einen entscheidenden Einfluss auf die Aktivierung von 
IRF3 bei Virus-Infektion haben. 
Der Hauptteil dieser Arbeit beschäftigt sich allerdings mit der zeitlich hoch-aufgelösten 
Charakterisierung der RIG-I-initiierten antiviralen Immunantwort. Hierzu haben wir eine 
Methode entwickelt die es uns ermöglicht eine Vielzahl von Zellen gleichzeitig mit Virus-
ähnlicher Doppelstrang-RNA zu aktivieren. Im Gegensatz zur in vitro-Infektion oder 
klassischen Liposomen-basierten Transfektion erreichen wir hiermit eine hohe zeitliche 
Präzision zur exakten Messung der Signal-Weiterleitung. Die Quantifizierung dieser 
Messungen hat zum einen die enorme Geschwindigkeit der Aktivierung und Signal-
Weiterleitung innerhalb des RIG-I-Signalweges gezeigt. Zum anderen konnten wir im 
Gegensatz zu bisherigen Publikationen zeigen, dass die Aktivierung des RIG-I-Signalweges 
sehr deterministisch ist und kaum Variationen von Zelle zu Zelle aufweist. 
Weiterhin haben wir eine Zeit-aufgelöste Genexpressions-Analyse nach Aktivierung des RIG-
I-Signalweges durchgeführt. Diese hat eine überraschend große Gruppe an Genen gezeigt 
deren Expression direkt durch die initiale IRF3-Aktivierung induziert wird und mit den 
bekannten klassischen ISGs nach IFN-Stimulation übereinstimmt. Nur weniger dieser Gene 
waren strikt von der Aktivität des IFN/JAK/STAT-Signalweges abhängig. 
Diese Arbeit zeigt als erste eine detaillierte Charakterisierung der Dynamiken der 
Signalaktivierung und –weiterleitung auf molekularer Ebene in der Zelle nach Virus-Infektion. 
Die gewonnenen Daten können aufgrund ihrer hohen Zeitauflösung und der genauen 
Quantifizierung als Basis zur Entwicklung eines mathematischen Modells dienen, welches die 
Dynamiken der Virus-Replikation mit denen der antiviralen Signalwege vernetzt. Solch ein 
Modell kann helfen den Verlauf und das Ergebnis von Virus-Infektionen vorherzusagen 
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1.0 Introduction 
 
1.1 The immune system 
 
The immune system of the vertebrate has come a long way in its evolution in order to 
establish defences from invading intracellular or extracellular pathogenic 
microorganisms, which would seek to exploit their hosts rich abundance of nutrients. 
The immune system is one of the fundamental pillars of survival, without an immune 
response, hosts are unable to protect themselves from a myriad of dangerous and life-
threatening microorganisms. The immune system itself is a collection of defences and 
responses that work in unison together to mount an effective reaction to sterilise the 
host environment and maintain homeostasis. In humans, in order to achieve this, there 
are specialised subsets of cells that play specific rolls in mounting a protective 
response against invading microorganisms [Figure 1.1].  As shown, these cells release 
soluble mediators that confer a specific protective response, be it cell type-cell type 
communication/activation or a direct and/or indirect response against the invading 
pathogen.  
Figure 1.1 Cells of the immune system  
 
 
Figure 1.1. Male et al. Immunology 8th edition, Elsevier Saunders. Cells of the immune 
system.  
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Commonly referred to as white blood cells, leukocytes, or lymphocytes, these cells 
originate from hematopoietic stem cells and circulate via the lymphatic system of the 
human body. Each lymphocyte subtype has a specific role to play in the systemic 
immune response, producing soluble mediators that directly effect the type of immune 
response. These responses can be subdivided into two categories; the innate immune 
response, and the adaptive immune response. 
 
1.2 cells of the immune system  
Figure 1.2 Immune stem cells 
 
 
Figure 1.2 Male et al. Immunology 8th edition, Elsevier Saunders. Origin of cells of the 
immune system. 
 
As described previously, leukocytes originate from hematopoietic stem cells that are 
largely located in the bone marrow, but also found in fetal liver tissue. Furthermore, 
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the two axes of immune system (adaptive/innate) contain specific cell lineage subsets. 
For example, the innate axis of the immune system comprises of the myeloid cell 
lineage (meaning bone marrow derived); monocytes/macrophages, 
polymorphonuclear granulocytes, mast cells, and platelets. The adaptive axis of 
immune system comprises of lymphoid cells such as thymus matured lymphoid cells 
(T cells) and bone marrow matured lymphoid cells (B cells), and in addition, natural 
killer cells (NK cells), which are lymphoid in origin despite being primarily associated 
with the innate axis of immunity.  
 
1.2.1 Immune cells and their functions 
 
1.2.1.1 Myeloid cells 
 
Myeloid cells are defined as cells originating from the bone marrow, where they supply 
the peripheral blood system with leukocytes. These include monocytes and 
granulocytes. Monocytes can be matured into a range of cells, depending on the tissue 
in which they reside. For example, monocytes can be terminally matured into 
macrophages, which are present as kupffer cells in the liver, alveolar macrophages in 
the lungs, osteoclasts in the bone, and mesangial macrophages in the kidneys. 
Monocytes may also differentiate into specific dendritic cells (DCs). These are present 
in lymphoid organs (DCs) and in the skin (Langerhans cells)[1].  
 
1.2.1.2 Antigen presentation  
 
DCs are considered “professional” antigen presenting cells (APCs). Their specific 
function is to present peptides for inspection by the adaptive immune cells (T cells and 
B cells) in order to differentiate non-host derived peptides from host derived peptides, 
such that an immune response can be mounted [2]. A common cellular function of 
these DCs is the regular turnover of proteins within the cell. Special receptors known 
as Major histocompatibility complexes (MHCs type I and II), are expressed in DCs and 
post translationally processed. During this processing, the MHC molecules are sent to 
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the ER and, in a random fashion, bind cellular peptides that are generated during cis 
degradation mechanisms. Thus, by regularly binding peptides that are produced from 
constitutively active proteosomal degradation, any protein derived from a foreign 
microorganism that is degraded in addition to host proteins, will be bound by MHC 
molecules and presented on the surface of the APC for recognition by T/B cells [3]. 
DCs, and indeed monocytes and macrophages, are particulary important for the 
immune response because they can not only express MHC molecules that present 
endogenously derived peptides, but due to phagocytosis, also possess the ability to 
express MHC molecules that present exogenously derived peptides. MHC class I 
expressing cells (Non B cells) are present in every major tissue investigated, with the 
exception of the brain parenchyma, however, whereas MHC class II is exclusively 
expressed on specific myeloid cells (DCs, monocytes, macrophages) [4]. 
The primary goal of the immune system is to first determine what is “self” and what is 
“non-self”. The hypothesis that differentiation of self and non-self was due to a clonal 
selection mechanism of genetically distinct mother/daughter/sister T and B cells during 
development was first postulated in 1957 by Burnet [5]. Extensive research has shown 
that Burnet’s initial modification of the theory was correct. Indeed, genetically unique 
T and B cells are only clonally selected if they do not respond to host derived peptides 
during development and maturation. This critical determination of “self” versus “non-
self” is carried out by specific receptors of cells within the body. In the case of T cells 
and B cells, DCs provide a mechanism by which these adaptive immune cells can 
investigate the human body for invading pathogens by presenting molecular structures 
derived from potentially pathogenic microorganisms on their surface via MHC 
molecules [6, 7].  
 
1.2.1.3 Lymphoid cells 
 
As with myeloid cells, lymphoid cells originate from hematopoietic stem cells and 
confer the adaptive axis of the immune system [8-11]. T and B cells are the primary 
lymphoid cells, however it is known that NK cells are in addition defined as lymphoid 
cells, despite the fact they are not classically defined as adaptive immune cells [12]. T 
and B cells are responsible for the adaptive axis of the immune system, and rely on 
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the foundations of the innate axis of the immune system to confer their effector 
function. T and B cell activation requires the antigen presentation system of the innate 
immune system, once activated, the adaptive immune system can begin on 
coordinating its immune response.  
 
1.2.1.4 The adaptive immune response  
 
T cells are subdivided into several types that are transformed from a pluripotent stem 
cell using epigenetic mechanisms and transcriptional control [13-15]. These 
transformation mechanisms, in addition to T cell receptor (TCR) rearrangements, 
commit T cell progenitor cells to specific subtypes of T cells, which are defined by their 
TCR and transcriptional control [14]. The different effector T cells consist of Helper T 
cells which are marked as being CD4+ T cells (TH1, TH2, TH17, TH9, and TfH cells) 
[16], and Cytotoxic T cells or Cytotoxic lymphocytes (CTLs) (CTLs, TC2, TC17, and 
TC9 cells) which are marked as being CD8+ T cell [17]. The main role for APCs, in the 
context of lymphoid cells, is to activate the lymphoid effector function. APCs will engulf 
extracellular pathogens, or be infected by intracellular pathogens and present peptides 
derived from these foreign microorganisms, if the correct signalling conditions are in 
place, the APC will activate a specific clone of a T cell [17]. CD4+ and CD8+ T cells, 
although sharing similar T cell receptor gene identity, require different MHC class 
molecules in order to be activated. CD4+ T cells and their TCR require a co-stimulation 
by its cognate peptide sequence displayed by MHC class II molecules, while CD8+ T 
cells and their TCR require co-stimulation by MHC class I molecules. Despite 
recognition of a non-host molecular pattern displayed by MHCs, further stimulation is 
necessary. TCR activation requires a non-host molecular pattern accompanied by the 
inflammatory cytokine IL-12, and the co-expression of CD80/86 on the APC that is 
cross-presenting the antigen. Only with the trifecta of co-stimulatory signals will a T 
cell become activated [18].  
 This is an excellent example of the coordinated machinery involved in 
regulating the immune response. These necessary “permission” steps define the 
coordination of the systemic nature of the immune system. If this highly regulated 
system was to become unregulated, then the host can suffer from auto-immune 
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related diseases such as diabetes mellitus type 1, multiple sclerosis, inflammatory 
bowel disease, rheumatoid arthritis, or systemic lupus erythematosus. 
 Activated T cells then coordinate with B cells via the B cell receptor (BCR) and 
TCR in order to activate the production of antigen specific antibodies through clonal 
expansion and antibody maturation [19]. The B cell receptor is a complex multimeric 
receptor that undergoes a considerable amount of regulation during its activation 
initiation signal [19-22].  B cells can become activated in a similar fashion to T cells 
(APC depending activation), but can also be directly activated by T cells that have 
already recognised and been activated by a foreign molecular pattern [19, 23]. Once 
activated, the antigen specific BCR expressing B cell will proliferate (clonal expansion) 
and produce and excrete the antigen specific antibody in vast numbers in order to 
clear the infection. 
 Thus, activation is dependent on the intricate organisation of a considerable 
range of molecules, requiring the coordination of not only both intracellular signalling 
pathways and intercellular communication, but additionally the coordination of immune 
cell subtypes (figure 1.3). As previously introduced, the cell-cell coordination and 
regulation is of the utmost importance for a regularly functioning immune system. This 
is another example of the intricate regulation involved in the immune response, but on 
the intracellular level of a single cell.   
 The innate axis of the immune system provides a rapid, and relatively 
nonspecific, initial response to pathogens that is necessary to recruit and activate the 
adaptive axis of the immune system (figure 1.4). Together, the immune system confers 
four classic features of a protective response, namely; specificity, memory, diversity, 
and self/non-self discrimination. In the case of virus infections, the innate immune 
system, as with any other infection, will coordinate with the adaptive immune system 
in order to fully clear the virus and protect the host. 
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Figure 1.3 Immune response to a virus 
 
Figure 1.3:  schematic overview of the general response of the immune system as a 
coordinated system, in response to a virus infection.  
 
Figure 1.4 Time dependent responses of the immune system 
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Figure 1.4: schematic representation of the general responses over time to a virus 
infection: The rapid response of the innate immune system (factors include IFNs, 
TNFa, and interleukins such as IL12) is followed cell specific activation dynamics 
which ultimately results the activation of B cells and the production of antigen specific 
antibodies.  
 
As described in the chapter thus far, and shown in figure 1.3 and 1.4, the immune 
system as a whole relies on various cell types and responses in order for a successful 
coordinated systemic immune response to occur. What is also clear is that the innate 
system provides a pillar on which the immune system stands in order to effectively 
respond to invading pathogens. Without the early detection and alarm systems, the 
adaptive immune system cannot effectively exert its response of ‘clearing’ the specific 
pathogen due to the lack of activation by the innate immune system. The primary focus 
of this thesis is the innate immune response to a virus infection. 
 
 
1.3 The innate immune response to viruses 
 
Viruses are the most abundant pathogens that the human immune system is 
challenged with. They are the most diverse and rapidly evolving class of pathogens to 
date, and therefore represent a significant threat to health. As introduced previously, 
the innate immune axis provides an essential role for the immune system. Without a 
fully functional innate immune system, many serious diseases may arise. An example 
of this is IKKg (NEMO) deficiency syndrome, which presents itself as a severe form of 
hypohidrotic ectodermal dysplasia, which is characterised by severe abnormalities in 
skin, nail, hair, and sweat gland development [24, 25]. Additionally, for TLR3, which is 
receptor associate with the recognition of viruses, there are studies suggesting it is 
redundant, however it is specifically necessary in protecting the CNS from HSV-1 
infection. TLR3 deficiency syndrome results in a clinical manifestation of HSV-1 
induced encephalitis [25-27]. Other immunodeficiency related diseases regarding the 
innate immune system include MyD88 deficiency (caused by an inherited mutation in 
the gene MYD88 and results in early-life invasive bacterial infections that can be life 
threatening), IRAK4 deficiency (another inherited disorder resulting in bacterial 
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infections), WHIM syndrome, Epidermodysplasia verruciformis (a rare skin disorder 
with a high risk for cancer development), and Chronic mucocutaneous candidiasis (a 
T cell disorder resulting in chronic infection by candida fungi) [25]. 
Viruses must be rapidly detected in order to protect the host. The innate 
immune system provides the first line of defence against virus infections. In the early 
2000’s, almost nothing was known about the cellular machinery or mechanisms by 
which viruses were detected, resulting in the subsequent production of IFN and 
inflammatory cytokines. It is now well understood how receptors, known as pattern 
recognition receptors (PRRs), which are ubiquitously expressed in different tissues of 
the human body and specifically detect molecular patterns of viral origin (pathogen 
associated molecular patterns (PAMPs). A significant body of research has lead to a 
monumental shift in the understanding of the host defence against viruses compared 
to 20 years ago [28-31].  
 There are two subfamilies of PRRs that responsible for detecting and 
responding to viruses. The first family is the toll-like receptor (TLR) family that, in 
humans, is made up of TLR1-10, while TLR3, TLR7, TLR8, and TLR9 are specific 
antiviral innate immunity [32].  There are however cases where classically bacterial 
associated TLRs play a role in antiviral immunity, for example, TLR4 specifically 
binding a viral protein from respiratory syncytial virus to initiate innate immune 
signalling [33]. The second family of PRRs is the RIG-I-like receptor (RLR) family of 
PRRs, which is encompasses RIG-I (DDX58) MDA5 (IFIH1), and LGP2 (DHX58). Viral 
nucleic acids (both RNA and DNA ss/ds) provide the all-important pathogen 
associated molecular pattern (PAMP) that is recognised and bound by the PRRs, 
discriminating self from non-self. This thesis will specifically focus on RIG-I mediated 
detection of dsRNA and signal transduction.  
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1.3.1 RIG-I signalling 
 
1.3.1.1 Structure and function of RIG-I 
 
Figure 1.5 Domain structure of RIG-I 
 
A 
 
 
B 
 
 
Figure 1.5: (A) Colour coordinated schematic overview of the domain structure of 
RIG-I. (B) Colour coordinated crystal structure of RIG-I in its open conformation, 
Rawling et al., 2014 [34]. 
 
As shown in figure 1.5, RIG-I is divided into different domains which each serve a role 
for RIG-I functionality. There is a tandem CARD domain (caspase activation and 
recruitment domain) on the N-terminus and a regulatory domain on the C-terminus 
(CTD), linked to a pincer domain. These domains surround the ATPase core of RIG-
I, which is made up of a SF2 RNA helicase domain. RIG-I helicase domain is 
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separated into three subdomains, HEL1, HEL2, and HEL2i, however only HEL1 and 
HEL2 interact with functional groups of the RNA [35, 36].  All RLR’s are formed around 
this ATPase core with the homologous SF2 RNA helicase motif ‘DExD/H box’. For 
these RLRs the RNA helicase structure has a relatively unique set of modifications. 
For example, two of the three alpha-helices within the helicase domain are orientated 
very differently. Normally in SF2 RNA helicases, the alpha-helices are found parallel 
to the beta sheet. In RIG-I they protrude out towards the pincer domain, this functions 
to allow the RLRs to bind RNA in a duplex formation. Around the helicase core of RIG-
I, there are two tandem caspase activation and recruitment domains (CARD) on its N-
terminus which are found as an inactive form of the protein in a “closed” conformation 
[37]. The C terminal domain (CTD, or regulatory domain (RD)) of RIG-I is responsible 
for the binding of 5’triphosphorylated (5’3P) dsRNA, a non-self molecular pattern [37-
41]. Unlike other helicase enzymes, RIG-I does not unwind the duplex, but rather 
translocates to the 5’3P of the dsRNA for binding. This results in a conformational 
change of the tandem CARD domains to an “open” position, where they are exposed 
for post translational modifications, which is required for the activation of downstream 
effector molecules [36, 39, 42, 43]. Furthermore, it has been shown that RIG-I binds 
in an oligomeric fashion, resulting in filament formations of RIG-I along the length of 
the dsRNA, which is suggested to be a prerequisite for functional downstream 
signalling to occur [44-46]. The process of oligomerisation of RIG-I along dsRNA has 
been demonstrated to require binding of unanchored K63-link polyubiquitin chains [47, 
48].  Downstream of the helicase domain and upstream of the CTD/RD lies a pincer 
domain, which has been demonstrated to be required for the facilitation of dsRNA 
binding, via a ‘nano mechanical’ bridging mechanism, and is essential for efficient IFN 
production [34, 49, 50].  
 
1.3.1.2 LGP2 and MDA5 
 
LGP2, otherwise known as DHX58, lacks the essential CARD domains necessary for 
the interaction with MAVS, a mitochondrial associated adaptor protein (which will be 
discussed in detail in 1.3.1.4). Its role in RLR mediated signal transduction has been 
inconsistently reported, with several groups offering evidence of a positive role for 
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signal transduction, while other groups offer evidence for a negative role [51-53].  More 
recently however, the role LGP2 plays in terms of positively regulating MDA5, has 
been made unambiguous [54, 55]. LGP2 cooperates with MDA5 in order to enhance 
signalling by binding dsRNA via its C-terminus and initiating nucleation of MDA5 [56]. 
 MDA5’s PAMP has been relatively unknown, however it has been suggested 
that the primary PAMP is long dsRNA molecules, and that MDA5 oligomerises along 
the dsRNA molecule in order to initiate signal transduction, with the help of LGP2 [44, 
56]. The regulation of its activation is yet to be fully elucidated, although binding of 
unanchored ubiquitin chains and/or SUMOylation are post translational modifications 
which may play an important role [48, 57].  
A comparison between the structural domains of each RLR can be seen in 
figure 1.6. Given that RIG-I and MDA5 are structurally quite similar, and the fact that 
LGP2 lacks the tandem CARD domains, there may be strict post translational 
regulatory steps involved in the divergence of the modes of activation between RIG-I 
and MDA, and to a certain extent, LGP2.  
 
Figure 1.6 RLR structure homology  
 
Figure 1.6: Schematic overview of the RLRs’ structures; RIG-I, MDA5, and LGP2, 
modified from Chiang et al., 2014 [58] 
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1.3.1.3 RIG-I signalling overview 
 
Due to the potential for pro-inflammatory cytokine production of the innate antiviral 
immune response, an uncontrolled, overzealous, or disproportionate response can be 
detrimental to the host, therefore the entire signalling system is tightly controlled. 
Conversely, upon viral infection, the response by RIG-I and IFN must be rapid in order 
to protect the host. As such, several positive and negative regulators exist for 
controlling the RIG-I signalling cascade [32].  
The primary ligand required for RIG-I activation is 5’3P duplex RNA or dsRNA, 
but it has been demonstrated that the dependence on the 5’3P group decreases as 
the length of the RNA molecules increases [28, 38, 40, 42, 45, 59-62]. Despite being 
specific to a certain type of PAMP, RIG-I has been reported to recognise and respond 
to various forms of dsRNA, which can be reviewed in figure 1.7, in addition to DNA 
viruses. Furthermore, literature suggests that sequence motifs of dsRNA also play a 
role in the amplitude of RIG-I mediated IFN responses, and that RIG-I can not only 
respond to 5’3P but also 5’2P dsRNA [63, 64]. Additionally, there is a report suggesting 
that RIG-I is responsible for directing the antiviral response against CCHFV, which is 
harbours 5’1P dsRNA PAMP [65].  
The canonical steps following RIG-I recognition of viral RNA/DNA, which will be 
discussed in detail in sections 1.3.1.4-7, include the interaction with an adaptor protein 
known as MAVS (mitochondrial antiviral stimulator) via the tandem CARD domain of 
RIG-I, causing MAVS aggregates to form (MAVS nucleation) [66]. Activated MAVS 
complexes then recruit a variety of adaptor proteins which have been described to 
mediate the signal transduction via formation of a large signalling complex. At this 
point, RIG-I signalling diverges into two canonical signalling pathways, leading to 
IRF3/7 activation and NFkB activation [67]. However, RIG-I signalling is primarily an 
antiviral associated signalling pathway and thus IRF3/7 activation is more predominant 
than NFkB activation. Once MAVS has recruited its adaptor proteins, specific kinase 
enzymes are phosphorylated in order to mediate transcription factor activation. For 
the IRF3/7 canonical signalling, the essential kinases that are required are TBK1 and 
IkKe, which directly phosphorylate IRF3/7 [68]. For NFkB canonical signalling, the 
kinases that are responsible for mediating activation include IkKa/b/g. Together they 
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cause the disassociation of NFkB from its inhibitor IkBa. IkBa becomes 
phosphorylated by IkKa/b and then dissociates from NFkB where it is then targeted 
for degradation [69]. These steps and the proteins involved have been defined as the 
canonical steps in RIG-I signalling, leading the production of interferon, interferon 
stimulated genes, and pro-inflammatory cytokines and ultimately generating an 
antiviral state.  
 
Figure 1.7 RIG-I ligands  
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Figure 1.7: Overview of putative RIG-I ligands that may initiate signal transduction, 
reviewed by Schlee and Hartmann, 2010 [70].  
 
1.3.1.4 RIG-I activation of MAVS  
 
Once RIG-I has bound to its cognate PAMP and initiates its conformational changes 
previously described, the CARD domains of RIG-I become ubiquitinated (K63-linked 
ubiquitination) by E3 ligase enzymes TRIM25 and RNF135 (RIPLET) [71-74], a 
process which requires initial dephosphorylation of RIG-I. This is mediated by PP1a/g, 
which target S8 and T160 of RIG-I in order facilitate ubiquitination [75, 76]. More 
recently, T667 has also been shown to be an important phospho-site for RIG-I [77]. 
RIG-I CARD domains, which are exposed and ubiquitinated upon recognition of 
dsRNA, interact with the CARD domains of an adaptor protein known as MAVS, which 
is found primarily on mitochondrial membranes [36, 78, 79]. Overexpression of MAVS 
leads to an enhanced IFNb response, and contrastingly, depletion of MAVS in mice 
leads to impairment of the antiviral responses [80, 81], and additionally, virally induced 
dissociation of MAVS from the mitochondrial membrane also perturbs the antiviral 
responses [82]. Thus, MAVS has been revealed to be an important protein in antiviral 
signalling. 
 MAVS undergoes its own strict post translational modifications. Most 
importantly, activated MAVS forms prion-like aggregates on the surface of the 
mitochondrial membrane, these aggregates act as a robust signalling platform for 
downstream molecules to continue signal transduction [46, 83]. RIG-I CARD domains 
transiently interact with the CARD domain of MAVS, which requires a tetrameric 
formation of RIG-I molecules (hence the perquisite for oligomerised RIG-I for induction 
of signalling). RIG-I interaction with MAVS results in the nucleation of MAVS 
molecules, and the transient nature of the interaction allows MAVS to recruit inactive 
MAVS, ultimately forming an aggregate of activated MAVS on the surface of the 
mitochondrial membrane [46]. It is here, at the surface of the mitochondrial membrane, 
where signal transduction is rapidly induced using two canonical signalling pathways 
that activate specific transcription factors involved in the expression of ISGs, 
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inflammatory cytokines, and most importantly, type I/III IFNs. These transcription 
factors are IRF3/7 and NFkB. 
 
1.3.1.5 MAVS mediated signal transduction    
 
Several proteins are recruited to the signalling platform formed by MAVS aggregates 
upon RIG-I activation in a spatio-temporal specific manner. A family of proteins 
recruited to MAVS is the tumour necrosis factor (TNF) receptor-associated factor 
proteins (TRAF) [84]. TRAF proteins are required for downstream signalling to occur, 
and this is mediated by the TRAF-interaction motif found on MAVS. One such member 
of the TRAF family is TRAF3, which has been shown to be required for the activation 
of IRF3 (but not NFkB) and production of IFNb, and more recently than that, TRAF5 
has been implicated in IRF3 activation [85-88]. Consequently, it was discovered that 
recruitment of E3 ligases to activated MAVS was an essential process in the 
transmission of the signal to transcription factors IRF3/NFkB. TRAF2, TRAF3, TRAF6, 
and LUBAC, are all E3 ligases that are recruited to MAVS during antiviral signalling 
[84, 89]. Recruitment of these E3 ligases is mediated by the interaction with death 
domain (DD) containing proteins; Fas-assciated death domain (FADD) protein, TNF 
receptor-associated death domain (TRADD), and RIP1 [90-93]. While FADD and RIP1 
have been demonstrated to be specific for the NFkB (both TNFaR and RIG-I 
mediated), literature points out that TRADD, FADD, and RIP1 form a complex at the 
MAVS signalling platform, and that it is from this complex that the canonical signalling 
pathways (IRF3/ NFkB) are separated from one another. 
  
1.3.1.6 IRF3/7 activation  
 
TRAF3, a crucial E3-ligase enzyme involved in IRF3 activation, is first ubiquitinated 
by E3 ligases cIAP1/2 (K63-linked ubiquitination) [94]. Polyubiquitinated TRAF3 then 
interacts with specific kinases that were found to be essential for the activation of IRF3 
via phosphorylation. These kinases are ‘TRAF family member associated NFkB 
activator TANK-binding kinase 1’, or more commonly referred to as TBK1, and the 
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inducible IkBa kinase known as IkK-i or IkKe (henceforth referred to as IkKe) [68, 95-
97].   
 TBK1 and IkKe are pivotal regulators of the IFN response, in fact, loss of both 
of these kinases impairs IFNb production in response to virus infection [96, 98, 99]. A 
study carried out by Hemmi et al., 2004., suggested that there is a certain level of 
redundancy regarding both kinases, although they are essential for IRF3 activation, 
the exact differences between their roles (if any) is yet to be fully elucidated. These 
two kinases, once activated by the multimeric complex at MAVS described previously, 
interact with TANK, NAP1, and SINTBAD, which have all been shown to be necessary 
for type I IFN production [96, 98, 100-103].  
 Functional studies by Goncalves et al., 2011., demonstrate that there is a 
requirement for the interaction with aforementioned proteins, which act as 
adaptor/recruitment proteins, such that if TBK1, defective in binding these proteins, is 
expressed in mice lacking wild-type TBK1, then the mice have an impaired ability to 
induce IFNb [103]. Despite this, there is a study that was carried out that describes 
mice with no apparent impairment of type I IFN production when lacking TANK  [104]. 
It has also been described that DDX3, another DEAD box helicase, is activated by 
active TBK1, and that this process is necessary for the production of IFNb, however 
the mechanism behind these findings are yet to be fully determined, although it is 
suggested that DDX3 couples IkKe to IRF3, potentially via a direct interaction with 
TRAF3 and/or IkKe [105-107]. More studies on DDX3 are required to fully clarify its 
role on IRF3 activation.  
TBK1 and IkKe are attributed with a ubiquitin-like domain (ULD) within their 
kinase domain (KD), in addition to a scaffolding/dimerisation domain (SDD), which is 
shared among all IkK related kinases. Like other IkK related kinases, TBK1 and IkKe 
require a scaffold in order to become phosphorylated, and thus carry out their effector 
function. Both TBK1 and IkKe require phosphorylation at Ser172 in order to become 
active [108-111]. Preceding phosphorylation is K63-linked ubiquitination at the ULD, 
which is mediated by MIB1/2 [112].  Phosphorylation at the Ser172 site is described 
to be mediated by a trans-autophosphorylation mechanism, which is facilitated by the 
scaffolding complex [69]. The scaffolding complex is formed from the adaptor proteins 
described previously that are recruited to the MAVS complex via TRAF3 [110, 113, 
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114]. As described, TRAF3 ubiquitination provides the means for this scaffolding 
complex to form, and this allows the autophosphorylation event of TBK1 to occur. It 
has been suggested by Clark et al, 2011, that TBK1/ IkKe  Ser172 autophosphorylation 
event is mediated by an interaction with IkKb, as specific inhibitors of resulted IkKb 
resulted in diminished phosphorylation of TBK1/IkKe [113]. Despite more work being 
required to fully define the mode of phosphorylation of these kinases, it has been 
shown that IkKb get in close proximity with TBK1/IkKe, mediated by a bridge formed 
by NEMO (also known as IkKg) from the canonical NFkB pathway [69, 113-115]. It 
has been described that NEMO bridges IkKb to TBK1 by binding to the K63-linked 
polyubiquitin chains formed on TBK1 by MIB1/2 [114].  
Despite the unclear mechanism of phosphorylation of TBK1/IkKe, when 
activated (defined by their Ser172 phospho-site), they work to phosphorylate the 
transcription factor IRF3, and once expressed, IRF7 in addition. This has been defined 
as a canonical step in IRF3/7 activation, which can only be achieved through MAVS 
nucleation upon RIG-I stimulation. 
 IRF3 and IRF7 activation occurs in the cytoplasm through their C-terminal 
domain [68]. In IRF3, there are 7 phospho-sites (Ser/Thr) on the C-terminus, between 
Ser385-Ser405. Only one phosphorylated residue between Ser396-Ser405 is 
necessary to mediate the interaction with CREB binding protein (CBP), a protein that 
mediates the activation of transcription, while Ser385 and Ser386 [116] mediate 
dimerisation and translocation from the cytoplasm to the nucleus [97, 117-120]. While 
IRF3 in constitutively expressed in most cells that have been examined, IRF7 is only 
expressed in lymphocytes and myeloid cells, or upon treatment of cells with IFNa 
[121]. IRF7 is activated much in the same way that IRF3 is activated, and upon 
phosphorylation, can form homodimers or heterodimers with IRF3/5 in order to 
translocate to the nucleus for transcription [122]. The IRF family of transcription factors 
all contain a DNA binding domains (DBDs) where they bind interferon stimulated 
response elements (ISREs) and mediate the transcription of ISGs and type I/III IFNs 
[123-126].    
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1.3.1.7 NFkB 
 
Similar to IRF3 activation, with regards to RIG-I mediated signal transduction, NFkB 
requires MAVS aggregation on the surface of the mitochondrial membrane, but via a 
separated signalling pathway (canonical IkK dependent signalling). TRAF2 and 
TRAF6 interact with MAVS to mediate the recruitment of the adaptor proteins 
necessary for the scaffold that activates the canonical kinases involved in NFkB 
activation, although it has been shown there is a strong level of redundancy regarding 
the E3 ligases recruited to MAVS in this respect [79, 84].  
 NFkB is encoded for by five polypeptides that assemble in various 
combinations of subunits to form the NFkB transcription factors. The stability and 
affinity of the subunit interactions is mediated specific amino acid residues, however 
the most stable and commonly found NFkB transcription factor is made from RelA and 
p50 [127]. Each subunit contains the Rel homology region (RHR) at its N-terminus, 
followed by the dimerisation domain (DD). The two domains are linked via flexible 
linker sequence, and at the C-terminus the nuclear localisation signal (NLS) can be 
found. Three of the five sequences encoded for NFkB (RelA, c-Rel, and RelB) contain 
the transcription activation domain (TAD), which is necessary for the NFkB specific 
gene expression. The DD mediates the formation of hetero and homo dimers between 
the 5 different subunits of NFkB, for a possible total of 15 unique dimers, and of these, 
12 have been described in vivo [127, 128].  
NFkB is constitutively inactive within the cytoplasm of cells due to its interaction 
with a family of inhibitory proteins, such as IkBa, b, and e, which are classically found 
in the cytoplasm, however IkBa is by far the most predominant and prevalent inhibitor. 
There are, in addition, nuclear IkB proteins (Bcl-3, IkBz, and IkBNS), [27, 127, 129-
131]. Nuclear IkB’s are themselves products of NFkB transcription, and unlike 
classical IkB’s specifically bind homodimers of p50 [132]. Nuclear IkB relevance must 
not be underestimated however, despite being non-classical, a study carried out in 
2004 by Yamamoto et al., described the loss of the ability of mice lacking IkBz to 
produce IL-6, a central pro-inflammatory cytokine [133]. 
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Of the former mentioned cytoplasmic inhibitors (IkBa/b/e), each contain six 
central Ankyrin repeats (~33 Amino acids), which mediate the interaction with NFkB. 
Domains also found on IkB’s include the phosphorylation site necessary for activation 
of NFkB (S32 and S36), and the functional nuclear export signal NES. Despite the 
NES, the IkB interaction with NFkB functions to mask the NLS sequence on NFkB 
[134]. NFkB:IkB classical complexes (IkBa/b mediated) reside stably in the cytoplasm, 
whereas IkBe acts as a negative feedback inhibitor [127, 135].  
 Following MAVS activation, while TRAF3 mediates the recruitment of adaptor 
proteins necessary for IRF3 activation, TRAF2/6 mediate the recruitment of adaptor 
proteins (TRADD, FADD, RIP1) for NFkB [84, 88, 94, 136]. These adaptor proteins 
form a scaffold by which the canonical kinases required for NFkB activation, IkKa/b, 
are recruited for their phosphorylation and subsequent activation [137-139]. 
Ubiquitination of IkKa/b allows NEMO to bridge IkKa/b, forming a kinase complex that 
facilitates autophosphorylation [139-143]. The active form of IkKa/b, formed with 
NEMO, is responsible for the phosphorylation of IkBa/b/e, which, in the case of IkBa, 
results in the direct K48-linked ubiquitination by the Ubc5/E3RSIκB E3 ligase pair [139, 
144, 145] ultimately leading to its degradation, and thus releasing NFkB from being 
localised to the cytoplasm, where it is phosphorylated in addition to IkBa/b. RelA is 
the target for phosphorylation at S536, and once phosphorylated and free of IkBa, 
NFkB translocates to the nucleus to mediate transcription of pro-inflammatory 
cytokines [27, 113, 139, 144, 146, 147]. Figure 1.8 provides an overview of RIG-I 
mediated signal transduction.  
 
 
 
 
 
 
 
 
 
 
 
28 
Figure 1.8 Overview of RIG-I signalling  
 
Figure 1.8: Overview of RIG-I mediated activation of IRF3 and NFkB in response to 
dsRNA.  
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1.4 IFN signalling 
 
There are 3 types of classical IFNs, deemed type I, II, and III IFNs. Type I/III IFNs are 
mostly related to antiviral induced signalling while type II (IFNg) is specifically produced 
by “professional” immune cells such as NK cells and T cells. Type I and III IFNs are a 
family of cytokines that are related by structure, regulation, and function. All the type I 
IFN genes across mammalian species share clear homology sequences and 
chromosome location, suggesting a divergence from a single ancestral protein. Type 
I IFNs include IFNb, IFNK, IFNw, and IFNa, of which there are 13 known sub-types 
[148]. In contrast to type I IFNs, type III IFNs (IFNl1 (IL29), IFNl2 (IL28A), IFNl3 
(IL28B)) are more closely related in structure and chromosome location to IL10, an 
immune response inhibitory cytokine [149]. Once type I/III IFNs are produced, they are 
excreted and bind to specific receptors. There is little known about the exact 
mechanism of the secretory pathway for type I/III IFNs, although for IFNg it has been 
described that it is stored in granules in close proximity to the membrane surface ready 
for release, which is a similar secretory method for other cytokines such as IL4 and 
TNFa [150, 151].  For type I/III IFNs, it likely they exploit the same basic mechanism 
of secretion as most other cytokines, which is via site-specific (signal peptide) 
glycosylation [151]. Indeed, for IFNb, it is glycosylated at N80, suggesting classic 
secretion mechanism, although the regulation of secretion of IFNs requires further 
research. IFNa/b bind to the ubiquitously expressed IFNaR made up of the IFNAR1 
and IFNAR2 chains [152]. However, literature suggests the affinity and site binding on 
the IFNAR may vary depending on which IFN is binding it [153].  
 IFNl, binds to an unrelated receptor composed of the IL10 receptor and IFNl 
receptor (IL10R2 chain and IFNLR1 chain, respectively), which is mainly expressed 
on epithelial cells and DCs [154]. The importance IFN signalling must not be 
underestimated; of the very few cases of individuals born with defective IFN receptors, 
none have survived infancy [155].  
The IFN receptors are formed from the Janus tyrosine-kinase receptor family 
chains (specifically Jak1 and Tyk2), which form stable dimers and autophosphorylate 
each other in order to mediate signal transduction. This results in the recruitment and 
phosphorylation of STAT proteins, namely STAT1 and STAT2, and in addition, with 
 
 
30 
regard to IFNl, STAT3. STAT1/2 forms heterotrimers with IRF9 (forming a complex 
known as ISGF3) or, additionally, STAT1 forms homodimers, and these complexes 
act as the primary downstream transcription factors which express ISGs [112, 120, 
156-163]. The ISGs production and kinetics induced by IFN signalling vary depending 
on the type of IFN signalling induced, for example, type I IFN signalling results in a 
short but rapid burst in ISG expression, while type III IFN signalling yields a weaker, 
but a longer sustained expression of ISGs [164]. There are even reported differences 
in the level of gene expression for type I IFNs, for example, the gene Beta-R1 is 
expressed due to IFNb, but not IFNa, despite binding to the same receptor [153]. 
Type I IFNs are primarily related to ISGF3 activation, while IFNg signalling is 
related to STAT1 homodimer activation. The phosphorylation of STAT1 and STAT2 
(at Y701 and Y690 respectively) is a necessary post translational modification required 
for transcription factor activation and ISG expression [165].  
 
1.5 Signalling dynamics and modelling 
 
As discussed thus far, the development of our understanding of the molecular biology 
of antiviral signalling is extensive. Identifying proteins involved in the molecular 
machinery of the cell is a major step forward with regard to research and medicine, 
but identifying a protein and understanding its regulation and interaction dynamics on 
a quantitative level, is another thing entirely. If one can understand the exact nature of 
the dynamics of the activation at the molecular level, one can gain insight into its 
regulation, potentially leading an understanding of the progression of disease states, 
in addition to the prevention of disease progression. This requires a multidiscipline 
approach, encompassing a wide range of skills. Mathematical modelling describes 
those observations by mathematical equations (ordinary differential equations – 
ODE’s) and are based on the molecular biology behind those processes, which can 
be measured using various biochemical or molecular biological techniques. 
Mathematical modelling can provide a deeper insight into the regulation of changes 
within a biological process, as one could use the model to examine conditions not so 
easily observed from a molecular biology point of view. An excellent example of 
applying a model to further elucidate the nature of signalling dynamics and regulation 
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is a study published in 2002 by Alexander Hoffmann, where he and colleagues 
demonstrated a bimodal signal processing characteristic with respect to NFkB 
stimulus duration, and its regulation by IkBa/b/e, which had not been characterised 
before [166].  
This study quantitatively analyses the molecular events that regulate RIG-I 
signal transduction from the level of detecting viral RNA to the level of transcription 
factor activation. This is achieved by resolving the time dependent activation states of 
canonical signalling proteins within the RIG-I signalling cascade that lead to both IRF3 
activation and NFkB activation. By monitoring the phosphorylation levels and other 
activation states of specific proteins in the signalling cascade, namely TBK1, IkKe, 
IkKb, IkBa, IRF3, and RelA of NFkB, quantitative data can be used to formulate a 
mathematical model that describes these changes. Furthermore, ISG production, and 
indeed IFN signal transduction, is also examined in terms of the time dependent 
expression/activation rates of genes and proteins of interest. By applying the basic 
knowledge of the kinetics of regulatory steps during signal transduction to 
mathematical modelling, the temporal dynamics of the RIG-I signalling cascade will be 
elucidated and further our understanding of how the cell responds to a virus under 
certain conditions, how the virus succeeds in establishing an infection, or how it fails 
to establish an infection. 
 
1.6 Ubiquitination 
 
Ubiquitin is one of the most versatile post-translational modifications that occur in 
human cells, and is without a doubt indispensable for cellular homeostasis and fully 
functioning intracellular networks. The prevalence and importance of ubiquitination 
emerged in the 1970s, where the discovery of ubiquitin was just the tip of the iceberg 
of a complex and pivotal regulatory system [167-170]. Ubiquitins, named so because 
they are ubiquitously expressed in all cells, are processed into peptides of 76 amino 
acids. The key features of ubiquitins are the 7 lysine residues (K6, K11, K27, K29, 
K33, K48, and K63, in addition to Methionine 1) [171, 172], all of which can be modified 
with further ubiquitins, giving rise to isopeptide-linked ubiquitin chains which are the 
basis for ubiquitination as a post-translational modification. Many proteins contain a 
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ubiquitin binding domain (UBD) and are post translationally modified with either mono- 
or poly-ubiquitin chains to modify their function. This process is a multistage process 
involving three families of enzymes, named E1, E2, and E3 [172, 173]. Ubiquitin is first 
activated by E1 enzymes (activating enzyme) which produce a high-energy thioester 
bond involving the use of ATP [174, 175]. Ubiquitin is then transferred to E2 enzymes 
(conjugation enzyme) [176], and with the help of E3 enzymes (ligase enzymes), 
substrate specificity is determined, where ubiquitin is then conjugated to the e-amino 
group of the lysine residue specified by the E3 ligase on the target protein [174, 177, 
178]. Ubiquitinated proteins are recognised by specific receptors or adaptor proteins 
that contain a ubiquitin binding domain homology (UBD), which have many roles in 
cells resulting in multitude of different signals [172] . Further, these ubiquitinated 
proteins are deactivated through interactions with deubiquitination enzymes (DUBs) 
[179]. During the process of ubiquitination, each of the 7 lysine residues can be utilised 
for the formation of ubiquitin polypeptides, and each ubiquitin chain takes on a distinct 
tertiary structure which results in recognition by specific E3 ligase enzyme [180]. The 
type of ubiquitination is determined by the lysine residue targeted for ubiquitination, 
for example, K48-linked ubiquitination is renowned for its targeting of protein for 
proteosomal degradation, an essential process in terms of cellular homeostasis [181]. 
K63-linked ubiquitination on the other hand is associated with a non-
degradative/activatory modification [182] 
 While there only a handful of E1 and E2 enzymes, there are over 600 E3 
enzymes encoded by the human genome which control various aspects of the 
complex cellular networks within human cells. The RIG-I signalling network is no 
exception to this fact, and in truth, ubiquitination is one of the most important features 
of the regulation of the antiviral system and has been intensively studied [84, 183-
190], many of which have already been described in section 1.3.1. The emerging role 
of ubiquitination, and indeed deubiquitination in RIG-I mediated signalling has been 
gaining increased attention, and has been reviewed by Maelfait and Beyaert in 2012 
[191]. Considering this, it is evident that research on the ubiquitination on antiviral 
signalling in general will continue to play an important role in defining our 
understanding on innate antiviral immunity and the pathogenesis of viruses. Taking 
this into account, we decided to investigate E3 ligases in more detail to expedite the 
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research in this regard. A comprehensive siRNA screening approach was devised in 
order to determine the extent of the missing links regarding E3 ligase regulation of 
RIG-I signalling. In 2008, a group published an extensive genome-wide and functional 
annotation of putative E3-ligases based on UBDs [192], and this became the basis for 
our approach to determine novel E3 ligases regulating RIG-I signal transduction 
(described in section  4.3).  
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2.0 Materials 
2.1 Cell Culture  
Table	1	Cell	culture	reagents	
Table of Cell Culture Reagents 
Reagent Components 
Cryo solution 90% FCS, 10% DMSO 
DMEM - - - Gibco ® Dulbecco’s Modified Eagle Medium 1X +4.5g L-Gitumaine - Pyruvate 
DMEM + - - DMEM FCS free and antibiotic free + MEM (1x) 
DMEM + - + DMEM Antibiotic free + MEM (1x) + 10% v/v Fetal calf serum (Gibco ®) 
DMEM + + + DMEM complete + MEM (1x) + 100U/mL Penicillin and Streptomycin (Gibco ®) + 10% v/v Fetal calf serum (Gibco ®) 
Microscope Media 
DMEM complete without phenol red + MEM (1x) + 100U/mL 
Penicillin and Streptomycin (Gibco ®) + 10% v/v Fetal calf serum 
(Gibco ®) 
jetPEI ® Polyplus jetPEI ® transfection reagent 
Lipofectamine 2000 ®  Invitrogen Lipofectamine 2000 ® transfection reagent 1mg/mL 
MEM Gibco ® Minimal Essential Amino Acids 100X 
Opti-MEM Chemically defined medium with low serum requirement (Gibco ®) 
PBS 1X Phosphate buffered saline solution 
Trypsin 0.05% trypsin + 0.02% EDTA in PBS 
Cytomix 
120 mM KCl, 0.15 mM CaCl2, 10 mM KPO4 (pH 7.6), 25 mM Hepes, 
2 mM EGTA, 5 mM MgCl2 adjusted to pH 7.6 with KOH, 
supplemented with 2 mM ATP and 5 mM Glutathione 
 
 
Table	2	Mammalian	cells	
Mammalian Cells 
Name Expression and Resistance  
A549 N/A 
A549 eGFP-IRF3 eGFP-IRF3 Puromycin 
A549 eGFP-IRF3 mCherry-RelA eGFP-IRF3 Puromycin mCherry-RelA Neomycin 
A549 Tet-on Tet repressor (trans-activator) Blasticidin 
A549 Tet-on NLS-mCherry-2A-RIG-I2CARD Tet repressor (trans-activator) Blasticidin NLS-mCherry-2A-RIG-I2CARD Hygromycin 
HEK293T N/A 
HEK293T RIG-I RIG-I Blasticidin 
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Huh 7 LucUbiNeo-ET  HCV RNA replicon with stable production of Firefly luciferase Neomycin 
Huh 7.5 RIG-I  RIG-I Blasticidin 
Huh 7.5 RIG-I eGFP-IRF3 RIG-I Blasticidin eGFP-IRF3 Puromycin 
 
2.2 DNA and RNA  
Table	3	DNA	and	RNA		
Table of DNA and RNA Reagents and Kits 
Reagent/Kit Company/Components 
Annealing buffer 150 mM NaCl, 5 mM Tris 
10mM dNTPs PeqLab 
25mM rNTPs Roche 
5X RRL buffer (400mM Hepes pH 7.0, 60mM MgCl2, 10mM spermidin, 200mM DTT 
Midori Green ® Nippon Genetics 
50X TAE Buffer 2 M Tris, 2 M Acetic Acid, 50 mM EDTA, pH 8.3 
6X DNA loading dye 
45mL 50% glycerol, 1mL TAE 50X, 0.5 mL 
100 mM EDTA pH 8.0, 0.13g orange, ddH20 
to 50 mL   
Accuprime ® high fidelity polymerase Thermo Fisher 
Fidelitaq ® polymerase Affymetrix 
Gatewway ® LR/BP clonase ® enzyme 
cloning kit Invitrogen 
High capacity cDNA Reverse transcriptase 
® kit Applied Biosystems 
NEB Assorted Restriction Enzymes New England Biolabs 
NEB buffer 1.1 New England Biolabs 
NEB buffer 2.1 New England Biolabs 
NEB buffer 3.1 New England Biolabs 
NEB buffer CutSmart ® New England Biolabs 
NEB T4 DNA ligase New England Biolabs 
Nucleospin ® Gel and PCR clean up kit Machery-Nagel 
Nucleospin ® Plasmid extraction kit Machery-Nagel 
Nucleospin ® RNA plus kit Machery-Nagel 
Q5 ® high fidelity polymerase New England Biolabs 
RNAse ® inhibitor Promega 
RQ1 RNAse Free DNAse ® Promega 
T4 DNA ligase buffer 50 mM Tris-HCl (pH 7.5), 10 mM MgCl2 1mM ATP, 10mM DTT 
T7 RNA polymerase  
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2.3 Plasmids 
Table	4	Plasmids	
Table of Plasmids 
Recombinant DNA Promoter Tag Vector Resistance 
Firefly Luciferase ISG56 - pGL3B - 
Fos CMV Guassia Fragment (N2) pcDNA3.1 - 
IRAK2 CMV Guassia Fragment (N1) pcDNA3.1 - 
IRF3 EF1-a LifeAct-mTurquoise pWPI Puromycin 
IRF3 EF1-a eGFP pWPI Puromycin 
IRF3 EF1-a mCherry pWPI Puromycin 
Jun CMV Guassia Fragment (N1) pcDNA3.1 - 
LGP2 CMV Guassia Fragment (N2) pcDNA3.1 - 
MAVS ROSA26 N/A pWPI Blasticidin 
MAVS CMV Guassia Fragment (N1) pcDNA3.1 - 
MAVS CMV Guassia Fragment (N2) pcDNA3.1 - 
mVenus ISG56 N/A pWPI Blasticidin 
NLS-Mcherry-2A-
RIG-I2CARD EF1-a N/A pWPI Blasticidin 
NLS-Mcherry-2A-
RIG-I2CARD P-tight P pgk pWPI Blasticidin 
NLS-Mcherry-2A-
RIG-I2CARD P-tight P pgk pWPI Hygromcyin 
NS3/4A (Con1) EF1-a GFP-GUN pWPI Neomycin 
NS5A EF1-a HA pWPI Puromycin 
RelA EF1-a BFP pWPI Neomycin 
RelA EF1-a BFP pWPI Hygromcyin 
RelA EF1-a mCherry pWPI Neomycin 
Renilla Luciferase SV40 - pGL3B - 
RIG-I EF1-a CFP pWPI Puromcyin 
STAT1 CMV Guassia Fragment (N1) pcDNA3.1 - 
STAT2 CMV Guassia Fragment (N2) pcDNA3.1 - 
Tet operator TRE PGK promoter pLVX Puromycin 
Tet operator TRE PGK promoter pLVX Blasticidin 
TRAF2 CMV Guassia Fragment (N1) pcDNA3.1 - 
TRAF2 CMV Guassia Fragment (N2) pcDNA3.1 - 
TRAF3 CMV Guassia Fragment (N2) pcDNA3.1 - 
TRAF6 CMV Guassia Fragment (N2) pcDNA3.1 - 
TRIM25 CMV Guassia Fragment (N1) pcDNA3.1 - 
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2.4 Protein Biochemistry  
Table	5	Protein	biochemistry	
Table of Protein Biochemistry Related Buffers/Kits 
Name Company/Components 
10X PBS 80 mM NA2HPO4, 1.4 M NaCl, 2.7 mM KCl, 1.76mM KH2PO4 
TBS (10x), pH 7.5 20 mM Tris-Hcl, 150 mM NaCl, adjust pH to 
7.5 with NaOH 
10X TGS 150 mM Tris, 1.92 M Glycine, 1% w/v SDS 
Cross-linking buffer 1% PFA in 1X PBS  
Cross-linking quenching buffer 1.25M Glycine in 1X PBS  
Laemmli Protein extraction Buffer 
9.75 mL 0.5 M Tris (pH 6.8), 15 mL glycerol, 
10 mL 10% SDS, 3.75 mL b-marcaptoethenol, 
3mg Bromophenol Blue, 6.5 mL ddH2O 
Lumikine ® human IFNb ELISA kit InvivoGen 
Resolving Gel Buffer 1.5 M Tris, 0.8% w/v SDS (pH 8.8) 
RIPA Protein extraction buffer  
50 mM Tris HCl, pH 8.0; 150 mM NaCl, 
1% (v/v) NP-40, 0.5% (w/v) sodium 
deoxycholate, 0.1% (w/v) SDS 
Stacking Gel buffer 1 M Tris, 0.8% w/v SDS (pH 6.8) 
Western Blot BSA Blocking Buffer 1X TBS, 5% w/v BSA 0.2% v/v Tween-20 
Western Blot Milk Blocking Buffer 1X PBS, 5% w/v Protease Free Milk powder 0.2% v/v Tween-20 
Western Blot Wash Buffer 1X PBS/TBS 0.2% (v/v) Tween-20 
 
 
2.5 Primary Antibodies  
Table	6	Primary	antibodies	
Table of Primary Antibodies 
Antibody Origin Specificity Company Reference 
Calnexin rabbit poly Enzo Life science ADI-SPA-865-F 
GAPDH mouse mono Santa Cruz sc-47724 
IFIT1 rabbit mono Abnova H00003434-DO1 
IkB-alpha rabbit mono Cell Signaling 9242 
IKK beta Rabbit mono Cell Signaling D3OC6 
IKK epsilon Rabbit Poly Abcam ab7891 
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IRF1 Rabbit mono Cell Signaling D5E4 
IRF3 (FL-425) rabbit poly Santa Cruz sc-9082 
IRF7 (pSer477) Rabbit mono Cell Signaling D7E1W 
IRF9 Rabbit Poly Abcam ab126940 
MAVS  rabbit poly Enzo Life science AT107 
NF-Kappa-B p65 Mouse mono Cell Signaling L8F6 
P-IKK-alpha (S176) / 
IKK-beta (S177) 
(C84E11) 
Rabbit mono Cell Signaling 2078 
P-IRF3 (S396) (4D4G) rabbit mono Cell Signaling 4947 
pDDX58 (RIG-I) (pS8) rabbit poly Abnova PAB15905 
pIKK-epsilon 
(pSer172) rabbit poly Millipore 06-1340 
pNF-kappa-B p65 
(S536) rabbit mono Cell Signaling 3033 
pSTAT1 (pY701) mouse mono BD 612232 
pStat2 (pY690) Rabbit mono Cell Signaling D3P2P 
pTBK1 (pS172) rabbit mono abcam ab109272 
RIG-I rabbit poly Enzo Life science ALX-210-932-C100 
STAT1 mouse mono BD 610115 
TBK1 rabbit mono Cell Signaling 3504 
β-Actin mouse mono Sigma-Aldrich A5441 
 
 
2.6 Secondary Antibodies 
Table	7	secondary	antibodies	
Table of Primary Antibodies 
Antibody Origin Specificity Company Reference 
Mouse-HRP Goat poly Sigma-Aldrich AP130P 
Rabbit-HRP Goat poly Sigma-Aldrich AP186P 
Goat-HRP Donkey poly Santa Cruz Sc-2020 
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2.7 Molecular probes and dyes 
Table	8	probes	and	dyes	
Table of probes and dyes 
Name Company Application 
DAPI (4’,6-diamidino-2-phenylindole dihydrochloride) Invitrogen Fluorescence (fixed) 
Hoechst 33258 (2′-(4-hydroxyphenyl)-5-(4-methyl-1-
piperazinyl)-2,5′-bi-1H-benzimidazole trihydrochloride hydrate) Sigma-Aldrich Fluorescence (live) 
Aminoallyl-UTP - ATTO-647N (C12H20N3O15P3 - 
ATTO 647N) Jena Bioscience Fluorescence (dye) 
 
2.8 Luciferase Assay Buffers and Reagents 
Table	9	luciferase	assay	
Table of luciferase assay buffers and reagents 
Name Components  
0.1 M KPO4 17ml KH2PO4 + 183ml K2HPO4 200ml H2O 
0.2 M EGTA 15.2g EGTAL (380.35 g/mol) in 200 mL ddH2O, adjust to pH 7.8 (does not dissolve until pH is adjusted 
0.2 M K2HPO4 34.83g (174,18g/mol) in ddH2O 
0.2 M KH2PO4 27.21g KH2PO4 (136,09 g/mol) in ddH2O 
0.5 M Glycylglycine Glycylglycine in ddH2O 
1 M MgSO4 15.2g EGTA (380.35 g/mol) in 200ml H2O, adjust pH to 7.8 using KOH. 
Coelenterazine 5 mg coelenterazine (PJK) in 11.8 mL Methanol  
D-Luciferin 84.1 mg D-luciferin (PJK) in 300 mL, 25 mM Glycylglycine 
Luciferase Assay Buffer 
200 mL: 10 mL Glycylglycine (0.5 M pH 7.8), 30 mL KPO4 (0.1 
M pH 7.8), 3 mL MgSO4 (1 M), 4 mL EGTA (0.2 M pH 7.8), 153 
mL ddH2O 
Luciferase Lysis Buffer 
500 mL: 5 mL Triton-X100, 25 mL Glycylglycine (0.5 M pH 7.8), 
7.5 mL MgSO4 (1 M), 10 mL EGTA (0.2 M pH 7.8), 50 mL 
glycerol, 402.5 ddH2O 
PCA Assay Buffer 1X PBS 10 µM Coelenterazine 
 
 
2.9 Primer sequences 
Table	10	primer	sequences	
Table of primer sequences 
Name Sequence (5’-3’) Application 
2A RIG-I Rv CTTTTGTTCCATAGACGCCATGGGCCCGGGATTTTCCTCCAC PCR 
2A RIG-I-CA overlap Fw GTGGAGGAAAATCCCGGGCCCATGGCGTCTATGGAACAAAAG PCR 
Asc1 mCherry Fw ATCTATGGCGCGCCGATGGTGAGCAAGGG PCR 
attB NLS Fw GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGAGCAGCGATGATGAAGCGACCG PCR 
attB RIG-I CA Rv GGGGACCACTTTGTACAAGAAAGCTGGGTCTTATGAATTCTCACTAAGATTCTG PCR 
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BFP Linker CTCGAGATCTGAGTCCGGAATTAAGCTTGTGCCCCAG PCR 
BFP linker p65 overlap Fw GGGGCACAAGCTTAATTCCGGACTCAGATCTCGAGAAGACGAACTGTTCCCCC PCR 
BFP linker p65 overlap Rv GGGGGAACAGTTCGTCTTCTCGAGATCTGAGTCCGGAATTAAGCTTGTGCCCC PCR 
cPPT F AAAAGAAAAGGGGG PCR 
EMCV2 R CGGCAATATGGTGGAAAATAAC PCR 
GAPDH Fw GAAGGTGAAGGTCGGAGC qRT-PCR 
GAPDH Rv CAAGATGGTGATGGGATTTC qRT-PCR 
IFIT1 Fw GAAGCAGGCAATCACAGAAA qRT-PCR 
IFIT1 Rv GAAACCGACCATAGTGGAA qRT-PCR 
IFNb Fw GACGCCGCATTGACCATCTA qRT-PCR 
IFNb Rv GACATTAGCCAGGAGGTTCTC qRT-PCR 
IFNl Fw GCAGGTCAAATCTCTGTCACC qRT-PCR 
IFNl Rv AAGACAGGAGAGCTGCAACTC qRT-PCR 
IRF3 AsiS1 Rv ATAGATGCGATCGCTTAGCTCTCCCCAGGGCCCTGGAAATC PCR 
Linker p65 Fw CCGGACTCAGATCTCGAGAAGACGAACTGTTCCCCCTCATC PCR 
mCherry - p65 linker Fw GGCGGCCGCTCGAGTCTCCGGACTCAGATCTCGAGAAGACGAACTGTTCCCCC PCR 
mCherry - p65 linker Rv GGGGGAACAGTTCGTCTTCTCGAGATCTGAGTCCGGAGACTCGAGCGGCCGCC PCR 
Mcherry 2A overlap Fw CACAGTGGCGGCCGCTCGAGTCACCGGTAGAGCCGAGGGC PCR 
Mcherry 2a Rv GCCCTCGGCTCTACCGGTGACTCGAGCGGCCGCCACTGTG PCR 
mCherry Linker CTCGAGATCTGAGTCCGGAGACTCGAGCGGCCGCCACTG PCR 
mTurquoise Asc1 Fw ATCTATGGCGCGCCATGGGCGTGGCCGACCTGATCAAGAAGTTCG PCR 
mTurquoise IRF3 linker 
overlap Fw 
GGACGAGCTGTACAAGTCCGGACTCAGATCTCGAGAAATGG
GAACCCCAAAGCC PCR 
mTurquoise IRF3 linker 
overlap Rv 
GGCTTTGGGGTTCCCATTTCTCGAGATCTGAGTCCGGACTT
GTACAGCTCGTCC PCR 
mTurquoise IRF3 ovrlp Fw GGCATGGACGAGCTGTACAAGGGAACCCCAAAGCCACGGATCCTG PCR 
mTurquoise IRF3 ovrlp Rv CAGGATCCGTGGCTTTGGGGTTCCCTTGTACAGCTCGTCCATGCC PCR 
mTurquoise linker overlap 
Fw GGACGAGCTGTACAAGTCCGGACTCAGATC PCR 
mTurquoise linker overlap 
Rv GATCTGAGTCCGGACTTGTACAGCTCGTCC PCR 
mVenus Apa1 Rv GCCCGTGGGCCCTTACTTGTACAGCTCGTCCATGC PCR 
mVenus BamH1 Fw ACCCGGGGATCCATGGTGAGCAAGGGCGAGGAG PCR 
p65 AsiS1 Rv ATAGATGCGATCGCTTAGGAGCTGATCTGACTCAGC PCR 
pDONR primer F TCGCGTTAACGCTAGCATGGATCTC PCR 
pDONR primer R GTAACATCAGAGATTTTGAGACAC PCR 
pLV-pwpi promoter module 
1 Fw CGAGCGCTGTGCCTTGGAATGCTAGTT PCR 
pLV-pwpi promoter module 
1 MscI Rv GGTATCGATGTCGACGATAATGGCCA PCR 
pWPI mTurquoise-IRF3 
deltaGAp4446 Fw 
GGATGCACAGCAGGAGGATTTCGGAATCTTCCAGGCCTGGG
CCGAGG PCR 
pWPI mTurquoise-IRF3 
deltaGAp4446 Rv 
CCTCGGCCCAGGCCTGGAAGATTCCGAAATCCTCCTGCTGT
GCATCC PCR 
RIG-I CA delta G-A Fw GATAAGATGGAAACTTCTGACATACAGATTTTCTACCAAGAAG PCR 
 
 
41 
RIG-I CA delta G-A Rv CTTCTTGGTAGAAAATCTGTATGTCAGAAGTTTCCATCTTATC PCR 
Tag-BFP Asc1 Fw ATCTATGGCGCGCCATGAGCGAGCTGATTAAGGAGAACATG PCR 
Tag-BFP p65 ovrlap Fw GCAAACTGGGGCACAAGCTTAATATGGACGAACTGTTCCCCCTCATCTTCCCGGCAG PCR 
Tag-BFP p65 ovrlp Rv CTGCCGGGAAGATGAGGGGGAACAGTTCGTCCATATTAAGCTTGTGCCCCAGTTTGC PCR 
v2 NLS Mcherry overlap Fw CGAAGAAAAAGCGCAAAGTGATGGTGAGCAAGGGCGAGGAG PCR 
v2 NLS mCherry Rv CTCCTCGCCCTTGCTCACCATCACTTTGCGCTTTTTCTTCG PCR 
 
2.10 Viruses  
Table	11	viruses	
Table of Viruses  
Name Origin 
Influenza A virus (SCM35) (DNS1_2A_Gaussia) Martin Schwemmle, University Freiburg 
Influenza A virus (WSN1) Georg Koch, University Freiburg 
Mengo Virus Frank Van Kuppefeld 
Sendai Virus Rainer Zawaztsky, DKFZ 
 
2.11 Bacteria and Bacterial cultures  
Table	12	Bacteria	
Table of Bacteria and Bacterial Cultures 
Name Components 
Ampicillin 100mg/mL in ddH2O, filter sterilised 
E.coli DH5a Chemically competent bacteria 
Gentamycin 50mg/mL (Gibco ®)  
Kanamycin  30mg/mL in ddH2O  
Lysogeny broth (LB) Agar 30 g Bacto-Trypton, 15 g Yeast extract, 15 g NaCl, 15 g Agar in 3 l ddH2O and autoclaved 
Lysogeny broth (LB) medium 50 g Bacto-Trypton, 25 g Yeast extract, 25 g NaCl in 5 l ddH2O and autoclaved 
One Shot® ccdB SurvivalTM 2 T1R 
(Invitrogen) Chemically competent bacteria 
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2.12 Software  
Table	13	software	
Table of Software  
Name Supplier Application 
Bio-Rad CFX Manager Bio-Rad Laboratories, Hercules, California, USA 
qRT-PCR evaluation and 
quantification 
GraphPad Prism 6.0h GraphPad Software, San Diego, California, USA 
Generation of graphs and 
figures 
ImageJ Wayne Rasband, NIH, USA  Western Blot evaluation and figure generation 
INTAS Chemostar INTAS Science Imaging, Göttingen, Germany 
Western Blot image 
acquisition 
Labimage1D INTAS Science Imaging, Göttingen, Germany Western Blot quantification 
SnapGene GSL Biotech LLC, Chicago, Illinois, USA 
Plasmid design and in silico 
cloning 
 
2.13 Equipment 
Table	14	Equipment	
Table of Equipment 
Name Supplier 
Analytical balance LP-3102 VWR International GmbH, Germany 
Analytical fine balance LA-124i VWR International GmbH, Germany 
Biological safety cabinet Safe 2020 Thermo Fisher Scientific, Germany 
C1000 Touch Termal Cycler Bio-Rad Laboratories GmbH, Germany 
Centrifuge 5424 Eppendorf AG, Germany 
Centrifuge 5424 R Eppendorf AG, Germany 
Centrifuge 5810 R Eppendorf AG, Germany 
Centrifuge HeraeusMultifuge 3S-R Thermo Fisher Scientific, Germany 
Centrifuge Sorvall RC-5C plus Sorvall, Germany 
CFX Connect™ Real-Time PCR Detection 
System Bio-Rad Laboratories GmbH, Germany 
CO2 Cell Incubator MCO-20AIC Panasonic Healthcare Co., Ltd., Japan 
CUY900-13-3-5 Cell-Culture-Plate Electrode Nepa Gene co. Ltd., Japan 
ECL ChemoCam imager 3.2 INTAS Science Imaging Instruments, Germany 
Electric Power Supply EPI 500/400 Amersham Pharmacia Biotech, Germany 
ELISA plate reader Multiskan Ex Thermo Fisher Scientific, USA 
Freezer Liebherr Premium Liebherr-International Deutschland GmbH, Germany 
Fridge Med Line Liebherr-International Deutschland GmbH, Germany 
Gel-iX-imager Intas Science Imaging Instruments, Germany 
GenePulser XcellTM Bio-Rad Laboratories GmbH, Germany 
Haemocytometer Brand GmbH, Germany 
Heidolph Duomax 1030 Heidolph Instruments GmbH & Co. KG, Germany 
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HI-2211 Bench Top pH & mV Meter HANNA instruments Deutschland GmbH, Germany 
Ikamag Reo Magnetic stirrer IKA®-Werke GmbH & CO. KG, Germany 
Leica Fluorescence Microscope Leica CTR MIC Leica, Germany 
Microfuge B Beckman, Germany 
Microscope Primovert Zeiss, Germany 
Microwave Oven CLAtronic, Germany 
Mini Trans-Blot® Cell Bio-Rad Laboratories GmbH, Germany 
Mini-PROTEAN® Tetra Handcast Systems Bio-Rad Laboratories GmbH, Germany 
Mini-PROTEAN® Tetra Vertical 
Electrophoresis Cell Bio-Rad Laboratories GmbH, Germany 
Mithras LB 940 Multimode Microplate 
Reader Berthold Technologies, Germany 
Mithras² LB 943 Multimode reader Berthold Technologies, Germany 
Multi-Axle Rotating mixer NeoLab, Germany 
Multi-channel pipette 10-100 Eppendorf, Germany 
Multi-channel pipette 10-300 Eppendorf, Germany 
NanoDrop NP-1000 Thermo Fisher Scientific, Germany 
neoLab Mini Vacuum pump and 
compressor NeoLab, Germany 
Nikon Eclipse Ti Fluorescence Microscope Nikon Corporation, Japan 
Olympus confocal Microscrope Olympus Corporation, Japan 
PerfectBlue™ Gelsystem Mini S VWR International, Germany 
Pipetboy Acu 2 Integra Biosciences GmbH, Germany 
Pipette P10 Eppendorf AG, Germany 
Pipette P1000 Eppendorf AG, Germany 
Pipette P20 Eppendorf AG, Germany 
Pipette P200 Eppendorf AG, Germany 
PowerPacTM Basic Bio-Rad Laboratories GmbH, Germany 
PowerPacTM Hc Bio-Rad Laboratories GmbH, Germany 
ThermoForma Incubator 3862 Labotect, Germany 
Thermomixer Comfort 1.5 ml Eppendorf AG, Germany 
Thermomixer F1.5 Eppendorf AG, Germany 
Trans-Blot® SD Cell Bio-Rad Laboratories GmbH, Germany 
Trans-Blot® Turbo™ System Bio-Rad Laboratories GmbH, Germany 
UV Transilluminator VilberLourmat, Germany 
Vacuubrand BVC professional Vacuubrand GmbH & Co. KG, Germany 
Vortex Genie 2 Scientific Industries Inc., USA 
Waterbath GFL 1083 GFL, Germany 
 
2.14 Consumable materials 
Table	15		Consumables	
Table of General Materials 
Name Supplier 
1,5 ml reaction tube Sarstedt AG & Co., Germany 
10 cm bacteria culture plate Falcon Corning GmbH, Germany 
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12 well cell culture plate Corning GmbH, Germany 
15 ml Falcon Corning GmbH, Germany 
2 ml reaction tube Sarstedt AG & Co., Germany 
24 well cell culture plate Corning GmbH, Germany 
24 well glass bottom cell culture plate In vitro scientific (P24-1.5H-N) 
50 ml Falcon Corning GmbH, Germany 
6 well cell culture plate Greiner Bio-One GmbH, Germany 
96 well cell culture plate Corning GmbH, Germany 
96 well flat bottom plate Corning GmbH, Germany 
Cell scraper Sarstedt AG & Co., Germany 
CELLSTAR® Cell Culture Dishes  6cm Greiner Bio-One GmbH, Germany 
CELLSTAR® Cell Culture Dishes 10cm Greiner Bio-One GmbH, Germany 
CELLSTAR® Cell Culture Dishes 15cm Greiner Bio-One GmbH, Germany 
Cover slips Glaswarenfabrik Karl Hecht GmbH, Germany 
Cryo vials Greiner Bio-One GmbH, Germany 
Extra thick blotting paper Bio-Rad Laboratories GmbH, Germany 
Face mask Rösner-Mautby Meditrade Holding GmbH, Germany 
Filter 0,2 µm GE Healthcare, USA 
Filter 0,45 µm GE Healthcare, USA 
Glas slides SuperfrostTM Thermo Fisher Scientific Inc., USA 
Hard-Shell® 96-Well PCR Plates Bio-Rad Laboratories GmbH, Germany 
Neubauer counting chamber Neolab, Germany 
PVDF Western Blot membrane Bio-Rad Laboratories GmbH, Germany 
Scalpel B. Braun Melsungen AG, Germany 
Sealing sheets PCR plates Bio-Rad Laboratories GmbH, Germany 
Stericup® 0,22 µm Thermo Fisher Scientific Inc., USA 
Stericup® 0,45 µm Millipore, Germany 
Stripetten 2, 5, 10, 25 and 50 ml Corning GmbH, Germany 
Syringe 5, 10, 20 ml BD, Germany 
Tips 10, 100 and 1000, filtered STARLAB GmbH, Germany 
Tips 10, 200 and 1000 µl, refill pack Greiner Bio-One GmbH, Germany 
Tips 10, 200 and 1000, Stecksystem STARLAB GmbH, Germany 
Whatman filter paper GE Healthcare Life Sciences, UK 
XCEED Nitrile Gloves, S Barrier Safe Solutions International, Inc., USA 
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3.0 Methods 
3.1 Cloning and bacterial culturing  
 
3.1.1 Transformation of competent bacteria 
 
100 µL of chemically competent E.coli DH5α bacteria were thawed on ice and mixed 
with 100-500 ng plasmid DNA for retransformations, with 5 µL  of ligation reaction, or 
with the total volume of LR/BP reaction. DNA was incubated with bacteria for 20 min 
on ice followed by 45 sec at 42°C (heat shock). After a recovery period of 2 min on 
ice, 200 µL of LB medium was added and bacteria were incubated on a shaker for 1h 
at 37°C. Bacteria were plated onto LB-agar plates containing restriction antibiotics 
(Ampicillin (0.1 mg/mL), Kanamycin (0.3 mg/mL), Gentamicin (7 µL/mL) or 
spectinomycin (50 µg/mL)). 
 
3.1.2 Plasmid amplification and purification 
 
Plasmid DNA was amplified in E.coli DH5a. Clones were picked from plates and grown 
in LB medium supplemented with plasmid-specific restriction antibiotics overnight at 
37°C while shaking. 
 
3.1.3 Small scale plasmid purification 
 
Transformed bacterial clones were incubated in 3 mL of LB medium containing the 
respective restriction antibiotics. Overnight cultures were centrifuged at 11,000 x g for 
5 mins and LB medium was removed. DNA was purified from bacterial pellets using 
the Nucleospin ® plasmid purification kit according to manufacturer’s instructions. 
Concentrations were determined using the Nanodrop photospectrometer. 
Large scale plasmid purification 
Transformed bacterial clones were pre-cultured for 8 hrs in 9 mL antibiotic-containing 
LB medium. Bacterial cultures were centrifuged at 10,000 x g and plasmid DNA was 
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extracted from overnight cultures using the Nucleobond ® PC 500 plasmid purification 
kit according to manufacturer’s instructions. DNA pellets were resuspended in sterile 
ddH2O and concentrations were determined using the Nanodrop photospectrometer. 
 
3.1.4 Polymerase chain reaction 
 
Polymerase chain reactions (PCRs) were performed using the Q5 ® High-Fidelity DNA 
Polymerase according to the manufacturers protocol: 
Q5 ® PCR reaction mix 
Table	16	PCR	reaction	mix	
Component 50 µL  reaction 
10 mM dNTPs 1 µL  
10 µM Primer fw 2.5µL 
10 µM Primer rv 2.5 µL 
5x Q5 ® GC Enhancer 10 µL 
5x Q5 ® reaction buffer 10 µL 
Nuclease-free ddH2O ad 50 µL 
Q5 ® High-Fidelity Polymerase 0.5 µL 
Template DNA variable (~ 100 – 500 ng) 
 
PCRs using the Q5® High-Fidelity polymerase were incubated according to the 
following protocol. 
Q5 PCR program: 
Table	17	PCR	program	
Step Temperature (°C) Seconds Cycles 
Initial denaturing 98 30 1 
Denaturing 98 5 – 10 25 
Annealing 50 - 72 10 – 30 25 
Elongation 72 20 – 30 25 
Final elongation 72 120 1 
 
PCR products were resolved on 1% agerose gels and purified using the PCR and Gel 
clean up kit.  
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3.1.5 Overlap-extension PCR 
 
In order to combine two ssDNA fragments into one dsDNA fragment of a given 
sequence, overlap-extension PCR was carried out. For the combining of two ssDNA 
fragments, the two respective dsDNA fragments were amplified together using the 
PCR protocol described previously, however, the 5’-3’ ssDNA (sense orientation) 
fragment produced from the first dsDNA fragment during the PCR protocol was 
designed to overlap with the 3’-5’ ssDNA (antisense orientation) from the second 
dsDNA fragment, which was produced during the PCR protocol. Fw and Rv primers 
specific for the 5’ end of the sense strand and the 3’ of the antisense strand allowed 
for the amplification of a single strand of dsDNA which would be the combination of 
two dsDNA fragments. The PCR fragments were resolved on a 1% agarose gels to 
confirm the correct height of the product. Products were then purified from the gel 
using the using PCR and Gel clean up kit and eluted in 30 µL ddH2O. The final PCR 
product was either ligated into a specific vector or used for BP recombination by 
Gateway® cloning technology. 
 
3.1.6 GatewayTM cloning 
 
GatewayTM cloning is a system that employs a two-step selection reaction to generate 
recombinant DNA plasmids. Firstly, it is used to shuttle any PCR product or gene of 
interest into a vector known as an "entry vector”. From this entry vector the PCR 
product/gene of interest can be shuttled, in one reaction step, from the entry vector 
into a variety of template destination vectors. These destination vectors allow for the 
rapid generation of recombinant plasmids that are equipped with various tags from 
different vector systems. The BP reaction (first step) mediates the recombination of 
PCR fragments flanked by attB sites into pDONR vectors harbouring attP sites. This 
reaction results in an entry vector containing the PCR product/gene of interest flanked 
by attL sites. As a side product, a linear fragment (encoding for bacterial toxin ccdB) 
is removed from the vector. In case of a non-successful recombination bacteria 
transformed with non-recombined pDONR plasmids will express the ccdB gene and 
die, thereby selecting for positive colonies. pDONR vectors can be used in an LR 
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reaction to shuttle the gene of interest into a destination vector (pDEST) that again 
harbours the ccdB gene flanked by attR sites. As with the pDONR vector, non-
recombined pDEST will be negatively selected by the expression of the ccdB gene.  
 
3.1.6.1	Generation	of	entry	clones	(BP	reaction)	
 
Primers were designed which harboured the attB sites necessary for recombination. 
A start codon was added to the fw primer and a stop codon to the rev primer. 
 
Table	18	GW	primers	
Name Sequence 5’ – 3’ 
attB fw GGGGACAAGTTTGTACAAAAAAGCAGGCTTC 
attB rev GGGGACCACTTTGTACAAGAAAGCTGGGTC 
 
By PCR amplification attB-flanked inserts were generated, separated on a 1% agarose 
gel and purified. DNA inserts were resuspended in 30 µl ddH2O. BP reactions were 
set up according to the following protocol. 
 
Table	19	GW	reaction		
Component 10 µL reaction 
pDONR/pENTR 150 ng 
attB-flanked Insert 150 ng 
BP clonase 1 µL 
1x TE buffer To 10 µL 
 
BP reactions were incubated for at least 2 hrs at 25°C and subsequently transformed 
into competent DH5a bacteria. Successful BP cloning was visualised by digesting 
pDONR plasmids with BsrGI which, due to cutting both recombination sites and the 
vector backbone, generated three specific fragments. Plasmids were sequenced to 
ensure the desired sequence was amplified. 
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3.1.6.2	Generation	of	expression	clones	(LR	reaction)	
 
LR reactions were carried out by combining desired destination vectors with generated 
pDONR vectors. LR reactions were set up according to the following protocol. 
 
Table	20	GW	shuttling	
Component 10 µL reaction 
pDONR/pENTR 150 ng 
pDEST 150 ng 
LR clonase 1 µL 
1x TE buffer ad 10 µL 
 
LR reactions were incubated for at least 2 hrs at 25°C and subsequently transformed 
into competent DH5a bacteria. Successful LR cloning was visualised by digesting 
pDEST plasmids with BsrGI which, due to cutting both recombination sites, generated 
two specific fragments. Plasmids were sequenced to ensure the desired sequence 
was cloned. 
 
3.1.7 Sequencing analysis of plasmid DNA 
 
Purified plasmid DNA was diluted to 100ng/µL. 5µL of the plasmid was mixed with 
5mL of 5μM sequencing primer. The DNA/primer mixture was sent to GATC Biotech 
Ltd. for LIGHTrun ® sequencing. The returned sequence was analysed using the 
Snapgene ® program.  
 
3.2 Cell Culture  
 
3.2.1 Cell culturing 
  
All cell lines were cultured in DMEM+++ (standard cell culture medium) and kept at 37 
°C, 95% relative humidity, and 5% CO2. For passaging cell lines, medium was 
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removed and cells were washed with 1X PBS. Cells were detached by adding Trypsin-
EDTA and incubating for up to ~5 min at 37°C. Detached cells were washed off the 
dish using FCS containing DMEM to halt trypsinisation, diluted to desired 
concentration, and added to a new cell culture dish. Cells were passaged before 
confluency was reached. Stable expression of recombinant plasmids within cell lines 
were grown in presence of 1 mg/mL G418, 5 µg/mL puromycin, µg/mL zeocin and/or 
5 µg/ml blasticidin, respectively, unless stated otherwise for a specific cell line. 
 
3.2.2 Cryopreservation of mammalian cells  
 
For the cryopreservation of mammalian cells, a confluent 15 cm dish was detached as 
described previously. Detached cells were spun down and resuspended in 9 ml fetal 
calf serum containing 10% DMSO which was distributed to 9 cryovials before they 
were stored at -80°C for at least 48h. For long term storage cells were then transferred 
to liquid nitrogen (-180°C). Revival of mammalian cells was achieved by quickly 
thawing contents of cryovials. Semi-thawed cells were added to pre-warmed standard 
cell culture medium and incubated until they had attached to the plate. Medium was 
changed to remove DMSO the following day.  
 
3.2.3 Determining cell numbers in solution  
 
From a cell suspension, the number of cells per mL was determined by using a 
hemocytometer. 10µL of single cell suspension were loaded to the chamber and living 
cells (determined by morphology) within the four large quadrants were counted using 
an inverted light microscope. Given that the space over each quarter section has a 
defined volume of 0.1 µL, the number of counted cells multiplied by 10,000 and divided 
by 4 is the number of cells per mL. 
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3.2.4 Transfection of recombinant DNA 
 
3.2.4.1	Lipofectamine	2000	®	
 
Cells were transfected with recombinant DNA plasmids for transient expression of 
specific genes of interest using lipofectamine 2000 ® reagent mixed with OptiMEM. 
For a 24-well format, per well, 1 µL of lipofectamine 2000 ® mixed with 49 µL of 
OptiMEM, and separately, up to 1000 µg of the respective recombinant DNA plasmid 
mixed to a total volume of 50 µL OptiMEM. These mixtures were allowed to warm to 
room temperature and after 5 mins, the lipofectamine 2000 ® mixture was combined 
with the DNA mixture and incubated for a further 20 mins. During this incubation time, 
a media change was carried out for the target cells, fresh DMEM+-+ was added to 
each target well and allowed to warm to 37°C. Finally, 100 µL DNA/lipofectamine 2000 
® mixture was added to a single 24-well. The target cells were incubated with the 
transfection reagent mixture for at least 6 hours before changing media again to 
DMEM+++. Expression of the recombinant gene of interest can then proceed.  
 
3.2.4.2	jetPEI	®		
 
Cells were transfected with recombinant DNA plasmids for transient expression of 
specific genes of interest using jetPEI ® reagent mixed with 150 mM NaCl. For a 24-
well format, per well, 8 µL of jetPEI ® mixed with 42 µL of 150 mM NaCl, and 
separately, up to 2000 µg of the respective recombinant DNA plasmid mixed to a total 
volume of 50 µL 150 mM NaCl. These mixtures were allowed to warm to room 
temperature and after 5 mins, the jetPEI ® mixture was combined with the DNA 
mixture and vortexed for 5 secs and then incubated for a further 20 mins. During this 
incubation time, a media change was carried out for the target cells, fresh DMEM+-+ 
was added to each target well and allowed to warm to 37°C. Finally, 100 µL DNA/ 
jetPEI ® mixture was added to a single 24-well. The target cells were incubated with 
the transfection reagent mixture, no media change is required. Expression of the gene 
of interest can then proceed.  
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3.2.5 Transduction of recombinant DNA 
 
3.2.5.1	Lentiviral	mediated	stable	integration	of	recombinant	DNA			
 
Stable indiscriminate expression of a gene of interest was achieved by lentiviral 
transduction of target cells. Lentiviral particles were produced by a combination 
transfection of a lentiviral vector (e.g pWPI containing the gene of interest), with two 
packaging plasmids (gag-pol and VSV-G expression plasmid). Lentiviral particles 
were produced in 293T cells, harvested, and used to infect target cells. To produce 
lentiviral particles 0.8x106 293T cells were seeded in a 6cm dish. Medium was 
changed the next day and cells were transfected with pWPI lentiviral vector, gag-pol 
(psPAX2) and VSV-G expression plasmid (pMD2.G) using CalPhos™ Mammalian 
transfection kit. 6.4 µg pWPI, 6.4 µg psPAX2 and 2.1 µg pMD2.G were diluted in a 
final volume of 438 μl sterile H2O and 62 µL 2M CaCl2 were added on top. 500 µL 2X 
HBS were added drop wise to the mix while air was blown into the liquid to provide 
oxygen aiding precipitate formation. The transfection mix was added slowly and drop-
wise to 293T cells. 8 hrs post transfection medium was changed. 48 hrs after 
transfection supernatants were collected and passed through a 0.45 µm-pore filter to 
prevent contamination with particle producing 293T cells. Filtered supernatants were 
added onto target cells that were seeded the day before. Supernatants of transfected 
293T cells were harvested again after 8 hrs and 24 hrs and handled the same way as 
described above. After 1-3 rounds of target cell infection the medium was replaced 
with standard cell culture medium containing the appropriate restriction antibiotic. 
Antibiotics were kept while passaging stable cell lines, as described previously, to 
ensure constitutive expression of the gene of interest, unless experiments were 
performed on the target cells.  
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3.2.6 In vitro transcription 
 
In vitro transcription of RNA was carried out using T7 RNA polymerase to transcribe 
RNA from DNA using the following reaction mixture:  
Table	21	in	vitro	transcription	of	RNA	
Component 50 µL  reaction 
25 mM rNTPs 12 µL  
5x buffer RRL 20µL 
RNAsin (40U/µL)  2.5µL 
T7 RNA polymerase 4 µL 
DEPC treated ddH2O 51.5 µL 
Template DNA variable (~ 500-1000 ng) 
 
 
3.2.7 Generating Double Stranded RNA 
 
Double stranded RNA (dsRNA) was generated using the TLR3 template DNA. Primers 
were designed to amplify the sense and antisense orientation of the specific sites 
within the TL3 DNA sequence, using various positions of annealing, different lengths 
could be generated. The primers used generated two sets of dsDNA with lengths of 
100, 200, and 400 base pairs. These dsDNA fragments were used as templates for In 
vitro transcription of ssRNA fragments (described previously). The ssRNA fragments 
from both dsDNA templates are complimentary for each other, the resulting products 
of the In vitro transcription are mixed together in a 1:1 ratio. This mixture is then mixed 
again in a 1:1 ratio with annealing buffer (see materials). This mixture is incubated at 
98°C for 1 min, the heat is turned off and allowed to slowly cool until room temperature 
is reached. The dsRNA that is the product of the annealed ssRNA fragments was 
purified by size exclusion chromatography by Dr. Stefan Seitz, Molecular Virology, 
Heidelberg University, Heidelberg.  
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The following primers were used to amplify specific segments of the TLR3 gene 
sequence (1=Fw primer, 2=Rv primer, S=Sense, A=antisense):  
Table	22	dsRNA	primers	
Primer  Sequence 
Primer T7 TAATACGACTCACTATAGGGAGATGCTTTCTCTTGGTTGGGC 
Primer T7.2  GGGAGATGATGCTTTCTCTTGGTTGGGC 
1S40 GGGAGATAGGTGGCCCAACCAAGAGAAAGCATCATCTCCCTATAG 
1A40 TAATACGACTCACTATAGGGAGATGATGCTTTCTCTTGGTTGGGC 
2S40 GGGAGATGATGCTTTCTCTTGGTTGGGCCACCTATCTCCCTATAG 
2A40 TAATACGACTCACTATAGGGAGATAGGTGGCCCAACCAAGAGAAA 
1-100 GGGAGATCTCCATTCCTGGCCTGTGA 
2-100 TAATACGACTCACTATAGGGAGATCTCCATTCCTGGCCTGTGA 
1-200 GGGAGAGCATCAGTCGTTGAAGGCTTG 
2-200 TAATACGACTCACTATAGGGAGAGCATCAGTCGTTGAAGGCTTG 
1-400 GGGAGAACCACCAGGGTTTCGCTGTTT 
2-400 TAATACGACTCACTATAGGGAGAACCACCAGGGTTTGCGTGTTT 
 
3.3 Biochemical and Molecular Biological Assays 
 
3.3.1 Protein Complementation Assay  
 
3.3.1.1	PCA	Constructs		
 
Developing the constructs for the application of protein complementation assay (PCA) 
involved the separation of Gaussia princeps luciferase (GLuc) protein into two 
fragments, N1 and N2, where by N1 corresponds to amino acids 1-93, and N2 
corresponds to amino acids 94-169, excluding the 16 amino acids of the N terminal 
end that correspond to the secretion signal sequence. GLuc N1 and GLuc N2 are then 
tagged by way of GatewayTM cloning (described previously) to pairs of proteins of 
interest, such that protein X is linked to GLuc N1 and protein Y is linked to GLuc N2. 
Sequence identity is confirmed prior to application.  
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3.3.1.2	Assay	procedure		
 
To preform PCA, two constructs pertaining to the proteins of interest, linked to GLuc 
N1 and GLuc N2 respectively, are transfected into 293T cells using a 96-well format, 
with 3x104 cells seeded per well and cultivated in 100 µL DMEM +++. It is essential to 
ensure even distribution of cells within the 96-well. This is most easily achieved when 
seeding the cells by stabilising the plate flat and horizontal and to move swiftly and 
thoroughly back and forth. Then, rotating the plate on its axis so that it is now still flat, 
but vertical in comparison, preforming the same shaking manoeuvre as before 
achieves a perfect distribution of the cells within the 96-well. Optimal transfection 
conditions involve the application of the jetPEI ® transfection reagent protocol, 
combining 100ng of the respective proteins of interest linked GLuc N1 and GLuc N2 
DNA plasmids for a total transfection of 200ng DNA per well. The cells can then be 
incubated for 24-96 hours, however, 48 hours was chosen as the optimal length of 
incubation time. To control for random interaction of the respective proteins, GLuc N1 
linked to no protein is co-transfected with GLuc N2 linked to the protein of interest, and 
separately, the reverse is also applied (GLuc N2 linked to no protein, GLuc N1 linked 
to protein). Each condition, of which there are three (X-GLuc N1 + Y-GLuc N2, Empty-
GLuc N1 + Y-GLuc N2, X-GLuc N1 + Empty-GLuc N2), is performed in triplicate on 
the 96-well plate as described previously, the inclusion of these “empty” partner 
controls allow for the calculation of the normalised luminescence ratio (NLR) outlined 
by Madden et al, 2011 (REF#). The NLR is the basis on which the protein:protein 
interaction is analysed, a high NLR compared to negative control suggests a strong, 
rapid, or stable interaction (due to the transient nature of full GLuc reconstitution).  
To optimise the sensitivity of NLR acquisition, it is essential to perform a kinetics 
assay, whereby the luminescence ratio is measured every 0.1-1 secs post substrate 
addition for up to 600 secs. The time at which the peak NLR is reached will vary slightly 
from PPI to PPI, and may greatly affect positive signals. Furthermore, it is essential to 
measure the luminescence using a high sensing filter for the emission wavelength of 
Gaussia princeps luciferase post substrate addition, as this too, increases the 
sensitivity of NLR acquisition. Additionally, several parameters were examined that 
failed to alter the sensitivity of the assay to any meaningful extent; lysis conditions, not 
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lysing the cells, substrate concentration/saturation, alternative cell line origins, and 
alternative substrate derivatives. 
 
3.3.2 Luciferase Assay  
 
On day 0, cells are seeded on a 24-well format (0.75-1.5x105 cells/well). On day 1, 
cells are transfected using the Lipofectamine 2000 ® protocol described previously. 
The DNA reporter plasmids (Firefly-IFIT1 and Renilla-SV40) are co transfected. 9 
hours later cells were stimulated either by poly(I:C), or plasmid transfection, or by SeV 
infection (MOI 5). If not indicated otherwise, cells were stimulated for 16h before 
medium removal and lysis in 100 µL/24-well luciferase lysis buffer (day 2). Plates can 
be stored at -80°C until measurement.  Samples were measured using Mithras² LB 
943 Multimode reader or Mithras LB 940 Multimode Microplate Reader. Measuring 
Firefly-IFIT1 based luminescence was achieved using luciferase assay buffer 
supplemented with 1:20 D-luciferin stock solution, 1:100 100 mM ATP and 1:1000 1 
M DTT (see materials). Additionally, the Renilla substrate, Coelenterazine, was diluted 
1:700 in luciferase assay buffer to measure Renilla-SV40 based luminescence. 
Enzymatic reactions were halted using the addition of 10% SDS.  
24-well plates were measured using the following protocol on a well-by-well basis, and 
each sample was performed in triplicate: 
 
Table	23	luciferase	assay	protocol	
Luciferase Assay Program 
Action Procedure 
Dispense firefly substrate 4x100 µL 
Shake 2 sec 
Measure (No filter) 10 sec 
Dispense Renilla substrate 4x100 µL 
Shake 2 sec 
Measure (480nmBRET-hisense filter) 10 sec 
Dispense 20% SDS 100 µL 
Shake 2 sec 
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3.3.3 Western Blot 
  
3.3.3.1	 Sodium	 Dodecyl	 Sulphate	 Polyacrylamide	 Gel	 Electrophoresis	
	
Sodium Dodecyl Sulphate polyacrylamide gel electrophoresis (SDS PAGE) resolving 
gels containing 6-15% polyacrylamide (PAA) were prepared using 40% 
acrylamide/bisacrylamide (ratio 29:1) stock solution diluted in resolving gel buffer (see 
materials). N,N,N',N'-Tetramethylethylenediamine (TEMED) and saturated 
ammonium peroxydisulfate (APS) solution were added (1:500 each) to initiate the 
polymerisation reaction. The Solution was immediately cast using the Mini-
PROTEAN® Tetra Handcast System (Bio-Rad) and carefully overlaid with 100% 
isopropanol to ensure a level and consistent resolving gel portion. 4% PAA stacking 
gel solution was prepared using 40% acrylamide/bisacrylamide (ratio 29:1) stock 
solution diluted in stacking gel buffer. TEMED and APS supplemented gel solution 
was cast on top of the resolving gel after residual isopropanol was removed, and 
specific combs (either 10-well or 15-well) were used to form the stacking gel portion. 
Cell lysates for protein sample analysis were extracted using either a final 
concentration of 2X Laemmli buffer, or RIPA buffer supplemented with protease 
inhibitors (see materials). Samples in RIPA buffer were immediately frozen, thawed 
and debris was pelleted by centrifugation at full speed for 10 min.  
Cells with DMEM --- were mixed with 6X Laemmli to a final working concentration of 
2X in order to immediately lyse whole cells for protein analysis. Protein samples were 
denatured by boiling for 5 min at 95°C, unless stated otherwise. If necessary, samples 
were treated with Benzonase ® prior to gel loading. Equal volumes of samples were 
loaded into each lane within the SDS-PAGE gels. A lane with pre-stained protein 
marker was included to determine size of detected proteins (see materials). Gels were 
run in 1X TGS buffer for 30 min at 70-80V and 1 – 1.5h at 125V, or until proteins were 
adequately resolved.  
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3.3.3.2	Western	Blot	Electrophoresis		
 
SDS-PAGE gels with resolved proteins embedded in the gel were transferred to a 
Western Blot chamber (see materials). The gels were transferred onto a membrane 
(PVDF (requires Methanol or ethanol activation) or nitrocellulose), and separated from 
the housing cassette by filter paper and sponges.  The proteins were subsequently 
transferred to the membrane using electrophoresis by applying a constant ampage of 
0.3 A, which resulted in a variable voltage of between 40-60 V. Transfers of protein 
was carried out for 2 hours under these conditions. Western Blot transfers were carried 
out using 1X wet transfer buffer supplemented with 20% methanol. 
  
3.3.3.3	Western	Blot	staining		
 
Protein transferred to either PVDF membranes or Nitrocellulose membranes were 
stained using specific primary antibodies to visualise and quantify proteins of interest. 
To achieve this, PVDF membranes were taken directly after transfers and soaked in 
100% methanol for 5 seconds. The membranes were then hung to dry until no longer 
translucent. Once dried, membranes were rehydrated using 80% ethanol, and washed 
3x using wash buffer (1X TBS/PBS 0.2% Tween-20). For Nitrocellulose membranes, 
the membranes were directly transferred to blocking buffer after transfers were 
completed and incubated for 2 hours at room temperature, and subsequently wash 3x 
5mins with the appropriate wash buffer. Membranes were then incubated overnight at 
4°C with the primary antibody (see materials for list) in either 1X TBS with 5% BSA 
and 0.2% tween-20 or 1X PBS with 5% Milk and 0.2% tween-20. Membranes were 
then washed 3x 5mins with the corresponding wash buffer before applying the 
appropriate secondary antibody for 2 hours at room temperature or overnight at 4°C. 
The membrane was again washed 3x 5mins with the appropriate wash buffer. Western 
Blots were then developed using the ECL Western Blot detection solution (see 
materials) to induce chemiluminescence whereby proteins of interest were imaged by 
Intas ChemoCam ECL imager and quantification could be consequently carried out.  
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3.3.3.4	Western	Blot	Quantification		
 
Proteins of interest were quantified in terms of their expression levels for specific 
samples by their luminescence signal strength that was imaged, as described 
previously, using Lab Image 1D software. Quantification of samples includes the 
protein of interest, and additionally an appropriate general protein to act as a sample 
loading control, these loading control proteins include GAPDH, b-Actin, g-Tubulin, and 
Calnexin.  
 
3.3.4 Synchronised Dynamics Analysis 
 
3.3.4.1	Synchronised	Dynamics	Sample	Acquisition	
 
In order to measure the dynamics of proteins of interest, quantitative Western Blotting 
must be applied. The problem, dynamics, arises when comparing samples over a time 
course, this is negated by using a synchronised grouped cell response system. The 
following methodology describes the approach to synchronising PRR (in this case 
RIG-I) mediated signal transduction and harvesting protein for quantitative Western 
Blot analysis. 12x106 A549 cells are harvested for each experiment. The cells are 
centrifuged and resuspended in 1.2 mL cytomix buffer containing 2mM ATP and 5mM 
Glutathione (see materials). The cytomix cell suspension is distributed into 3 0.4cm 
electroporation cuvettes (Bio-rad). Each cuvette contains 400 µL of the cytomix cell 
suspension. Prior to adding the cell suspension to each cuvette, 0.8 pmol of purified 
dsRNA of a defined length is added to each cuvette (2 nM). Each cuvette is entered 
into the CE module of the Bio-rad GenePulser XcellTM electroporator. The cuvette is 
pulsed with an electrical current for 10 ms (150V exponential decaying pulse), 
immediately proceed with the next cuvette to be electroporation, and once all are 
pulsed, take up all the cells in the cytomix with a glass pipette tip and transfer to a 15 
mL Falcon containing 2 mL DMEM +--. It is absolutely essential that this media is pre-
warmed to 37°C. Once the pulsed cells have been transferred, quickly distribute the 
cells in a pre-warmed 37°C cell culture plate, according the experimental design. For 
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short, fine time courses, cells were distributed into 14 wells of a 24-well plate (200 µL 
per well). In order to take a 0 hour time point, 200 µL is immediately added to a 1.5 
mL eppindorf tube containing 100 µL 6X Laemmli buffer for a final concentration of 2X 
Laemmli buffer, containing whole cell lysate. The plate is incubated at 37°C. Heat 
management must be carefully maintained/regulated. For each time point where 
protein must be harvested, 100 µL 6X Laemmli buffer is added to the well in question 
and whole cell lysate is transferred to a 1.5 mL eppindorf tube. All samples are then 
denatured at 95°C for 5 mins, whereby they can then be loaded on to an SDS-PAGE 
gel for Western Blot analysis. Samples can be kept frozen at -20°C for an extended 
period of time (>1 year).  
 
3.3.5 Live Synchronised Cell Imaging  
 
Fluorescently labelled proteins stably expressed in cells can be imaged in terms of 
their localisation over time using a synchronisation approach. A cell culture plate 
electrode (see materials) purchased from Nepa Gene company was modified to be 
compatible with the Bio-rad GenePulser XcellTM electroporator. 0.75x105 A549 cells 
stably expressing eGFP-IRF3 and mCherry-RelA were seeded on high performance 
cover glass bottom black 24-well plates (In vitro scientific). The following day the media 
is removed and cells are stained with Hoechst 33258 (see materials) for 10 mins at 
room temperature at a dilution of 1:10000 in 1X PBS. Cells are wash with 1X PBS and 
fresh media is added and the plate is placed back into the incubator to bring the cells 
back  37°C . After 30 mins, the media is removed and 100 µL cytomix buffer is added 
on the cells. 0.1-1pmol dsRNA of a defined length is added to the cytomix buffer and 
carefully shaken back and forth to ensure even coverage of the buffer on the cells. 
The in-well electrode is placed in position in the well and steadily held while the 
electrical pulsing program is initiated. The in-well electrode pulses the cells with 150V 
for 10 ms with the block pulse protocol. Immediately after pulsing the cells, pre-
warmed microscope media (37°C) is added on the cells and the plate is placed in the 
microscope incubator for live cell imaging (at 37 °C, 95% relative humidity, and 5% 
CO2). Imaging of the 405 nm w/v, 488 nm w/v, and 565 nm w/v channels are carried 
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out every 0.5-2 mins using the Olympus FV1000 confocal microscope to determine 
the localisation of the tagged proteins over time, in a synchronised manner.     
 
3.3.6 ELISA 
 
ELISA (enzyme linked immunosorbent assay) was used to measure the production of 
IFNb/l. The follow protocol pertains to IFNb (LumiKineTM, invivogen) and incubation 
times may differ for IFNl. Capture antibodies diluted in 1X PBS were incubated 
overnight at room temperature on the appropriate 96-well plate. Excess liquid was 
removed and the plates were dried by gently patting the plate on paper towels. 
Blocking buffer (5% BSA 0.05% Tween-20) was then added to each well and 
incubated for 2 hours at 37°C. This solution was removed and the plate dried as 
described previously. Samples, including standards, were appropriately diluted in 
reagent diluent (see materials/manufacturers protocol), and added to coated wells of 
the plate. The samples and standard were incubated for 2 hours at 37°C. each well 
was then washed 3x using wash buffer (1X PBS 0.05% Tween-20) and the plate was 
dried as described previously. A linked detection antibody, in the case of IFNb, a 
biotinylated detecting antibody is incubated for 2 hours at 37°C. Samples are washed 
again as before, and finally the signalling antibody is incubated for 30 mins at 37°C 
before a final washing step. The plate can now be measured for the abundance of the 
protein of interest relative to the standard, using the appropriate measuring instrument.  
 
3.3.7 RNA and quantitative PCR 
 
3.3.7.1	RNA	isolation		
 
RNA isolation was performed using the Nucleospin ® RNA Plus kit according to the 
manufacturer’s instructions. Cells were washed with 1X PBS prior to lysis in LBP 
buffer. Lysates were stored at -80°C until RNA extraction. Purified RNA was 
resuspended in nuclease-free ddH2O and used for ExpandTM RT or cDNA preparation 
for quantitative Real-Time PCR. Reverse transcription was performed using the High 
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Capacity cDNA Reverse Transcription kit (Applied Biosystems). Reaction mixes were 
prepared according to the following protocol: 
 
Table	24	A	and	B	cDNA	synthesis	protocol	
Component 6.6 µL reaction 
100 mM dNTPs 0.25 µL 
10X random hexamer primers 0.66 µL 
10X reaction buffer 0.66 µL 
Nuclease-free H2O 1.07 µL 
Reverse Transcriptase 0.33 µL 
Isolated RNA 3.3 µL 
RNase inhibitor 0.33 µL 
 
 
 
 
 
All cDNA samples were diluted with ddH2O 1:20 or 1:10 depending on the yield. 
 
3.3.7.2	Quantitative	Real-Time	PCR	
 
Quantitative Real-Time PCR (qPCR) was performed using the iTaqTM Universal SYBR 
® Green Supermix and a Bio-Rad CFX Connect™ Real-Time PCR Detection System 
(see materials). All samples were measured in triplicates. Non-amplification and non-
target controls were included to control for specific amplification. 
qPCR reactions were prepared and carried out from each cDNA sample as previously 
described according to the following protocols: 
 
Table	25	A	and	B	qPCR	protocol		
Component 15 µL reaction 
2x iTaq SYBR® Green 7.5 µL 
cDNA sample  3 µL 
Nuclease-free H2O 1.5 µL 
Primer fw 1.5 µL 
Primer rev 1.5 µL 
 
Temperature (°C) Time 
25 10 min 
37 2 hrs 
85 5 min 
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Step Procedure Description 
1 95°C 3 min 
2 95°C 10 sec 
3 60°C 30 sec 
4 Quantify - 
5 Continue from Step 2 45 cycles 
6 65°C increase to 95°C 0.5°C/0.05 sec  
7 Measure every 0.5°C - 
 
qPCR data was analysed using the Bio-Rad CFX Manager software. Relative mRNA 
expression was calculated using the 2-DDCt method as described in REF#(find in Julia 
thesis) 
 
3.3.8 Illumina HumanHT-12 Chip expression profiling  
 
RNA was harvested according to section 3.3.7.1 using the synchronised stimulation 
approach described in section 3.3.4. Samples were generated in duplicate for A549 
wild type cells, and in addition, A549 IFN alpha/lambda Receptor knock-out cells, and 
sent to the Genomics and Proteomics core facility of the DKFZ in Heidelberg, 
Germany, where illumine Human HT-12 chips were used to analyse the expression 
mRNAs across the genome in response to dsRNA, over 24 hours with time intervals 
of 0, 1, 2, 4, 6, 8, 12, 18, and 24 hours.  
 
3.3.9 Proteome analysis   
 
2.4x107 A549 wild type cells were resuspended in cytomix containing ATP and 
glutathione, and evenly divided into 9 cuvettes. Cuvettes were each rapidly 
electroporated in the presence of 2 nM 400 bp dsRNA (taking 1min 57s). cells were 
transferred to 37°C media (totalling 9mL) and seeded evenly between 3 6cm cell 
culture dishes. At each specific time point, cells were harvested from 6cm dishes by 
forcefully pipetting 4°C sterile 1X PBS until all cells were lifted, cells were then spun 
down at 300 x g for 3 min, supernatant was removed and cell pellet was snap frozen 
in liquid nitrogen for storage at -80°C. 
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4.0 Results 
This study attempts to enhance our fundamental understanding of the antiviral 
signalling network through the characterisation of the regulation RIG-I signalling, and 
the characterisation of the dynamics of the RIG-I signalling events in response to the 
detection of dsRNA. Toward this, and taking into account the major role that 
ubiquitination has on the regulation of RIG-I signal transduction, as discussed 
previously, we designed an siRNA based screen that targeted a fully annotated list of 
functional and putative E3 ubiquitin ligases to determine the impact they had on the 
activation of IRF3 and NFkB. For the characterisation of the dynamics of RIG-I 
signalling, we sought to understand whether RIG-I signalling was indeed stochastic, 
as had been reported, and to characterise the kinetics of individual steps within the 
network in order to generate the fundamental data that could be used to build a 
mathematical model. Furthermore, we sought to understand the strict dependence 
ISGs had on the RIG-I/IRF3 signalling pathway and the IFN/JAK/STAT signalling 
pathway, we further hypothesised that these ISG inductions might differ in their 
kinetics and amplitudes depending on whether IFN/JAK/STAT signalling was present.  
This, we sought to characterise the kinetics of the host cellular responses triggered by 
the detection of dsRNA in extensive detail, and providing an excellent background for 
which mathematical modelling can be applied in order to quantitatively describe the 
molecular events involved in antiviral signalling, which will represent a strong tool to 
study the foundations of molecular basis for successful/unsuccessful viral infections.  
  
4.1 Identifying novel regulators of the RIG-I signalling network  
 
In order to identify novel regulators of the RIG-I signalling pathway, a robust read-out 
for activation of the signalling pathway needed to be developed. Initially, an ambitious 
project was planned to develop a cell line that would act as a multispectral read out 
for distinct aspects of RIG-I activation, using a five-channel fluorescence read-out. The 
initial cell line being developed would include the transcription factors IRF3 and NFkB 
fused to respective fluorescent proteins. In addition to this, a constitutively active 
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recombinant RIG-I protein (RIG-I2CARD), fused a fluorescent protein tagged with a 
nuclear localisation signal (NLS), but separated by a 2A signal sequence, would be 
used (Figure 4.1.1A). Thus, active RIG-I (and by extension the number of activated 
cells) could be quantified by measuring fluorescence in the nucleus. Upon initial testing 
it was observed that the NLS-mCherry-2A-RIG-I2CARD construct was successful in 
activating the RIG-I signalling cascade when transfecting Huh7.5 cells expressing 
IRF3-eGFP, and furthermore, was quantifiable (mCherry fluorescent signal in the 
nucleus) (Figure 4.1.1 B) 
 
Figure 4.1.1 RIG-I induction construct 
  
 
Figure 4.1.1: Constitutively active RIG-I construct. A) Graphic showing the 
recombinant gene construct of the pWPI plasmid comprising of the nuclear localisation 
signal tagged fluorescent protein mCherry, separated from the constitutively active 
form of RIG-I (RIG-I2CARD) by the cleavage signal site 2A. B) Proof of concept of the 
NLS-mCherry-2A-RIG-I2CARD functioning as intended in Huh 7.5 cells stably 
expressing RIG-I and IRF3-eGFP. Activated cells can be differentiated from non-
activated by either a cytoplasmic IRF3-eGFP signal (inactive) or a nuclear IRF3-eGFP 
signal (active). Activation is due to the expression of RIG-I2CARD and can additionally 
mCherry-NLSIRF3-eGFP Merged Channels
A
B
NLS-mCherry-2A-RIG-I 2CARD
2CARD
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be marked by the nuclear signal of mCherry fluorescence, which overlaps with 
activated IRF3-eGFP signal. 
 
This construct was overexpressed in the A549 cell line already overexpressing IRF3-
eGFP. NLS-mCherry-2A-RIG-I2CARD was stably expressed in this cell line with a 
transactivator that would only activate expression in the presence of doxycycline (Tet-
on system). This is due to a tet-response element (TRE). A TRE is 7 repeats of a 19-
nucleotide tetracycline operator (tetO) sequence, and is specifically recognized by the 
tetracycline repressor (tetR) which is stably co-expressed with NLS-mCherry-2A-RIG-
I2CARD. Endogenously, if doxycycline/tetracycline are present, tetR will bind to 
doxycycline and not to the TRE and therefor allowing transcription to proceed.  
Western Blotting shows the construct is technically functional in the A549 cells, such 
that mCherry (~27 kDa) separates from RIG-I2CARD (~29.7 kDa) due to the 2A signal 
sequence, and that it is specifically induced upon treatment with doxycycline (Figure 
4.1.2 A), however expression of the recombinant gene(s), using increasing 
concentrations of doxycycline, appeared to not reach a high enough threshold in order 
to activate the RIG-I signalling cascade, despite the mCherry nuclear fluorescent 
signal (Figure 4.1.2 A). This was not overcome by increasing the gene copy numbers 
within the cells and was subsequently removed from the reporter cell line generation 
project entirely (Figure 4.1.2 B).  
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Figure 4.1.2 RIG-I2CARD induction 
 
 
 
 
 
Figure 4.1.2: Specific induction of NLS-mCherry-2A-RIG-I2CARD. A) A549 cells stably 
expressing the transactivator which induces expression of NLS-mCherry-2A-RIG-
I2CARD upon doxycycline treatment were tested for their ability to express the construct 
and activate the RIG-I mediated antiviral signalling pathway. Increasing 
concentrations of doxycycline were used for induction, however, despite successful 
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induction of NLS-mCherry-2A-RIG-I2CARD, no activation was seen compared to non-
treated cells. B) Fluorescence microscopy images of A549 cells stably expressing 
IRF3-eGFP and NLS-mCherry-2A-RIG-I2CARD under the regulation of the tetR. The top 
row panel of images depict cells that were treated with a single round of transduction 
and the bottom row panel depicts cells that were treated with three rounds of 
transduction in order to increase copy numbers of the gene of interest.  
 
 
Despite these technical road blocks, the cell line persevered in the form of a 
straightforward and facile read out; IRF3-eGFP and NFkB-mCherry, two transcription 
factors which are both activated upon RIG-I stimulation. Activation and translocation 
to the nucleus results in transcription of type I and III interferons, interferon stimulated 
genes, and pro inflammatory cytokines. IRF3-eGFP was stably overexpressed in A549 
cells and the subunit of NFkB that translocates to the nucleus, RelA (p65), was N-
terminally fused to mCherry and also stably overexpressed in this cell line. It was seen 
that expressing RelA too highly would result in non-specific translocation of the protein, 
most likely due to over-exceeding the levels of its negative regulator (IkBa) (data not 
shown). Rather than express higher levels of RelA-mCherry in the cells and risk non-
specific activation, a transduction titration was carried out with the cells in order to 
yield cells expressing different intensities of mCherry that would not spontaneously 
activate without any treatment. The cells were then sorted by fluorescence intensity 
using fluorescence activated cell sorting (FACS). This resulted in a more homogenous 
expression of both IRF3-eGFP and RelA-mCherry in the A549 cells (Figure 4.1.3A-D) 
(henceforth these sorted cells will be referred to as A549IRF3-488/RelA-575).  This cell line 
was then used for screening purposes to identify the efficiency of translocation for 
either IRF3 and NFkB. 
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Figure 4.1.3 FACS sorting dual fluorescent cells 
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Figure 4.1.3: Cell line testing and FACS. A) A549 cells stably expressing IRF3-eGFP 
were transduced in a 1:1 ratio of supernatant containing lentivirus containing 
recombinant mCherry-RelA and fresh DMEM and tested for activation by assessing 
nuclear translocation of both IRF3 and RelA. A strong heterogeneous population was 
observed with this stable cell line. B) Fluorescence Activated Cell Sorting (FACS) of 
the brightly expressing cells for eGFP (488 nm w/v) and mCherry (561 nm w/v), 
respectively. C) FACS sorted cells were tested for their homogeneity and activation 
profile. D) Final cell line to be used for the siRNA screen for E3 ligases, depicting the 
nuclear translocation of activated cells for both IRF3 and RelA. 
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Once the cells were prepared and tested for their functionality as a read-out for 
RIG-I activation, an siRNA library was designed to identify novel E3 Ligase enzymes 
that are positively or negatively regulating RIG-I signalling, for either the canonical 
IRF3 or NFkB pathways. Li et al, 2008 annotated 617 putative functional E3 Ligase 
enzymes within the human genome, based on signature catalytic domains ([193]), and 
this was used as the basis for the customised siRNA targeting E3 Ligases. In total, 
616 genes were targeted for knockdown by siRNA, with 3 siRNAs per gene. Including 
positive and negative controls, a total of 641 genes were targeted. The siRNAs were 
spotted, in combination with lipofectamine 2000® on a high-density cell chip with 
microscopy quality glass plating (HDC2), which was developed in-house by group of 
Dr. Holger Erfle, head of ViroQuant-Cell Networks RNAi screening facility, at the 
Bioquant institute, Heidelberg, Germany. siRNAs/lipofectamine were spotted on each 
HDC2 using a spotter obtained from Graffinity pharmaceuticals. A549IRF3-488/RelA-575 
were then seeded 48 hours after spotting and a further 24 hours later were infected 
with Sendai virus, a virus that is specifically recognised by RIG-I. The cells were 
inoculated with the virus for approximately 4 hours prior to fixing and nuclear staining. 
The HDC2 chips, using channels 420/460nm Ex/Em, 488/515nm Ex/Em, and 
587/610nm Ex/Em were imaged using an Olympus IX 81 ® microscope, for Hoechst 
staining, eGFP, and mCherry respectively (Figure 4.1.4 A). 
Images were then processed and analysed using an automated high 
throughput fluorescence microscopy system [194]. Image analysis determined nuclei 
of Hoechst stained cells and measured the intensity and localisation of eGFP and 
mCherry fluorescence respectively, such that if RIG-I is activated, cells will have a 
stronger nuclear signal for their respective transcription factor. Thus, the number 
activated cells, in addition to the extent of activation, can be quantified by measuring 
the ratio of the nuclear signal and the cytoplasmic signal (Figure 4.1.4 B). Screening 
analysis was carried out by the group of Dr. Karl Rohr, Head of the Biomedical 
Computer Vision Group (BMCV), at the Bioquant institute, Heidelberg.  
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Figure 4.1.4 siRNA screening 
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Figure 4.1.4: siRNA screen. A) Schematic overview of the siRNA screen 
development, application, and analysis. B) statistically significant hits (by p-value) that 
are either positively or negatively regulating (median Z-score) the translocation of IRF3 
(GFP) and NFkB (mCherry), by either a specific siRNA (labelled “by siRNA”) or by 
gene hits encompassing all three siRNA’s (labelled “by gene”).   
 
Interestingly, PIAS1 from the protein inhibitor of STAT family, is a significant hit as a 
negative regulator of both IRF3 and NFkB activation, and so far, is only characterised 
as an inhibitor of the JAK/STAT signalling cascade, indicating a novel role for this 
protein in the RIG-I signalling cascade. Further, PIAS2 is one of the strongest hits as 
a positive regulator of IRF3 activation, with a stronger Z-score for positive regulation 
than that of TRIM25 and RNF123, both hits in our screen, and both published as 
positive regulators of RIG-I signalling [72, 195]. Deeper analysis and further work will 
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be carried out to define the role these hits have on RIG-I mediated signal transduction. 
A list of candidate genes that are not know to regulate RIG-I signalling can be found 
in the following table:  
 
Table	26	siRNA	screen	candidates		
siRNA Mean Z-score 
activation 
SD P-value Gene 
s1435 -1.1584 1.2702 2.56E-02 APC 
s226552 1.2047 0.6066 1.91E-03 ASB18 
s2515 -1.6790 1.4422 1.32E-02 CCNB1 
s230 -1.4205 1.7808 4.36E-02 CCND1 
s228 -0.6059 2.1847 4.3E-01 CCND1 
s2527 -1.3443 1.6868 4.38E-02 CCNF 
s2529 -1.7248 1.3097 7.41E-03 CCNF 
s238780 -1.1897 1.4642 4.07E-02 CDK1 
s17059 1.2391 0.8065 1.74E-03 HERC3 
s19597 -0.6788 0.4688 2.46E-03 HUWE1 
s41589 -0.5656 0.3316 9.10E-04 LMTK3 
s49101 1.1777 1.1575 3.60E-02 LOC283116 
s8629 -0.7097 0.5178 3.38E-03 MDM2 
s17486 -1.5706 0.9031 8.05E-04 NEURL 
s45186 -0.8802 0.6683 4.23E-03 PHF13 
s10438 -0.9743 0.6697 2.40E-03 PHF2 
s35611 -1.5522 1.4710 4.92E-02 PHF23 
s16286 1.1930 0.8419 2.79E-03 PIAS1 
s16285 1.2166 0.8970 3.59E-03 PIAS1 
s17285 -1.8338 1.2736 2.55E-03 PIAS2 
s46606 1.2198 0.9590 5.12E-03 PRICKLE2 
s15240 0.8514 0.6342 3.80E-03 RNF112 
s18452 1.2061 0.7449 1.26E-03 RNF14 
s25003 0.7858 0.5867 3.85E-03 RNF160 
s32087 -0.5164 0.3608 4.88E-03 RNF20 
s33570 1.5179 1.2372 6.21E-03 RNF213 
s12075 -0.6500 0.4588 2.80E-03 RNF4 
s12080 1.4681 0.6979 1.43E-03 RNF6 
s16470 0.7774 0.5842 4.00E-03 SOCS1 
s35578 0.9687 0.5438 6.90E-04 TRIM48 
s30233 -0.9232 0.6928 3.96E-03 TRIM68 
n329314 0.8464 0.6365 4.01E-03 UBE2I 
s40201 -0.6837 0.4664 2.29E-03 UBE3B 
s43508 -1.2465 0.7150 7.93E-04 UBR3 
s43507 -0.9281 0.5686 4.99E-03 UBR3 
 
Table 26: siRNA screen list of candidate genes that may significantly positively or 
negatively regulate the RIG-I signalling pathway leading to the activation of 
IRF3/NFkB.   
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4.2 RIG-I Signalling – From Tools to Dynamics Data  
 
Despite RIG-I signalling having been extensively studied, the dynamics and regulation 
of the signalling steps has been somewhat overlooked. In order to fully understand the 
relationship between the host and an invading virus, in terms of pathogenesis and 
disease progression, dynamics of a successful antiviral signalling response must be 
analysed. Using A549 cells stably expressing IRF3 tagged with eGFP and 
fluorescence imaging, we could track the activation of the RIG-I signalling pathway 
using transcription factor translocation in response to dsRNA as a read out. Toward 
understanding the regulation and kinetics of IRF3 activation in response to dsRNA, 
we used different concentrations (0.01-1 pmol dsRNA/well) and different lengths of 
dsRNA (100 base pairs or 400 base pairs) using a lipoma-transfection approach 
(figure 4.2.1). 
 
Figure 4.2.1 IRF3 translocation tracking 
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Figure 4.2.1: IRF3 activation tracking by microscopy. Individual cells were imaged 
every 15 min in response to dsRNA liposome-transfection and the % of cells that were 
activated over time was calculated, using poly(I:C) as a positive control and poly(C) 
as negative control.  
 
We could see a clear dose dependent and length dependent response to dsRNA in 
A549 cells, where 400 bp dsRNA at all three concentrations acted as a stronger and 
faster inducer of IRF3 translocation when compared to 100 bp dsRNA. We observed 
a strong heterogeneity in terms of the time of translocation of IRF3 between the cells 
that were tracked, and while we were able to track individual cells, the experiment 
highlighted specific aspects of RIG-I signalling measurements that needed to be 
addressed. We speculated that the observed heterogeneity of IRF3 translocation in 
response to dsRNA delivery was due to staggered uptake (endocytosis) of the 
liposome-dsRNA transfection complex. Using IRF3 translocation in response to 
dsRNA-liposome transfection, we limited ourselves to observing the very downstream 
point in signalling. Further, we could not determine the moment in time of endocytosis 
of the liposome-dsRNA complex by each cell, and thus, without knowing this point in 
time, the dynamics of IRF3 activation could not be compared. In order to characterise 
the RIG-I signalling dynamics, we would have to extend our observations to the 
detection of dsRNA, as well as including the individual proteins involved prior to the 
activation of IRF3. To achieve a thorough analysis of RIG-I signalling, we would need 
to synchronise the delivery of dsRNA in order to compare the activation of IRF3 and 
other proteins involved. If RIG-I signalling was a stochastic event, as suggested by 
Rand et al. 2012, single cell read-outs would be necessary.  
 Thus, toward understanding the dynamic process of the RIG-I signalling 
cascade, the activation kinetics of the intermediate steps within the signalling cascade 
must be examined using a quantitative approach. Data published in Nature Methods 
(Remy & Michnick, 2006 and Madden et al, 2011) [196, 197] outlined a method for 
quantitatively measuring protein:protein interactions (PPIs).  The method was based 
off of the luminescent potential of enzyme Gaussia princeps luciferase (henceforth 
abbreviated as GLuc). In the case of Protein Complementation Assay (PCA), GLuc is 
split into two fragments, N1 and N2, where by N1 corresponds to amino acids 1-93, 
and N2 corresponds to amino acids 94-169, excluding the 16 amino acids of the N 
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terminal end that correspond to the secretion signal sequence. In order to measure 
PPIs, GLuc N1 and GLuc N2 are fused to proteins of interest that are known to interact. 
Upon close proximity, GLuc structure reconstitutes to form its functional native 
structure, where by its enzymatic activity is restored. Therefore, upon PPI, GLuc 
enzymatic activity is directly proportional to the affinity and rate of occurrence of the 
specific PPI. Since the read-out for GLuc activity is luminescence based, PPIs can be 
quantitatively measured using interacting proteins fused split GLuc and measuring 
luminescence.  
In order to account for random reconstitution of the GLuc within cells, control 
assays are included to calculate a normalised luminescence ratio (NLR). The assay 
involves the input of a protein of interest fused to GLuc N1, in addition to its interacting 
partner (putative or known), fused to GLuc N2 (henceforth this construct mix is referred 
to as C1). Separately, these proteins of interest are, in addition, used as input with 
their cognate GLuc fragment fused to no protein, such that Protein X-GLuc N1 + 
Empty-GLuc N2 will be measured (henceforth referred to as C2). Additional the 
reverse is also measured; Empty-GLuc N1 + Protein Y-GLuc N2 (henceforth referred 
to as C3). C1, if the protein partners do interact, will give a positive luminescent signal, 
the strength of which will be based on protein interaction affinity and rate of 
occurrence. C2 and C3 however, should not give a strong positive interaction signal 
due to the fact that the GLuc fragments will be separated by the empty control and 
should not specifically reconstitute to their native structure and therefore should not 
be able to produce a luminescent signal. It cannot be ruled out however that random 
close proximity of the protein fused GLuc fragment and the empty GLuc fragment 
occurs. This results in the generation of a base line luminescent signal to normalise to 
for the positive interaction input (C1). Thus, the normalised luminescent ratio is the 
quantification of the C1 input divided by the combination of the quantification C2 and 
C3 (illustrated and summarised in figure 4.2.2).  
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Figure 4.2.2 PCA overview  
 
Figure 4.2.2: Split Gaussia princeps luciferase based protein complementation assay 
illustration, and how normalised luminescence ratio (NLR) is calculated. Two proteins 
of interest are linked with each half of the split Gaussia princeps luciferase protein, 
upon addition of the substrate, if the two proteins are interacting the luciferase activity 
is reconstituted and a luminescence signal can be detected. Normalisation controls 
are also measured to verify for protein interaction specific signals. 
 
 
In order to examine whether PCA could be used to quantitatively measure the kinetics 
of PPIs within a cell, it was first tested if results obtained by Madden et al, 2011 could 
be reproduced using the same approach (figure 4.2.3). It was demonstrated that 
various incubation times post transfection of the cells yielded varying luciferase signals 
based upon PPIs (figure 4.2.3 A, C, and B). Despite the varying luminescence signal, 
it was determined that protein interactions could be detected and quantified using split 
Gaussia princeps luciferase, but that the sensitivity of the assay was not as 
reproducible as published by Madden et al, 2011 (figure 4.2.3D).  
 
Gluc N1
Protein	X
Gluc N2
Protein	Y
Reconstituted	GLuc
Protein:Protein Interaction
NLR =
Gluc N2
Protein	Y
Gluc N1
Protein	X
Gluc N1
Protein	X
Gluc N2
Empty
+
Gluc N2
Protein	Y
Gluc N1
Empty
C2 C3
C1
Coelenterazine
 
 
79 
Figure 4.2.3 PCA preliminary results 
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Figure 4.2.3:  Split Gaussia princeps luciferase linked to proteins of interest were 
tested for their luciferase activity (Protein Complementation Assay) as an experimental 
basis to quantify protein Interactions In vitro. HEK293T cells were transfected with 
50ng DNA constructs of proteins of interest, known to interact, linked to the N1 or N2 
fragments respectively of Gaussia princeps luciferase prior to incubation times and 
cell lysis by freeze-thawing. A) Analysis of protein interaction partners after 24 hours 
of transfection. B) Comparison of protein interaction partners after 24 or 48 hours. C) 
Analysis of luminescence over 24, 48, and 72 hours using positive interaction partners, 
assuming a background signal noise threshold of 1.0 as a cut off point for a positive 
interaction signal. D) Comparison of the data published for positive interaction partners 
versus data generated in our lab for the same interaction partners (labelled 
unpublished data), using the same methodology. Values are expressed as a mean +/- 
SD, except for (C) where only the mean is expressed, all conditions were carried out 
in triplicate, for (A and B) n=3, (C) n=1.  
 
To determine how the lack of reproducibility of the results shown in figure 4.2.3 D 
occurs, it was examined whether the technical application of the assay could be 
optimised in order to increase the sensitivity to a “benchmark” point where positive 
interactions could give a robust luminescence signal. The benchmark for positive 
interaction signals was given the arbitrary unit of 1, with regards to normalised 
luminescence ratio (NLR). Using an optimised assay approach (REF# appendix figure  
PCA), a panel of positive interaction protein partners were tested for their ability to 
approach the benchmark in terms of their positive luminescence signal. Despite an 
overall better signal for MAVS:MAVS regarding the newly optimised approach, only 
50% of PPIs tested were able to reach the benchmark (Figure 4.2.4 A). This may have 
been due, in part, to the unusually high signal to background noise ratio of a single 
plasmid construct: MAVS-N2 (C3 control). When examining the individual 
luminescence signals that are used to calculate the NLR, it was determined that 
MAVS, fused to GLuc N2, would give a positive luminescence signal despite not being 
co-transfected with a protein interaction partner (empty GLuc N1). This appeared to 
only affect MAVS, as it can be seen that TRAF2, when fused to either N1 or N2, and 
co-transfected with its cognate empty control, would give a remarkably low 
background luminescence signal when compared to MAVS-N2/empty-N1 (figure 4.2.4 
B).  
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Figure 4.2.4 PCA controls 
  
Figure 4.2.4: Positive protein interaction partners were tested for their reconstituted 
linked luciferase activity, using a threshold of 1 RLU as a baseline for a positive 
interaction signal over background noise. HEK293T cells were transfected with 100ng 
DNA constructs of proteins of interest, known to interact, linked to the N1 or N2 
fragments respectively of Gaussia princeps luciferase. A) The range of signals for 
positive interaction partners and, for some, their lack of positive luciferase signal 
(signifying protein:protein interaction). B) A breakdown of the negative control 
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luciferase activity (absolute light units) signals used to normalise the positive control. 
Dark grey signifies that MAVS is linked to the N2 fragment of Gaussia princeps 
luciferase, light grey signifies that a positive interaction partner of MAVS (here TRAF2, 
TRAF3, and TRAF6) is linked to the N1 fragment of Gaussia princeps luciferase. 
TRAF2:TRAF2 is shown in green as a MAVS-free control, highlighting the occurrence 
of a high background signal due to MAVS-Gaussia N2 binding empty N1. Values are 
expressed as a mean +/- SD (n=3). 
 
Given that PCA would be used to measure PPIs over time in order to analyse the 
dynamics of RIG-I mediated signal transduction, MAVS:MAVS and MAVS:TRAF3, two 
robust positive interactions regarding PCA, were analysed in terms of quantitative 
kinetic measurements, in order to determine if PCA was a suitable approach. It was 
demonstrated that, indeed, luminescence could be measured over time, but that the 
initial substrate binding resulted in a peak signal in the early seconds of the time 
course, but that the NLR appeared to reach a stable plateau (figure 4.2.5 A and B). 
Furthermore, it was demonstrated that re-addition of the substrate after 100 seconds 
from the original addition of substrate, resulted in only a minimal and very short spike 
in the NLR, such that it would return to its stable plateau (data not shown). A break 
down of the individual kinetics of MAVS:MAVS (C1, C2, C3 and NLR), display a robust 
measurement, and suggest the “peak” signal is due to a more rapid degradation of the 
C2 and C3 signals respectively (figure 4.2.5 C).   
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Figure 4.2.5 PCA based luciferase activity over time 
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Figure 4.2.5: Time course experiment to analyse the potential for quantitative kinetics 
analysis using PCA. HEK293T cells were transfected with 100ng DNA for each 
respective construct and 10µM Coelenterazine was used to induce a luminescent 
signal from time point 0 (seconds), luminescence was then measured every 2 seconds 
for 300 seconds total. A) MAVS:MAVS interaction based reconstituted luciferase 
kinetics. B) MAVS:TRAF3 interaction based reconstituted luciferase kinetics. C) Break 
down of the individual kinetics of each condition for MAVS:MAVS measured in order 
to calculate the normalised luminescence ratio (NLR). Values are expressed as a 
mean +/- SD, all conditions were carried out in triplicate, data representative from one 
of two experimental replicates.  
 
Given the appearance of a significant peak signal, it was examined whether varying 
delay and measurement times would affect the luminescent signal strength of 
MAVS:MAVS. It was observed that the varying delays and measurement windows 
results in dramatic changes to the NLR (data not shown). Thus, the measuring window 
may be specific for each individual interaction, which is highlighted by the peak in 
signal seen between the MAVS:MAVS interaction and the MAVS:TRAF3 interaction 
(figure 4.2.5 A and B). As such, it was decided that this tool would not be appropriate 
to measure the dynamics of RIG-I signalling, and an alternative approach was 
necessary. Since using infection with virus or liposome-transfection of dsRNA leads 
to an asynchronous activation dynamic within the cell pool due to the unknown time 
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point at which each cell was infected/activated (we speculated that dsRNA delivery by 
endocytosis of the dsRNA-liposome complex/virus particle occurs randomly on a cell 
to cell basis), and that we further could not effectively measure PPIs quantitatively, a 
synchronous activation approach was designed in order to analyse grouped cells 
efficiently regarding activation kinetics.  
 Cell suspensions were electro-transfected in the presence of dsRNA. 
Electroporation of cells results in the influx of the surrounding solution, in this case, 
dsRNA containing solution for the duration of the electrical pulse. The cells are 
exposed to an electrical pulse (150V) for a mere 10ms, thus, the influx of dsRNA into 
electro-transfected cells occurs at the exact moment in time for each cell. This 
ultimately results in the synchronisation of cell responses and allows for the analysis 
of kinetics regarding RIG-I signalling (Figure 4.2.6). 
 
Figure 4.2.6 Cell electroporation overview 
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Figure 4.2.6: A) Schematic overview of the electroporation of mammalian cells. Cells 
are suspended in electroporation buffer (cytomix containing 0.8pmol (2nM) dsRNA, 
and 4.0x106 A549 cells) in a 0.4mm cuvette. Cuvettes are pulsed with a block pulse 
of 150V for 10ms. dsRNA enters the cells and synchronises the RIG-I signalling 
cascade in activated cells. B) Schematic overview of the electroporation of 
mammalian cells adherent to a 24-well glass-bottom plate. Cells are electro-
transfected using a customised “in-well” electrode with 100uL buffer (cytomix 
containing 0.8pmol (8nM) dsRNA). Wells are pulsed with a block pulse of 150V for 
10ms. dsRNA enters the cells and activates the RIG-I signalling cascade, allowing for 
live cell imaging of synchronised responses. 
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4.3 RIG-I Signalling Dynamics 
 
Using an electro-transfection based approach to delivering dsRNA into the cells, we 
negate the random and unknown delivery kinetics by endocytosis, which would in 
theory synchronise RIG-I detection of dsRNA across all activated cells. In order to 
confirm the robustness of the synchronisation, a comparison was made between 
dsRNA liposome-transfected cells, which would mimic the kinetics/dynamics of a viral 
infection assay, and dsRNA electro-transfected cells. (Figure 4.3.1). There was a stark 
contrast between the kinetics of IRF3 activation, which was analysed based upon its 
phosphorylation at S396 and using GAPDH and total protein control, which is required 
prior to translocation to the nucleus, and in addition, the live cell imaging of IRF3-eGFP 
localisation. When comparing liposome-transfection against electro-transfection, we 
observed a much faster response for both phosphorylation, and nuclear localisation of 
IRF3 using the electro-transfection approach. As depicted in figure 4.3.1, under a 
transfection approach (asynchronous) IRF3 begins to be phosphorylated roughly 60 
minutes to 90 minutes post transfection, with a relatively strong phosphorylation signal 
seen after 120 minutes. Compared to the electroporation approach (synchronous), 
IRF3 begins to be phosphorylated much more rapidly, with a weak signal seen as early 
as 15 minutes, and quite a strong signal at 30 minutes after electroporation. Moreover, 
this strong signal is maintained, and even increases slightly for up to 120 minutes, as 
opposed to the more gradual and overall weaker signal increase seen in the 
transfection approach. Further, when analysing the localisation of IRF3-eGFP, it was 
seen that after 30 minutes post-treatment of the cells, there was a strong difference in 
the number of cells that had IRF3 localised to the nucleus when comparing liposome-
transfection and electro-transfection of dsRNA, where electroporation resulted in 
much higher number of activated cells. 
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Figure 4.3.1 Liposome- vs electro-dsRNA transfection  
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Figure 4.3.1: Comparison between transfection and electroporation of dsRNA using 
A549 cells. A) 2nM dsRNA liposome-transfected into A549 cells, which were lysed at 
specific time points and phosphorylated IRF3 was analysed by Western Blot. B) 2nM 
dsRNA electro-transfected into A549 cells, which were lysed at specific time points 
and phosphorylated IRF3 was analysed by Western Blot. C) and D) Analysis of eGFP-
IRF3 translocation from the cytoplasm to the nucleus 30 mins post liposome-
transfection (C) or electro-transfection (D) of 2nM 400 bp dsRNA.  
 
Thus, we decided to track the localisation of IRF3 over time in response to dsRNA 
delivery by either liposome-transfection or electro-transfection (figure 4.3.2).   
Figure 4.3.2 IRF3 nuclear translocation quantification 
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Figure 4.3.2: Comparison between liposome-transfected (A) 2nM 400 bp dsRNA 
(Asynchronous Responses – 10 min intervals) and electro-transfected (B) 2nM 400 
bp dsRNA (Synchronous Responses – 2 min intervals) using live cell imaging to 
measure and quantify the percentage of cells that have IRF3 in the nucleus.  
 
As depicted, when analysing IRF3 translocation over time, under a transfection 
approach, IRF3 translocation is more gradual, and somewhat delayed. This is in 
contrast to the electroporation approach, where IRF3 translocation appears to be 
earlier/rapid and simultaneous, as opposed to staggered/gradual. Thus, we could 
confirm the robustness of the synchronisation of RIG-I activation and the downstream 
activation of IRF3. Therefor we decided to endogenously measure the activation 
states, by quantitative phospho-specific Western Blots, of the canonical proteins 
involved in RIG-I signalling using the synchronisation approach (described in section 
1.3.1.3).  
 The electroporation of cells in suspension (outlined in figure 4.2.6 A) was used 
to stimulate the cells synchronously to allow for the measurement of activation markers 
(post translational modifications) for the specific sub steps of the RIG-I signalling 
cascade. These sub steps include TBK1, IkKe, IkBa, IkKb, IRF3, and RelA (subunit of 
NFkB). Due to technical difficulties regarding multiple antibodies targeting the same 
protein and poor signal acquisition of total protein controls, the native protein was not 
used as a control measurement when quantifying phosphorylation levels of each 
protein in the Western Blots, instead GAPDH/calnexin was used. Thus, it was pertinent 
to determine if the increase/decrease in phosphorylation levels of specific proteins 
over time was not due to increase or decrease of the target protein itself. As such, 
phosphorylated protein and native protein was measured separately and GAPDH or 
Calnexin was used as loading control in each case (Figure 4.3.3).  
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Figure 4.3.3 Canonical RIG-I signalling protein dynamics analysis 
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Figure 4.3.3:  Analysis of expression profiles of major RLR pathway components upon 
synchronous stimulation of A549 cells by electroporation of 2 nM dsRNA (400 bp). 
Total protein levels (A) or phosphorylated proteins (B) were detected by immuno-
blotting at specific time points after electro-transfection (as indicated). 
 
As depicted, the total protein controls appear to not increase or decrease dramatically 
such that it would majorly effect the quantification of the activation markers for each 
protein of interest. Furthermore, as indicated from figure 4.3.1, the activation markers 
under a synchronised approach appear to occur more rapidly and in unison, 
suggesting a robust and valid read-out. For example, it can be seen that IRF3 only 
becomes phosphorylated (15-20mins) after TBK1 and IkKe are increasing in their 
phosphorylation levels (5-15mins), further verifying synchronicity the assay. Similarly, 
for IkKb and RelA, the activation state of these proteins requires the degradation of 
IkBa. it can be seen that the phosphorylation of both IkKb and RelA occurs only after 
the initial decrease in total protein of IkBa. Thus, we can see in almost real time, the 
events of the signalling cascade happen from time point 0 mins (initial recognition of 
dsRNA), allowing us to follow the flow of the signalling steps from one “checkpoint” to 
another with respect to RIG-I signalling.  
The electroporation of mammalian cells (A549 cells) used to generate the 
phoso-specific Western Blots of the activation markers were quantified using Lab-
image 1D in the time resolved manner depicted in figure 4.3.3 in order to obtain 
accurate kinetic data regarding RIG-I signalling sub-steps leading to transcription 
factor activation (Figure 4.3.4A). The canonical pathways for IRF3 and NFkB are 
displayed separately for a more straightforward interpretation of each signalling 
cascade (Figure 4.3.4B). 
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Figure 4.3.4 Canonical RIG-I signalling protein dynamics quantification 
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B 
 
Figure 4.3.4: Quantification of the phosphorylation dynamics of the proteins of interest 
within the RIG-I signalling cascade. A) Quantitative data regarding the activation 
profile of the indicated protein after electroporation of 0.8pmol dsRNA at the indicated 
time points. B) Collation and overlay of the quantitative phospho-specific Western Blot 
data for the downstream RIG-I dependent canonical IRF3 and NFkB signalling 
pathways. Data points are mean values (+/- standard deviation) of four independent 
biological replicates. Values were normalised to the mid-range values for each protein 
analysed within each individual experiment. 
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Upon analysis of the canonical proteins and their activation profiles under 
synchronised RIG-I signalling, it was found that indeed signalling was not a stochastic 
event, and as depicted, appears to have pre-determined set of kinetics that is rapid 
and very predictable (deterministic event). We therefor believed that RIG-I mediated 
signal transduction was an ideal candidate for the application of mathematical 
modelling, as deterministic processes provide a more straightforward approach 
compared to stochastic processes. Teaming up with a Ph.D. student from the 
University of Greifswald, Darius Schweinoch in the group of Dr. Lars Kaderali, we set 
about designing a mathematical model that assess the kinetics of key signalling events 
within the RIG-I signalling cascade, extending from solely RIG-I mediated signal 
transduction to encompass gene transcription and IFN signalling.  
 Using synchronised cell responses as a basis for examining activation markers, 
the kinetic data generated was used to examine various parameters that would model, 
analyse, and simulate the cells responses that would most closely fit the experimental 
results (regarding RIG-I signalling – figure 4.3.4). Ultimately this combines theory with 
experimental data and achieves the simulation of complex molecular networks of a 
biological system. Modelling, carried out by Darius Schweinoch, simulates the rate of 
change (K) from one protein state to another (for example, non-phosphorylated protein 
to its phosphorylated state). Using ODEs, multiple parameters of each specific protein 
were tested. Specifically, the unknown rate constants, which describe the rate of 
change, were tested such that the model best describes the experimental data 
provided (deterministic parameters). It is important to note that multiple parameters 
may fit the experimental data, and therefore it is unknown which model truly reflects 
the natural molecular events within the cell. An overview of the modelling scheme and 
its basis can be seen in figure 4.3.5. 
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Figure 4.3.5 Mathematical modelling  
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Figure 4.3.5: Dynamic pathway model for RIG-I signalling pathway. A) Graphical 
illustration of a mathematical model for the RIG-I signalling pathway. The model 
consists of ordinary differential equations (ODEs) based on mass action kinetics and 
describes each of the major steps of signal transduction from RNA sensing by RIG-I 
to transcription of target genes and the production of their mRNAs. Kinetic rates of the 
individual reactions (i.e. model parameters) were taken from literature where possible 
(e.g. rate of mRNA synthesis) or estimated by model fitting to experimental data. B) 
As an example of quantitative, time-resolved data that was used to “train” the 
mathematical model, the time-course of IRF3 phosphorylation is shown, including the 
total protein control and GAPDH as a loading control. Data points in the graph 
represent means and SD from four independent experiments (see figure 4.3.4). C) 
After fitting of the model to measured data of all protein species (see figure 4.3.4), the 
ODE system can rather accurately simulate the dynamics of IRF3 activation upon 
stimulation with dsRNA. The solid black line is the model simulation, black crosses 
represent measured data used for fitting (without the 240 min value). All mathematical 
modelling was performed by Darius Schweinoch in the group of Prof. Lars Kaderali 
(University Medicine Greifswald). 
 
These parameters were then fit for each of the proteins analysed in figure 4.3.4, such 
that that the kinetics of the activation of each individual sub-step could be simulated 
by mathematical modelling (figure 4.3.6).  
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Figure 4.3.6 Parameter fitting 
 
 
 
Figure 4.3.6: Parameters that were fit for each individual sub-step of the RIG-I 
signalling cascade (by Darius Schweinoch) compared with experimental data obtained 
in our lab.  
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Having generated the basis for a mathematical model describing the dynamics and 
kinetics of RIG-I signal transduction, a more comprehensive overview of the antiviral 
innate immune response was desired. Therefor it was decided to extend the data 
analysis further such that it would encompass not only RIG-I dependent signal 
transduction, but additionally IRF dependent transcription of specific mRNAs, 
translation of these mRNAs, and ultimately include IFN dependent signal transduction 
too, which leads to further production ISGs. This could be incorporated in the 
mathematical model to provide an extensive overview of the processes involved in 
mounting an antiviral response. The electro-transfection experimental set up was used 
to analyse the mRNA expression profile of the synchronised cells over a period of 24 
hours. IFIT1, an ISG which is both expressed by the activation of RIG-I in addition to 
the stimulation of IFN receptors, was measured by qRT-PCR (Figure 4.3.7 A). Using 
the same experimental set up as previously described, mRNA for IFNb and IFNl, 
which is specific to RIG-I signalling in this experimental set up, was also measured 
(Figure 4.3.7 B-C).  
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Figure 4.3.7 ISG mRNA analysis 
 
 
 
 
B             C 
 
Figure 4.3.7:  Time-resolved quantification of target gene transcription. A549 cells 
were electro-transfected with 2nM 400 bp dsRNA and RNA was harvested at the 
indicated time points post electro-transfection. Production of mRNA downstream of 
IRF3 activation was determined by gene-specific qRT-PCR against A) IFIT1 (n=3 +/-
SD), B) IFNb (n=2 +/-SD) or C) IFNl (n=2 +/-SD). 
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Interestingly, it can be seen for IFIT1 that the mRNA, under a synchronised approach, 
peaks at 6 hours under this time course, where it begins to decrease at 9 hours, but 
increases again and stabilises between 12-24 hours. This, in comparison to IFNb/l 
mRNA produced under the same settings, shows a similar peak at 6 hours, but rather 
than decreasing at 9 hours and increasing again 12 hours, IFNb/l mRNA decreases 
at 9 hours, and continues to decrease until no mRNA is detected after 24 hours. With 
respect to IFIT1 mRNA and its increase from 9-12 hours, this is most likely due to the 
amplification effect of IFN protein that is translated by this time and then activates IFN 
signalling which results in expression of IFIT1, this amplification of mRNA is not seen 
for the IFNs because IFN signalling does not result in IFN mRNA expression.  
To further extend the comprehensiveness of the data, and indeed the model, 
we wanted to analyse the downstream events of IRF3 activation, which is mainly the 
expression of type I/III IFNs. We then proceeded to measure expression of IFIT1 
protein, which is thought to be similar to the expression kinetics of IFNb (figure 4.3.8). 
We further tried to measure the production of IFNb by ELISA and by an indirect bio-
assay (4.3.9)  
 
Figure 4.3.8 IFIT1 protein expression 
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Figure 4.3.8: Time-resolved quantification of target protein production. A549 cells 
were electro-transfected with 2nM 400 bp dsRNA and cells were lysed at the indicated 
time points post electro-transfection. Protein amounts of IFIT1, a major ISG, were 
determined by Western Blotting, and quantification of protein amounts is relative to 
GAPDH (values are expressed as mean +/- SD where n=3).  
 
Figure 4.3.9 IFNb analysis 
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Figure 4.3.9 Time-resolved quantification of target protein production. A549 cells were 
electro-transfected with 2nM 400 bp dsRNA and supernatant was harvested at the 
indicated time points. A) ELISA based quantification of the production and 
accumulation of IFNb in the supernatant of stimulated cells, data normalised to 0 hr 
value (n=1). B) Antiviral activity of secreted factors. Supernatants from 2nM 400 bp 
dsRNA electro-transfected A549 cells (two separate replicates) or supernatant from 
mock (no RNA) electro-transfected cells were collected at the indicated time points 
after electro-transfection. Stable HCV replicon cells (Huh7-LucUbiNeo/ET) were 
treated with supernatants for 16hrs and HCV luciferase activity was measured as an 
inversely proportional correlate of antiviral efficacy of the conditioned supernatants. 10 
IU/ml of IFNa were used as a positive control. Values are means +/- SD of 3 technical 
replicates (wells). 
 
Using the same synchronised experimental approach described thus far, the 
expression of IFIT1 protein was measured by Western Blot and quantified by 
Densitometry.  As shown in figure 4.3.8, translation of IFIT mRNA can be seen as 
early as 6 hours, and continues to increase in expression for up to 48 hours. This data 
is corroborated with the data that depicts the IFIT1 mRNA peaking in its expression at 
6 hours.  
 Furthermore, using supernatant from dsRNA electro-transfected cells, which 
would eventually contain secreted IFN protein (type I/III) from RIG-I activated cells, we 
attempted to quantify the accumulation of IFNb over time. Using an ELISA based read-
out, we could detect IFNb, but there was a high background and thus values were 
normalised to the 0 hour data point, this however resulted in very low sensitivity for 
IFNb detection, with less than 6 pg/mL after 24 hours (4.3.9 A). We also measured 
IFN production indirectly using the HCV replicon system (4.3.9 B). It was seen that 
after 4 hours this supernatant could block replication of the HCV using the HCV 
replicon system [198], which has Firefly luciferase incorporated into the genome, and 
thus replication can be measured by luminescence. A strong luminescent signal 
represents strong replication of HCV, and vice versa. This suggests expression and 
excretion of IFN protein as early as 4 hours post electroporation, as depicted by the 
weak luminescent signal, which is not supported by the ELISA results. Although it is 
possible that this is a type III IFN specific effect.   
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We then went on to examine the activation of IFN signalling itself, which further 
upregulates the expression of ISGs. These ISGs include RIG-I itself, as well as many 
of the factors involved in signalling, thereby constituting an important positive feedback 
that might contribute to the observed signalling quite significantly. Further, negative 
feedback regulators may also be upregulated as a response to IFN signalling, 
dampening ISG expression. Darius Schweinoch and Lars Kaderali then set out to build 
a model that would incorporate these factors and thus intertwine the RIG-I mediated 
signalling cascade with the IFN mediated signalling cascade. To support this, we 
examined activation markers of IFN signalling. 
 IFN receptor signalling results in the phosphorylation of STAT1 and STAT2, 
allowing the STAT proteins to form homodimers (STAT1:STAT1) and heterotrimers 
(STAT1:STAT2:IRF9 – ISG3). STAT1 and STAT2 were examined in terms of their 
phosphorylation status over time following the activation of RIG-I. interestingly, we saw 
a strong peak in the activation of STAT1 as early as 3 hours after RIG-I activation 
(figure 4.3.10 A), arguing for a strong early feedback response by IFN signalling on 
the dynamics of RIG-I signalling that we observe. Furthermore, this peak in the 
phosphorylation status of STAT1 is reduced from 3-6 hours, and stays reduced for up 
to 12 hours, where a much stronger level of phosphorylation is seen at 24 hours, 
peaking at 36 hours (data not shown). This phosphorylation is again reduced to 
background levels after 48 hours. To further investigate this early phosphorylation of 
STAT1, a finer time course (down to 5 min intervals) was applied within the first 4 
hours of electroporation (figure 4.3.10 B).  
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Figure 4.3.10 STAT1 analysis 
 
A        B 
  
 
Figure 4.3.10: Quantitative and time-resolved analysis of STAT1 phosphorylation. 
A549 cells were electro-transfected with 2nM 400 bp dsRNA and lysed after the 
indicated time points, either A) short-term high-resolution, or B) over a longer time 
course of 48 hrs. Phosphorylation of STAT1 was assessed by phosphorylation-
specific western blotting. Data are from a representative experiment out of 3 
independent repetitions. 
 
Strikingly, not only was there a strong phosphorylation of STAT1 between exactly 2 
and 4 hours, which, according to the previous experiment shown in figure 4.3.10A, is 
not present after 6 hours, but furthermore, there was a slight phosphorylation of STAT1 
seen between 10-20 mins after electroporation, which is extremely fast considering 
the previously shown dynamics of RIG-I/IFN signal transduction, indicating that there 
is another factor other than the RIG-I activation dependent production of IFN that is 
stimulating the phosphorylation of STAT1. To completely rule out that IFN is mediating 
this early activation on STAT1, supernatant from electro-transfected cells was 
immediately harvested (within 5 mins) and added on to freshly seeded A549 wildtype 
cells in addition to A549 IFNa/l double receptor knock-out cells (A549 IFNA/LR KO 
cells) to examine their expression profile of IFIT1. It was seen that the supernatant 
induced expression of IFIT1 in both WT and A549 IFNA/LR KO cells, suggesting IFN 
is not the origin of this early STAT activation (Figure 4.3.11).  
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Figure 4.3.11 Electro-transfection controls 
 
Figure 4.3.11: Control experiment for artefactual liberation of antiviral factors by 
electroporation of cells. A549 cells were electro-transfected either with 2nM 400 bp 
dsRNA as in the experiments before (EPO +RNA), or electro-transfected in the 
absence of RNA (EPO -RNA), electro-transfected in the absence of RNA with 2 nM 
400 bp dsRNA supplemented immediately after electroporation (EPO -/+ RNA) or left 
non-electro-transfected (mock). Cell supernatants were collected after 30 min and 
transferred to new A549 cells (A549 WT) or A540 IFNAR/IFNLR double-knockout cells 
(A549 IFNA/LR KO). 
 
Upon further examination of this induction by supernatant that was immediately 
harvested from electro-transfected cells, it was determined that very specific factors 
were necessary to provide this activation ability. dsRNA must be present during the 
moment of electrical pulsing of the cells (EPO+RNA), if it is not present (EPO-RNA), 
or added after electrical pulsing of the cells (EPO-/+RNA), then no induction is seen. 
Furthermore, only freshly harvested supernatant (harvested within 5 mins) post 
electroporation has the ability to induce activation, supernatant that has been frozen 
and thawed loses this ability to induce activation (data not shown). Due to dsRNA 
being essential during the moment of electrical pulsing, in addition to the fact that 
freeze thawing of supernatant negates the induction ability, it is possible that the RNA 
is being endocytosed through other means in order to initiate RIG-I dependent 
signalling.  
A549 IFNA/LR KO A549 WT
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An overview of the RIG-/IFN signalling dynamics can be seen in figure 4.3.12. We can 
see from time point 0 min the flow of signalling the dynamics of specific factors and 
their activation over time, TBK1 becomes rapidly activated, between as early as 5-10 
min, following this IRF3 becomes activated, starting at 10-15 min and peaking in its 
activation at around 60 min, activated IRF3 then mediates the transcription of ISGs 
such as IFIT1 (ISG56), IFNb, and IFNl. Here we can see transcripts beginning to be 
detected almost simultaneously after about 60 min, and peaking in their expression 
after 6 hrs, where the IFN mRNA diverge from the ISGs, being depleted after 24 hours 
where as ISG56 continues to be transcribed.  Translation of ISG56 can be detected 
as early as 6 hours and is rapidly translated between 12-24 hrs, with translation 
continuing for up to 48 hrs. IFN mediated signal transduction appears to be detected 
as early as 60 min, however this is diminished between 4-12 hrs, where STAT1 
activation is strongest after 24 hrs.  
 
Figure 4.3.12 RIG-I dynamics overview 
 
 
  
Figure 4.3.12: Compilation of time-course data for major signalling components. All 
values are normalized to the mean of their respective three most maximum values. 
Shown are mean +/- SD of three independent biological replicates (n=2 for IFNb and 
IFNl qRT-PCR).  
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In light of the synchronicity experiments for the quantification of the production of 
mRNAs measured from the moment cells activated, an opportunity presented itself; to 
examine the dynamics of ISG expression over time in wild type (WT) cells versus cells 
that did not express either IFNAR1 or IFNLR1 (IFNRKO), since we hypothesised that 
the ISGs induced by RIG-I/IRF3 might be different in their kinetics and dynamics 
compared to IFN/ISGF3. Furthermore, surprisingly little is known about ISGs that are 
specifically induced by IRF3, other than the IFNs and IFIT1. Thus, with IFNRKO cells 
we could determine which ISGs were dependent on which signalling cascade (RIG-I 
or IFN), and to what extent. Full time dependent transcriptome profiling upon 
synchronised RIG-I activation was carried out using WT cells and IFNRKO cells. 
Illumina humanHT-12 chips were used for the expression profiling and was carried out 
by the Genomics and Proteomics core facility of the DKFZ in Heidelberg, Germany.  
 This data-heavy analysis provided a significant and unique insight into antiviral 
signalling. Figure 4.3.13 A depicts the genes that were up or down regulated after 6 
hours, using 0 hours as a normalisation control. The threshold for cut-off were 5 fold 
for upregulated genes and -3 fold for downregulated genes. Using a gene ontology 
tool powered by PANTHER (www.pantherdb.org), the genes that were upregulated by 
dsRNA stimulated RIG-I, were organised into gene ontologies (cellular function 
categories) based on their enrichment score defined by panther (figure 4.3.13 B). As 
we can see, the majority of genes upregulated by dsRNA stimulated RIG-I are specific 
for immune system responses against viral infection and regulation of these immune 
system responses (e.g. regulation of TH2 type responses, response to endogenous 
dsRNA, negative regulation of viral genome replication, negative regulation of type I 
IFN responses etc.). This validates the data set as a tool to compare the IFNRKO data 
set with the WT data set.  
  
 
 
 
 
 
 
 
 
109 
Figure 4.3.13 ISG expression after 6 hours 
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B 
 
 
Figure 4.3.13: ISG expression analysis of transcriptome profiling upon electro-
transfection of 2 nM 400 bp dsRNA. A) ISGs upregulated or downregulated 6 hours 
post-delivery of dsRNA in wild-type cells (normalised to 0 hr value). B) Gene Ontology 
analysis of the genes upregulated, designated by enrichment score via PANTHER.  
 
 
 
 
 
 
 
 
 
Gene Ontology Analysis by PANTHER:
Upregulated Cellular Processes by Enrichment Score 
6h post stimulation compared to 0H
Total Enrichment Score =421.73
regulation of T-helper 2 cell cytokine production (pval=3.6e-3)
cellular response to endogenous dsRNA (pval=3.2e-4)
regulation of type 2 immune response (pval=6.3e-5)
negative regulation of viral genome replication (pval=5.3e-9)
type I interferon signaling pathway (pval=1.6e-11)
negative regulation of type I interferon production (pval=8.5e-4)
cellular response to interleukin-1 (pval=1.0e-3)
negative regulation of cytokine production (1.44e-10)
regulation of cytokine biosynthetic process (pval=1.7e-3)
regulation of transcription from RNA polymerase II promoter in response to stress (pval=2.0e-4)
negative regulation of lymphocyte activation (pval=5.0e-4)
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We have compared the genes and categorically certain ISGs organised into “early” 
(within 4 hours) induced genes, “intermediate” (within 12 hours) induced genes, and 
“late” (within 24 hours) induced genes (figure 4.3.14).  
 
Figure 4.3.14 Different phases of ISG induction 
 
 
Figure 4.3.14: ISG expression analysis of transcriptome profiling upon electro-
transfection of 2 nM 400 bp dsRNA. ISGs upregulated at different phases of the 
antiviral response using WT cells only.   
 
Further, we have compared the mean induction over time of the different IFN mRNAs 
induced in response to RIG-I signal transduction, and thus IRF3 transcription, 
compared to the IFNRKO cells which exclude IRF9 transcription (figure 4.3.14). 
Interestingly, there were contrasting results; IFNB1 and IL28A appeared to be largely 
unaffected by IFN mediated signal transduction, but the results for IL29 indicate that 
its expression is negatively regulated by IFN signalling, such that when you knock out 
the IFN receptors, IRF3 mediated transcription of IL29 is unhindered over time. The 
opposite is true for IL28B, where knocking out the IFN receptors results in a marked 
reduced expression of IL28B. 
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Figure 4.3.15 Type I/III IFN expression 
 
 
Figure 4.3.15: ISG expression analysis of transcriptome profiling upon electro-
transfection of 2 nM 400 bp dsRNA. IFN mRNA upregulated upon dsRNA treatment 
in WT vs IFNA/LR KO cells.  
 
We then examined the profiles of different ISGs in response to RIG-I for both the WT 
and the IFNA/LR KO cells. As shown from the dynamics of each ISG that was 
upregulated in response to dsRNA, it can be seen that IRF3 and IRF1 have little 
dependency on IFN mediated signal transduction, whereas IRF7 was only slightly 
reduced in its expression over time in the IFNRKO cells, suggesting that that IRF7 is 
partially regulated by IFN mediated signal transduction. Unsurprisingly, IRF9 
expression over time is drastically dependent on IFN mediated signal transduction, 
and is almost completely non-responsive to dsRNA stimulation in the IFNRKO cells. 
Astonishingly, the results indicate that many ISGs are not dependent on IFN signalling 
at all, and that IRF3 mediated expression of ISGs is sufficient. Of the ISGs IRF3, IRF1, 
IRF7, IRF9, IFIT1, IFIT2, IFIT3, MX1, ISG15, ISG20, DDX58, DHX58, and IFIH1, only 
MX1, IRF9 and to a certain extent, IRF7 and DHX58, appeared to be in any way 
effected by knocking out IFN mediated signal transduction (figure 4.3.16 A-B). 
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Figure 4.3.16 ISG expression 
A 
 
B 
 
Figure 4.3.16: ISG expression analysis of transcriptome profiling upon electro-
transfection of 2 nM 400 bp dsRNA. A) subset of ISGs upregulated upon dsRNA 
treatment in WT vs IFNA/LR KO cells, depicting no major dependence on IFN 
signalling. B) subset of ISG mRNA upregulated upon dsRNA treatment in WT vs 
IFNA/LR KO cells, depicting a dependence on IFN signalling.  
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With more in-depth analysis, it was found that only 5 genes were negatively regulated 
more than 3-fold when IFN signalling was knocked out (figure 4.3.17), RND1, MX1, 
IRF9, CH25H, CCL5. Interestingly, RND1, which appears to be specific to IFN 
signalling, has not yet been described as an ISG.  
  
 
Figure 4.3.17 IFN dependent ISGs 
 
 
 
Figure 4.3.17: ISG expression analysis of transcriptome profiling upon electro-
transfection of 2 nM 400 bp dsRNA, comparing the maximum fold change from the 0 
hour value between WT cells and IFNA/LR KO cells with a limiting threshold of 3-fold.  
 
 
 
Furthermore, with regard to extending the mathematical modelling and interlinking 
RIG-I signalling and its regulation by IFN signalling, we analysed the all the genes that 
up or down regulated depending on whether IFN signalling was present (figure 4.3.18 
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IFNA/LR KO cells. For example, IFIT2 is ranked as the one of most induced gene in 
both cell lines. 
Figure 4.3.18 IFN regulated ISG expression 
 
 
Figure 4.3.17: The maximum fold induction for each gene was examined in terms of 
the time point at which the peak was reached, this was then compared between both 
experimental replicates and both WT and IFNA/LR KO cells to determine the weighted 
rank difference in the presence or absence of IFN signalling, if there is a high weighted 
rank difference, as there is for IRF9, this indicates that the gene is positively regulated 
by IFN signalling, if it is low, it is negatively regulated by IFN signalling. Genes that are 
not regulated by IFN signalling have a weighted rank difference approaching 0 (for 
example IFIT2 and IFNB1).  
 
Furthermore, we cross referenced the transcriptome profiling for the E3 ubiquitin 
ligase hits that were found to positively or negatively regulate RIG-I signalling, we 
found that five of our E3 ligase screen hits are in fact ISGs that induced upon RIG-I 
activation, two of which are not yet described as regulators of RIG-I mediated signal 
transduction, CBX4 and KDM5B, (figure 4.3.19) 
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Figure 4.3.19 Transcriptome of siRNA screen based hits 
 
 
Figure 4.3.18: Transcriptome analysis of the E3 ubiquitin ligase siRNA screen hits 
that are induced upon dsRNA stimulation of the RIG-I signalling network. 
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5.0 Discussion  
To improve our understanding of the RIG-I signalling network we assessed a fully 
annotated list of E3 ubiquitin ligases to determine novel regulators of IRF3 and NFkB 
activation. We further characterised the kinetics of activation for canonical signalling 
proteins within the RIG-I signalling cascade using phospho-specific western blot 
quantifications of synchronised RIG-I activation. Furthermore, in order to achieve a 
comprehensive understanding of the transcriptional responses upon RIG-I stimulation, 
we have performed a time-resolved, full-genomic transcriptome analysis. To 
discriminate between direct IRF3 mediated transcription and secondary, IFNA/LR 
signalling mediated ISG transcription, we employed IFNAR/IFNLR double-knockout 
A549 cells in parallel to wildtype cells. To compliment this, we are carrying out a full 
proteome analysis in order to generate data on the expression of protein members 
involved in the regulation of the signalling cascade.  Together, this will form the basis 
of a mathematical model that will act as a strong tool in elucidating the pathogenesis 
of viral infections that are either cleared by the innate antiviral response, or are 
successful in establishing an infection that leads to chronicity.  
 
5.1 siRNA screen for E3 Ligases regulating RIG-I signalling  
 
The importance of RIG-I mediated signal transduction regulation extends to many 
aspects of post-translational modifications. Phosphorylation had been the focus of 
characterising the dynamics of RIG-I signalling, however the importance of 
ubiquitination is not to be underestimated. Building on the work carried out by Li et al., 
2008.,[192] an E3-ligase screen was carried out using a state of the art read-out 
system based off of stable expression of fluorescently tagged IRF3 and NFkB (RelA) 
and transient knock down of target E3-ligase enzymes by siRNAs out lined in section 
. Despite being unsuccessful in our endeavours to generate a multi-spectral cell line 
encompassing the most important aspects of RIG-I, we were able to produce a top-
quality cell line capable of yielding valuable data (Figure 4.1.3). Using a simple 
translocation determination approach (nuclear signal/no nuclear signal) we could 
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facilitate the discrimination between E3 ligases that are specific to either IRF3 
activation or NFkB activation with respect to RIG-I signalling against a virus infection 
[120, 139, 192]. Furthermore, the screening approach (figure 4.1.4 A) was optimised 
in such a way that under normal conditions (non-targeting siRNA’s) only ~70% 
activation efficiency could be achieved. This allows for the prospect of determining E3 
ligases that positively or negatively regulate either IRF3 activation, or NFkB activation, 
or both. With the help from the groups of Dr. Erfle and Dr. Rohr from the Bioquant 
institute in Heidelberg, Germany, microscopy based imaging and processing yielded 
statistically significant hits when taking into account all siRNAs or individually 
significant hits relative to a single siRNA for both IRF3 and NFkB (figure 4.1.4 B). The 
chosen candidates for further validation are summarised in table 26, section 4.1.  
 Unfortunately, further validation could not be completed in time for publication 
of this thesis, however it is planned to carry out a second round of screening to validate 
the candidate hits using a high throughput luciferase based read-out. Each triplicate 
siRNAs will be tested in quadruplicate using cells that contain promoter genes specific 
to either IRF3 or NFkB that express firefly luciferase. These cells will be stimulated 
with 400 bp dsRNA, and based off of the luminescence signal strength for each 
candidate siRNA, we will determine whether the hits are valid or not. This will pave the 
way for future projects characterising the regulation of RIG-I signalling by the validated 
target E3 ligases.  
 Despite more work being required, we have identified interesting candidates 
regarding RIG-I regulation, and furthermore, with our transcriptome profiling, we are 
able to determine whether these candidates are in fact ISGs. We identified CBX4, 
KDM5B, TNFAIP3, TRIM26, and TRIM38, as ISGs induced upon dsRNA stimulated 
RIG-I. while TRIM26 and TRIM38 are known as regulators of innate immune 
responses (according GO analysis). CBX4 and KD5MB are yet to be characterised as 
factors involved in antiviral signalling, although KD5MB is described as a therapeutic 
target in HBV infections [199], and is known to regulate AP-2 [200] transcription factor 
activity, which in itself has not been implicated in innate antiviral responses. TNFAIP3 
(also known as A20) is an interesting protein, as its homology analysis indicates it can 
act as an E3 ubiquitination enzyme and a deubiquitination enzyme, and has been 
described to affect TRAF2 and TRAF6, known pathway members of RIG-I signalling 
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[136, 190, 201]. Indeed, according to our screen, it acts as a negative regulator on 
RIG-I signalling, and, according to our transcriptome data, is an ISG that is itself 
slightly negatively regulated by IFN signalling (figure 4.3.19). Those that are not ISGs 
but are still of great interest include factors that are not yet reported to be involved in 
RIG-I signalling, for example PIAS1 and PIAS2, the different RNF proteins, and the 
different TRIM proteins, to name a few (table 26). These are novel findings which may 
contribute to our knowledge of RIG-I signalling regulation. 
 
5.2 Measuring PPIs 
 
5.2.1 PCA 
 
Due to advancing technology, studying individual PPIs is becoming more and more 
common. Thus, using such technologies to examine the dynamics of signalling events 
within the RIG-I signalling pathway, or indeed any signalling pathway, was an exciting 
prospect. We initially wanted to develop a tool that could be used in to quantify the 
kinetics of interactions between proteins involved in the transduction of RIG-I 
signalling. To this end, several technologies were available for such an application. 
One option was to use fluorescence resonance energy transfer (FRET), which uses 
the excitation and emission of one fluorescent protein, who’s emission compliments 
the activation of another fluorescent protein. Thus, protein interaction partners tagged 
with complimentary fluorescent proteins could be used to examine their proximity to 
one another based on the activation of one of the fluorescent proteins [202]. The extent 
of the interaction could thus be quantified by measuring the intensity of the specific 
fluorescent signal.  
 Another mechanism of using fluorescence to measure the interactions of 
proteins is bioluminescence resonance energy transfer (BRET), which applies the 
same principal as FRET, but rather than using fluorescence to activate the probe, 
bioluminescence is used instead. Typically, Renilla luciferase bioluminescence is used 
to activate a fluorescent protein such as YFP, which will be dependent on the addition 
of the substrate for Renilla luciferase, coelenterazine [203, 204]. Both of these 
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technologies have limiting factors, such as forming stable interactions and the overall 
size of the modification [205, 206]. An alternative technology, termed Protein 
Complementation Assay (PCA) served as an alternative for examining its potential as 
a method for measuring the dynamics of a signalling pathway [197]. By following the 
protocol outlined in the nature methods paper published in 2011 [196], we attempted 
to reproduce the technology and apply it to generating quantitative data in the context 
of of RIG-I signalling dynamics. Firstly, a benchmark test was carried out in order to 
determine the extent of the differences of the application of PCA between the 
published data and our own data (figure 4.2.3). For the most part, the signal sensitivity 
was good in comparison to the published data, however for particular protein 
interaction partners, which are known to interact (for example IRAK2 and TRAF6), 
there was only background noise, despite the published data providing a strong 
positive signal for the interaction. 
 
5.2.2 PCA suitability  
 
Given that other interactions were yielded a robust positive signal when tested, it was 
examined whether optimising the protocol may solve the lack of signal for positive 
interaction partners. Several parameters regarding PCA were tested; lysis method, 
different cell clones, substrate concentration, incubation timing, measuring windows, 
and substrate derivatives. However, the only parameter that had any impact on the 
sensitivity of the assay was increasing the input concentration of each DNA plasmid 
expressing the construct of interest. Using the optimised protocol, a panel of PPIs 
were tested for the extent of their positive interaction signal (figure 4.2.4 A). 
Unfortunately, 50% of the PPIs tested did not produce a positive interaction signal, 
suggesting a fundamental flaw in the use of PCA to measure PPIs. Therefor individual 
controls were analysed in detail (figure 4.2.4 B). The results depicted a single fragment 
of Gaussia linked to a protein of interest (MAVS) was generating a strong positive 
signal in terms of absolute light units measured. This suggested that MAVS, when 
linked to GLuc-N2 and transfected with the negative control Empty-GLuc-N1, was able 
to form PPIs with the free untagged portion of gaussia luciferase, and given the strong 
differences in absolute light units, this was not a negligible interaction, but a strong 
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binding of the untagged gaussia luciferase portion. This suggests that, somehow, 
GLuc-N1 is being localised to the membranes of mitochondria, where MAVS is 
expressed along with GLuc-N2. It was speculated that this may be in part due to 
increased hydrophobicity of the untagged GLuc-N1, since it is split, and only this 
specific half of gaussia luciferase produces the strong luminescence as seen in the 
MAVS:MAVS interaction. A more hydrophobic tertiary structure may form from this 
peptide and thus may arbitrarily localise to membranes within the cell.  
 Furthermore, When analysing MAVS:MAVS and MAVS:TRAF3 interactions in 
detail, it was seen that the sensitivity of the positive interaction signal was highly 
dependent on a specific point in time after input of the substrate, such that the 
measuring window may be drastically different between different protein interaction 
partners, and would thus have to be optimised for each individual PPI. For example, 
MAVS:MAVS interactions were most sensitively detected 14s after substrate addition, 
while MAVS:TRAF3 interactions were most sensitive detected ~2s after substrate 
addition (figure 4.2.5 A and B), making it difficult to make robust measurements of 
several interaction partners. Furthermore, it was unknown how efficient the expression 
of each plasmid was between experiments, requiring the need for measuring 
expression each protein of interest, as differential expression of proteins within the cell 
for a PPI may alter the signal acquired for the PPI. In addition to this drawback, a 
general problem with any transfection based method, such as PCA, is the artificial 
overexpression of the proteins of interest. It has been shown in many cases that 
expression levels of signalling proteins substantially influence the kinetics of signal 
transduction [207, 208]. For example, we know very well, that expression of MAVS or 
any of the downstream kinases lead to IRF3 activation even in the absence of an 
upstream stimulus (not shown). Therefore, the PCA system would represent artificial 
conditions and may very well not authentically represent the natural situation. Due to 
these drawbacks, we finally decided to halt our PCA efforts for measuring PPI 
dynamics in RIG-I signalling. However, the method still represents a potential tool for 
analysing specific PPIs. For example, it may be used as an artificial representation of 
an interaction (overexpression of proteins of interest) that may support or complement 
existing data for an unconfirmed PPI (e.g. co-immunoprecipitation of a protein).  
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5.3 RIG-I signalling 
 
5.3.1 Quantitatively measuring RIG-I signalling  
 
For the above outlined reasons, we decided to switch to an experimental system solely 
relying on the endogenous proteins levels. We opted to use quantitative western 
blotting using phospho-specific antibodies in order to measure the activation state of 
various signalling proteins within the RIG-I pathway. Phospho-specific western blots 
have been used in several studies to measure the activation of specific intermediate 
steps within a molecular network over time, including the RIG-I signalling network [77, 
190]. Several intermediate steps of RIG-I signal transduction require the 
phosphorylation of proteins, including TBK1, IkKe, IkKb, IkBa, IRF3, and RelA (NFkB), 
which were chosen as targets for the phospho-specific western blots. 
 Other tools at our disposal was the dual-fluorescent cell line used to track the 
localisation and hence activation of IRF3 and NFkB. As shown in figure 4.2.1, these 
provided excellent tools to monitor time dependent downstream activation at a single 
cell level. However, also these cells rely on the over expression of tagged variants of 
IRF3 and NFkB and are therefore not necessarily faithful to the physiological situation. 
Quantitative time-resolved western blotting for phosphorylated proteins of interest was 
thus chosen as the basis for characterising the dynamics of RIG-I mediated signal 
transduction.  
 
5.3.2 A question of stochasticity 
 
In the grouped cell context, it has been suggested that intracellular molecular networks 
have a degree of variability between cells [209], and that signalling dynamics may be 
stochastic in nature, resulting in large cell-to-cell variations in gene expression 
activation. In the context of this study, the question of stochasticity is of particular 
importance regarding IFN expression, which has been described on several occasions 
to be a highly stochastic event [210-212]. Thus, our aim was to determine the 
stochasticity of RIG-I mediated signal transduction; is RIG-I activation stochastic? Are 
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there cell-cell variations in the kinetics of RIG-I signalling, and thus are there stochastic 
dynamics within the RIG-I signalling network between cells? 
 To provide answers for these questions, we reverted to a tool that was first 
described in 1982, the electrical transference of nucleic acid from a solution to inside 
cells, termed “electroporation” due to the biophysical effect it has on the membranes 
of cells (increasing the permeabilisation of cell membranes) [213]. It has since been 
used a core technique to deliver DNA and RNA into plant and animal cells [214-217]. 
The advantage of electro-transfection of dsRNA rather than liposome-transfection is a 
that all cells are pulsed with the electrical current at the exact same time, whereas 
liposome-transfection relies spontaneous contact with cells adherent to a surface, 
requiring endocytosis in order for cytoplasmic delivery of the dsRNA to take place. 
This means that electrically pulsed cells will be delivered with dsRNA at a specific 
moment in time – a marked difference compared to liposome-transfection, where 
uptake of dsRNA-covered liposomes is a slow and asynchronous endocytic process. 
In fact, when we compared the two different modes of dsRNA delivery, we could 
demonstrate the effect of the staggered RIG-I activation in the liposome-transfected 
cells, which showed a substantially delayed and less strong activation of IRF3. In 
contrast, in electro-transfected cells IRF3 appeared to activated be much more rapidly 
and much stronger overall (figure 4.3.1).  
 To further confirm the advantages of electroporation over liposome-
transfection, we investigated IRF3 activation dynamics on a single cell level, using our 
cell lines expressing eGFP-tagged IRF3. We could track the nuclear localisation of the 
transcription factor, and hence the activation of the antiviral response, over time and 
in single cells. The liposome-transfected samples were activated in the expected 
staggered fashion, with the first cells getting activated at later times and the 
percentage of activated cells increasing significantly slower and over a longer period 
of time. Intriguingly, the electro-transfected samples activated virtually simultaneously 
and at much earlier time points, removing cell-to-cell variability almost entirely. All cells 
that became activated, were activated within ~6 min of each other (figure 4.3.2). The 
electro-transfection of adherent cells expressing eGFP-IRF3 demonstrated that, if 
cells receive dsRNA at the same moment in time, the activation window for IRF3 to 
translocate is ~15-20 min. This is in contradiction to liposome-transfection, where cells 
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become activated over-time for hours, where the percentage of cells activated only 
increases marginally between the 15 min intervals of measuring.   
  This is in contradiction to liposome-transfection, where cells become activated 
over-time for hours, where the percentage of cells activated only increases marginally 
between the 15 min intervals of measuring. This supports the notion that electro-
transfection of dsRNA results in a synchronised delivery system, and thus, 
synchronised activation of RIG-I. This is a marked advantage over liposome-
transfection, as it is generally accepted that RNA and DNA is translocated via 
endosomal uptake, cytosolic release and in the case of DNA, nuclear entry [218-220]. 
This is a highly stochastic mechanism and is largely dominated by rare processes 
within the cell. For dsRNA, the limiting steps of release into the cytosol revolve around 
the endosomal uptake and lysis, and release from the lipoplexes [221]. In conclusion, 
the dynamics of RIG-I recognition of dsRNA in the case of liposome transfection is 
stochastic, but not due to signalling, rather it is due to the randomly endocytosed 
dsRNA by cells over time, and that this stochasticity is negated by the use of electro-
transfection, which synchronises the uptake of dsRNA and ultimately synchronises the 
activation of RIG-I signalling between all the cells.   
 
5.3.3 Characterisation of RIG-I signalling dynamics – progress and limitations  
 
5.3.3.1	Progress		
 
While much is known about the RIG-I signalling cascade in terms of activation, PPIs, 
mechanisms, and downstream responses [123, 124, 222], it was postulated by Rand 
et al to be a stochastic “all or nothing” event, which differed from cell-cell [223]. Rand 
et al claimed that single cell intrinsic stochasticity is a prevalent feature of antiviral 
signalling and IFNb expression, and that this stochasticity is subverted by the 
paracrine signalling events induced by IFN signalling. We generated data that directly 
contradicts that claim (see figures 4.3.2 and 4.3.3). Given that RIG-I signalling appears 
to be a pre-programmed response that does not differ in terms of kinetics from cell-
cell, we sought to characterise the dynamics of RIG-I signalling kinetics in A549 cells, 
which are immune competent cells.  
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 As described previously, quantitative-Western Blotting was used to 
successfully determine the activation kinetics of individual steps within the RIG-I 
signalling cascade. Using this tool, we analysed the kinetics of activation of TBK1, 
IkKe, IkKb, IkBa, IRF3, and NFkB (figure 4.3.3) under synchronised response 
conditions, which generated temporal activation profiles for each protein of interest. 
 Using the mean of four independent experimental replicates, quantitative 
activation dynamics were produced. As shown in figures 4.3.2 and 4.3.3, the speed of 
activation relative to the published data of the signalling pathway was quite striking, 
where some published data depict a peak in phosphorylation of TBK1 over 12 hours, 
whereas our data demonstrates the peak of activation can be reached as early as 40 
min upon detection of dsRNA by RIG-I. It is known that the kinase enzymes 
responsible for transcription activation require phosphorylation in order to mediate 
their effector function [108-111], [137-139], TBK1, IkKe, and IkKb , appear to have 
very similar activation dynamics, with very early increase in phospho-levels after 5-10 
min, and similar peak time of ~35-40 min. This is congruent with published data for 
TNFa signalling and NFkB activation, where Nelson et al., 2001., described the 
kinetics of IkBa degradation and p65 translocation over time in response to 10ng/mL 
TNFa (also synchronised), depicting similar activation kinetics as we show [224]. In 
fact, the data published by Nelson et al for IkBa/ NFkB activation is almost identical to 
ours, thus supporting our kinetic data. Further, when comparing our data on pIRF3 to 
published data, very little is known about the kinetic potential of IRF3 activation. For 
example, it has been shown under viral infection assays that IRF3 is activated as early 
as 60 min [225], however our data provides evidence that this can and does occur 
much faster, as early as ~15 min.  
 For the signalling dynamics, we can see that IRF3 activation directly follows 
kinase activation, and that NFkB activation is directly proportional to the degradation 
of IkBa, which is directly followed by IkKb activation. All of these events are in 
agreement with described sub-steps of the canonical signalling steps (described in 
detail in section 1.3.1). We now have a detailed kinetic characterisation of these sub-
steps in the context of RIG-I signalling, which provides novel insight. For example, an 
interesting difference was found in terms of the kinetics of IRF3 and NFkB activation. 
The difference between the canonical pathway dynamics for IRF3 and NFkB lies in 
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the sustainment of activation, or lack thereof. IRF3 activation peaks at a similar time 
to NFkB, but the IRF3 activation peak profile is sustained for up to 4 hours – and 
phosphorylated IRF3 is detected for up to 6 hours (data not shown). NFkB on the other 
hand, once its peak is reached it is rapidly deactivated, reaching background levels 
after 4 hours. The fact that total protein levels of RelA did not change over this time 
course indicated that RelA is dephosphorylated rather degraded, returning to its 
inactive state (supported by data published by Nelson et al [224]), whereas IRF3 
dephosphorylation might not take place or at a much slower rate. Data published by 
Long et al., 2014., demonstrates that IRF3 deactivation occurs due to 
dephosphorylation by PP2A and RACK1, rather than degradation [226], suggesting 
that the deactivation of IRF3 and NFkB are differentially regulated, resulting in different 
deactivation kinetics. This requires further research to elucidate the origin of these 
differential dynamics. It is interesting to note here that expression of the gene NFKBIA, 
which encodes for the inhibitor IkBa, is one of the fastest and strongest expressed 
genes in response to synchronised RIG-I activation, ranking already 10th highest 
expressed gene at 0 hours, increasing 4-fold after only 2 hours, at which point it ranks 
as the 2nd highest expressed gene for up to 8 hours. To put this into perspective, the 
signal for NFKB1 gene expression is ~13-fold less than NFKBIA 2 hours post 
electroporation (appendix figure 8.1). Thus, it is possible that when including the major 
known positive and negative feedback regulators, based off our transcriptome data, 
into the mathematical model - we could describe the origin on the differential regulation 
of IRF3/NFkB post RIG-I activation. 
 Moreover, it has been described for a certain signalling pathways (MAPK and 
NFkB) that oscillations occur during their activation, such they oscillate between active 
and inactive. For example, it has been shown that in the MAPK signalling cascade in 
yeast sustains oscillations of the signalling network in absence of negative feedback 
regulators [227]. Furthermore, it has been suggested that positive feedback regulators 
are the origin of oscillations in activatory signals, and that NFkB benefits from positive 
feedback regulators by increasing its maximal nuclear translocation and prolonging its 
transcriptional activity [228]. With our fine-tuned temporal dynamics analysis, we show 
that oscillations in NFkB signalling by RIG-I stimulation does not occur, at least not 
under the same time dependency that has been described previously for NFkB 
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activation in BCR signalling, where a peak is shown within the first 60 min, but a 
second, less strong peak is shown after 120 min, which is not occurring under our 
experimental conditions [228]. However, it is important to note that different cell lines 
were used, where protein abundance may vary greatly and thus be may be one reason 
for the alternative kinetics.  
 To complement our data-heavy transcriptome profiling, which will be analysed 
in much greater detail, we are currently producing a proteome analysis, which will 
provide an even greater insight into the fate of the mRNAs that we have temporally 
characterised, and we will be able to determine the abundance of ISG proteins over 
time. Furthermore, with the proteome analysis completed, we will be able to determine 
the abundance of the canonical proteins within the RIG-I signalling network, as of right 
now we have only focused on the phosphorylation levels relative to steady state. This 
data will also be of great importance to the mathematical modelling, as we will be able 
to determine the abundance of known and putative feedback regulators. In addition, 
the E3 ubiquitin ligases found to affect RIG-I signalling to a substantial level may be 
validated as novel regulators of the RIG-I signalling network, with the proteome 
analysis, in conjunction with the transcriptome analysis, we could elucidate if they 
might serve as negative or positive feedback regulators, and whether they are induced 
upon RIG-I or IFN stimulation.  
 Further, Weber et al., 2013., concluded that RIG-I binding to the 5’3P dsRNA 
of viral nucleocapsids enables RIG-I to initiate antiviral signalling at the earliest 
possible time point of infection, however under their infection assays they were only 
able to detect RIG-I oligomerisation after 2 hours of treatment with the virus [229]. It 
would be interesting to determine the kinetics of RIG-I oligomerisation under our 
synchronised approach, rather than measuring the average of RIG-I activation in cells 
that are infected as well as cells that are uninfected. 
    
5.3.3.2	Limitations		
 
The limitations of our data set include a lack of detailed information regarding specific 
steps in the signalling network. For example, due to technical limitations, our data on 
RIG-I signalling begins rather downstream of RIG-I activation - at the kinases. The 
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most important factors that are yet to be measured are RIG-I itself, and MAVS. Several 
attempts were made to develop a system, based on published data, that could 
measure RIG-I activation. One such method was based on phospho-specific Western 
Blots of RIG-I. As described in section 1.3.1.3, one of the activation markers for RIG-
I is dephosphorylation at Serine 8 [75, 76]. An antibody specific to S8 was developed 
in-house in the group of Adolfo García-Sastre, which became commercially available, 
however, in our hands we could not get the antibody to provide a reliable 
phosphorylation signal, even in the positive control samples. One difference between 
the published data by Nistal-Villan et al on phospho-specific Western Blots of RIG-I 
[76] and our data, was that Nistal-Villan et al used purified (from bacteria and IFN 
treated A549 cells) RIG-I, which was used in much higher concentrations, whereas 
our sample detecting RIG-I were whole cell lysates. 
 Another form of detecting RIG-I activation was published in 2014 which 
involved the use of limited tryptic digestion [230], a tool that took advantage of the 
conformational rearrangements of RIG-I upon activation. Despite in some instances 
being able to detect the described pattern of cleavage products, the results were 
usually ambiguous and hard to reproduce (appendix figure 8.2).   
 We investigated yet another tool for its potential to measure RIG-I activation, 
which is known as fluorescence polarisation or fluorescence anisotropy, a tool based 
on the biophysical properties of a fluorescently labelled protein in a bound or unbound 
state [231]. To briefly explain, if a fluorescently tagged protein is unbound, it will have 
higher mobility (Brownian motion, tumbling), which can be detected based on the 
polarised excitation light. Once bound, the effective molecular weight of the protein of 
interest will increase, which directly affects its mobility. This can be measured using 
detectors of polarised emitted light. Given the oligomerisation potential of RIG-I, this 
would be an excellent tool to measure the rate of oligomerisation in real time. However, 
I was unsuccessful in measuring the polarisation using our Mithras2 LB 943 Multimode 
reader. 
 Finally, we tried using formaldehyde based cross-linking [232] in order to detect 
oligomerisation of RIG-I and MAVS in regular SDS-gel electrophoresis. This was more 
successful, reproducibly demonstrating time dependent oligomerisation of both RIG-I 
and MAVS in Sendai virus infection experiments (appendix figure 8.3). However, more 
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work will be necessary to fine tune this technique to our electroporation based RIG-I 
activation, in which we expect RIG-I to be activated within a few minutes, based on 
our observations of the kinases. 
 We have also demonstrated under a liposome-transfection approach that 
concentration and length of dsRNA used to stimulate cells has a noticeable effect on 
the number of cells activated and the speed at which they are activated (figure 4.2.1). 
Preliminary data (not shown) indicated that when comparing 400 bp dsRNA to 100 bp 
dsRNA, similar activation rates using liposome-transfection could be achieved if the 
concentration of the 100 bp sample set was increased 4-fold, such that four 100 bp 
strands will equal one 400 bp. Taken together, it is possible there is a degree of length 
dependency on the kinetics of activation, which requires further investigation. 
 
5.3.4 Analysing downstream signalling dynamics  
 
As stated previously, a comprehensive overview of RIG-I signalling dynamics was 
sought, thus RNA was analysed in order to determine mRNA production dynamics for 
particular ISGs by qPCR (IFIT1, IFNb, and IFNl). Interestingly, our results indicated 
that transcription of these genes was detected as early as 1 hour after delivery of 
dsRNA, and mRNA production peaked at 6 hours, where it began to decrease again. 
As described previously (figure 4.3.7) the mRNA expression dynamics of IFIT1 and 
the two IFNs are very similar for the first 9 hours, however it is at this point that the 
dynamics diverge. IFIT1, rather than continuing to decrease after 9 hours as IFNb and 
IFNl do, begins to increase in its expression for up to 48 hours, while IFNb and IFNl 
continue decreasing and return to background levels after 24 hours. Interestingly, 
when comparing the transcriptome data with the data obtained from qPCR, there were 
differences seen in the dynamics of IFNl. In qPCR, IFNl was measured as returning 
to background levels after 24 hours post RIG-I stimulation, however according to the 
transcriptome data, none of the 3 IFNLs were reduced to background levels, indicating 
that different dynamics can be seen depending of the sensitivity of the assay used, 
more experiments are required with stringent controls in order to determine if the 
qPCR assay is less sensitive than the transcriptome assay.  If the depletion of IFN 
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mRNA after 24 hours holds true, this suggests a regulatory switch from IRF3 mediated 
transcription to IFN signalling mediated transcription (ISGF3) IFIT1 production [152]. 
 We compared our qPCR data to our transcriptome data, and on a technical 
level, both in qPCR and the transcriptome analysis, the fold change is ISGs differed 
between replicates, while the dynamics did not. This was more evident in the qPCR 
data than the transcriptome data however, and thus may be an artefact of the assay. 
Another possibility is that A549 cells themselves may have been sensitised for 
expression based on growing conditions, which has been suggested to effect gene 
expression [233]. More stringently controlled experiments are necessary to define the 
origin of the variation.  
 Regarding the transcriptome data, we were able to define ISG production 
based on the phase of their kinetics (early, intermediate, late), we found that of the 
early kinetics for ISGs, Jun and Fos RNAs were detected. Jun and Fos form a 
transcription factor known as AP-1 (figure 4.3.14), which has been implicated in many 
processes including viral infection, apoptosis, stress, etc. [234, 235]. We are further 
going to test if Jun/Fos factors act as rapid ISGs in response to virus detection by RIG-
I, which would be a novel finding, or if they are simply strongly induced due to stress 
of the cell.  
 An important aspect of the transcriptome data is the ability to compare IRF3 
dependent ISG transcription and ISGF3 dependent transcription. Surprisingly, when 
individual ISG dynamics were analysed, comparing WT to IFNA/LR KO cells, only very 
few genes appeared to be effected in terms of knocking out IFN signalling – suggesting 
that IFN signalling is largely unnecessary to reach an antiviral state, and that IRF3 
activation is the all that is required factor in terms of ISG production and antiviral 
activity (figure 4.3.16). Of the classical ISGs, only MX1 and IRF9 gene expression 
appeared to be dominated by IFN signalling, as their expression was significantly 
higher when IFN signalling was present. Only a few other genes were shown to be 
dependent on IFN signalling, RND1 was an interesting hit, as it is yet to be described 
as an ISG. Other genes that were strongly dependent on IFN signalling included 
CH25H and CCL5 (figure 4.3.17). Moreover, we were able to determine the genes that 
were differentially expressed when IFN signalling was knocked out, which can be 
found in figure 4.3.18 and appendix table 27.  
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 Further analysis with knock down/knock out studies will determine whether 
RND1 is an important feedback regulator of RIG-I signalling. Interestingly, IRF7 and 
DHX59 appeared to be only partially negatively regulated by knocking out IFN 
signalling, suggesting a dual role for IRF3 and IFN signalling mediated transcription in 
this respect. Another noteworthy difference was the expression of IL29 and IL28B (IFN 
l1 and IFN l3), which was either upregulated (IL29) when IFN signalling was knocked 
out or downregulated (IL28B). It is likely that feedback regulators are induced upon 
type I or type III IFNR activation, which then positively/negatively impact the production 
of type III IFNs. 
  For the most part however, the ISGs IFIT1/2/3, ISG15, ISG20, IFIH1, DDX58, 
IRF1, IRF3, IFNB1, and IL29A, were unaffected or only very weakly affected by 
knocking out IFN signalling. This is somewhat against the dogma of innate antiviral 
immunity, which is that IFN signalling is required to reach an antiviral state within the 
cell. The striking aspect of the transcriptome analysis, which has so far been unknown, 
is that IRF3 can induce nearly all the ISGs that the STAT1/STAT2/IRF9 can.  
 
5.3.5 Interferon signalling 
   
With our development of insights into RIG-I signalling and ISG expression, the next 
stage in our campaign to characterise RIG-I mediated antiviral signalling was to 
examine protein production and IFN signal transduction. While much is known about 
IFN signalling [152, 156, 236], little progress has been made on the temporal interplay 
between RIG-I signalling and IFN signalling. We sought to address the kinetics of 
translation of mRNA and the initiation of IFN mediated signal transduction, leading to 
ISGF3 activation. We first looked at IFIT1 protein expression as a proxy for translation 
of ISGs upon recognition of dsRNA (figure 4.3.8). Using Western Blotting, IFIT1 
protein was quantified in its expression over the course of 48 hours under the same 
electroporation protocols as used in all previous experiments. Unexpectedly, IFIT1 
protein was only detected as early 6 hours, despite mRNA expression being detected 
as early as 1 hour. This is in contrast to RIG-I - encoded by the gene DDX58, RIG-I 
protein increases as early as 4 hours post electroporation (data not shown). Since its 
gene expression kinetics are relatively similar to IFIT1 in the earlier time points (0-6 
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hrs), this indicates differential ISG translation dynamics, although this may be due to 
the sensitivity of the tools at hand, which further highlight the importance of the 
proteome data that is being generated, which will greatly complement our signalling 
dynamics data.  
 Secreted IFNb was measured in supernatants by ELISA over time. It must be 
noted that due to a very unreliable lot of ELISA plates, the data is of mediocre quality 
and also only representative of a single experiment. By this assay, IFNb protein could 
be detected in the supernatant of A549 cells only from 8 hours after electroporation 
on, which was surprisingly late given the rapid dynamics of other ISGs such as IFIT1 
and RIG-I. To corroborate this data, supernatants were also subjected to a bio-assay 
highly sensitive to interferons and antiviral cytokines. The bio-assay was based on 
LucUbiNeo-ET cells, which stably replicate subgenomic HCV luciferase-reporter 
genomes that can be measured readily by luminometry (figure 4.3.9) [198, 237]. Thus, 
the supernatant containing IFN (b/l) will negatively affect the production of luciferase 
in the LucUbiNeo-ET cells [58]. The supernatant of cells 4 hours post electro-
transfection completely abolished luciferase expression, indicating the presence of 
significant levels of antiviral cytokines, most likely IFNb or IFNl, or both. Without 
further experimental work, it is unclear whether the ELISA data for IFNb is truly 
reflective of its expression dynamics, thus indicating that the early perturbation of the 
HCV replicon after 4 hours is solely due to IFNl or whether the ELISA is not sensitive 
enough to detect IFNb at such an early time point – this is the most likely reason, as 
there was a very strong background in the ELISA. Indeed, published data indicates 
that IFN mRNA can be rapidly produced as early as 1-2 hours [225], and protein can 
be detected as early as 4 hours [77].   
 As described in section 1.4, one of the read-outs for active IFN signalling is the 
phosphorylation of the STAT proteins, namely STAT1 and STAT2 [152, 236]. In order 
to quantify effective IFN signalling over time, we measured the phosphorylation of 
STAT1. Interestingly, STAT1 phosphorylation was highly dynamic, exhibiting various 
peaks and falls of various strengths (figure 4.3.10). The first strong activation of STAT1 
was observed already between 2 and 4 hours, which was well in line with the finding 
of 4h supernatants to contains substantial amounts of IFN. This activation was 
diminished at around 6 hours, possibly indicating the kicking-in of negative feedback 
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regulators such as SOCS, PIAS or USP18. In fact, according to our transcriptome data 
analysis, USP18 is upregulated 2.57-fold after 6 hours. SOCS1 is not upregulated 
after induction of RIG-I signalling, and neither is PIAS1-4, however, SOCS3 is induced 
as at 4 hours post induction is 3.79-fold increased. Moreover, the signal for PIAS1 
expression and PIAS4 expression is relatively high at 0 hours, despite not being 
induced (~5-fold higher than PIAS2/3). 
 Even with this very early STAT1 phosphorylation, the activation at 2-4 hours, 
and deactivation at 6 hours, it somewhat surprising to see an activation of STAT1 after 
~20 min, which suggests that pSTAT1 activation at this time may due to some factor 
other than IFN. In fact, it has been described previously that IkKe plays in role in STAT 
phosphorylation [238].   
 We were also able to show that very early IFN release was not the origin of this 
activation of STAT at 20 min post electroporation using indirect bioassays. As depicted 
in figure 4.3.11, the supernatant from the negative controls were unable to induce any 
IFN signalling, suggesting that IFN is not the cause of the early STAT activation. 
Interestingly, there was a specific signal in both WT and IFNA/LR KO cells from 
supernatant of dsRNA stimulated cells for IFIT1 mRNA indicating that the supernatant 
(harvested 30 min after electro-transfection) was specifically able to induce a 
signalling pathway that lead to the expression of IFIT1. dsRNA is may still be present 
in the supernatant, as the cells are not washed after electroporation, thus, it is possible 
that remaining dsRNA is taken up into the cell at a later time where it is detected by 
RIG-I. Further, this phenomenon appears to be highly specific to dsRNA 
electroporation conditions, which is a compelling point regarding a dsRNA mediated 
post electroporation-activation artefact of the experimental design.  
 Nonetheless, the pSTAT1 was measured and quantified using the same 
technique applied to the RIG-I signalling dynamics, thus completing the antiviral 
signalling events within cells that detect dsRNA: RIG-I mediated signal transduction, 
transcription factor activation, ISG expression, ISG protein production, IFN signalling, 
and IRF3/ISGF3 dependent transcription of ISGs. A depiction of the flow of these 
events using a synchronised system shows the individual sub-steps as they happen 
over time (figure 4.3.12); our system removes any stochasticity that may arise due to 
random time dependent endocytosis events, synchronises RIG-I activation, 
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synchronises signalling responses leading to transcription factor activation, and allows 
us to measure mRNA and protein production in a highly discriminatory manner (such 
as comparing early induced ISGs versus late induces ISGs). With our experimental 
approach, we have followed each “checkpoint” regarding the progression to an 
antiviral state within the cells in a time dependent quantitative manner.   
 
5.4 Modelling   
 
The consistent signalling profiles of our target proteins during RIG-I mediated signal 
transduction across approximately 1.2x107 cells per experiment suggests a pre-
programmed linear response system that does not deviate in terms of kinetics or 
dynamics, and that RIG-I mediated signal transduction is not stochastic. This linear, 
non-deviating dynamics profile for RIG-I signalling may be dependent certain limiting 
factors, such as cell cycle, abundance of proteins, or availability of substrate within the 
cell, which will be discussed later. The implications of these results indicate that, given 
the specific conditions of A549 cells, the RIG-I signalling pathway and thus antiviral 
innate immunity has a degree of predictability.  
 These activation profiles for RIG-I signalling provide an excellent opportunity 
for mathematical modelling. In the past, many cellular regulatory networks have been 
described using sets of ordinary differential equations (ODE’s) [227, 239-242]. 
Modelling of cellular networks endeavours to describe a molecular network in as much 
detail as necessary without being over complicated, such that simulations are feasible. 
While Boolean network models allow for the investigation of much larger networks due 
to the simple reduction of the values to a binary ‘on or off’ phenotype [243], ODEs can 
be used to describe more complex processes, however are much more limited in terms 
of the scale of the system they can describe [244]. For RIG-I signalling, as shown in 
the scheme in figure 4.3.5 A, ODEs to build a biochemical model, which describe the 
reaction rate for the change of one species to another, for example S1 will be TBK1, 
and S2 will be phospho-TBK1, where R1 will describe the rate of change from S1 Þ 
S2. Given that our data suggests the signalling dynamics are not stochastic, 
deterministic reaction kinetics were used in the model, where reaction rates are 
proportional to the product of concentrations of the reactant molecules involved. ODEs 
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used to describe the rate of change of species within the RIG-I signalling cascade 
were determined by Darius Schweinoch in the group of Lars Kaderali, University of 
Greifswald. In order for ODEs to best describe change of species within the RIG- 
network, different rate constants were tested to determine if the model could closely 
simulate the experimental results (parameter fitting). The combination of parameters 
used that best describes the experimental data can be seen in figure 4.3.6.  
 
For the few E3 ubiquitin ligases that we found to be transcriptionally induced upon 
RIG-I stimulation, in addition to the proteomic data intertwined with the transcriptome 
data, the next steps would be to knock down/out specific regulators of RIG-I signalling 
network and then assess the strength and duration of the antiviral signal. This could 
then further be included in the model to enrich it with even more feedback loops, which 
will eventually make it very robust and enhance its predictive power. With such a 
powerful model, it will become possible to in silico simulate the arms-race between an 
infecting virus and the host antiviral response – who would win? Will the invading virus 
establish a successful infection, or will the antiviral response overwhelm the virus first? 
Putting these two antagonistic processes together in a meaningful model will finally 
permit examination of the crucial determinants that ultimately decide if a virus can 
successfully infect a host or if it is likely to be well-controlled by the immune response.  
Particularly interesting will be the studying of persistent viruses, such as HCV or 
certain strains of LCMV, that are known to induce innate and adaptive antiviral 
immunity, but evolved mechanisms to undermine the innate antiviral responses such 
that they can coexist (virus and immune response). Understanding this will bridge the 
gap in our knowledge on how to break persistence through therapeutic means.  
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7.0 Presentations and Publications 
7.1 Poster/oral presentations 
 
I. Heidelberg Young Scientist Conference, DKFZ, oral presentation, 2015 
- “Antiviral response mediated by RIG-I” Jamie Frankish, Marco 
Binder. 
   
II. Intrinsic and Innate Immunity to Pathogens, Novara congress centre, 
poster presentation, 2016.  
- “Dynamics and Regulation of the RIG-I Signalling Network” Jamie 
Frankish, Darius Schweinoch, Lars Kaderali, Marco Binder. 
 
III. Annual Meeting for the Society of Virology, Marburg University, poster 
presentation, 2017. 
- “Dynamics and Regulation of the RIG-I Signalling Network” Jamie 
Frankish, Darius Schweinoch, Lars Kaderali, Marco Binder. 
- Awarded best poster presentation. 
 
7.2 Publications 
 
I. HBV bypasses the innate immune system and does not protect HCV 
against the antiviral activity of interferon – in review as of 21.08.17 
 
Authors: 
Pascal Mutz1,2,&, Philippe Metz1,7 Florian Lempp1, Silke Bender1,2,8, Bingqian Qu1, 
Katrin Schöneweis1, Stefan Seitz1, Agnese Restuccia1,2,9, Jamie Frankish2, Benjamin 
Schusser3, Ronald Koschny4, Georgios Polychronidis5, Peter Schemmer5, Katrin 
Hoffmann5, Thomas Baumert6, M. Binder1,2, Stephan Urban1 and Ralf 
Bartenschlager1,2 
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8.0 Appendix  
Table 27. Gene regulated by IFN signalling 
Gene	 WRD	 Gene	 WRD	 Gene	 WRD	
LOC100129236 -1.472603 PTGS2 -0.784 SNORA61 -0.625 
SPRYD5 -1.365622 LOC647334 -0.7817509 LOC100134364 -0.6218097 
VCX2 -1.236284 SGK -0.7745098 FBXO33 -0.6135458 
PHLDA2 -1.194748 DNAJB6 -0.7698864 SLC5A8 -0.6118501 
STC2 -1.15528 RAGE -0.7628083 LOC440093 -0.6072131 
SERPINE1 -1.124682 TUBB4Q -0.7593308 SNORA57 -0.6057386 
VCX-C -1.061728 RAXL1 -0.7578806 LOC644884 -0.6026201 
LOC649346 -1.04878 LOC100132394 -0.7561837 USP38 -0.6022393 
HPS5 -1.045764 LOC340970 -0.7522013 ANKRD57 -0.6021922 
ZNF280C -1.025 HSPA5 -0.7457098 TRIM39 -0.6001406 
VCX -1 FAM90A2P -0.7438017 PTGR2 -0.5982028 
ADM -1 EHD1 -0.7431907 C3orf19 -0.595211 
FLJ10374 -0.9813849 C1orf128 -0.7430556 PNO1 -0.5790408 
CTGF -0.9613259 SAV1 -0.7411487 LOC653506 -0.5737399 
ATF4 -0.9565218 LOC158160 -0.7348018 ID2 -0.5719626 
FOS -0.9333333 LOC100133760 -0.7299864 CLCF1 -0.5613079 
SGK1 -0.9333333 NR1H4 -0.7225258 RRAGC -0.5610561 
RNU4ATAC -0.9240349 LOC791120 -0.7206267 PIM1 -0.5575916 
MYLIP -0.9218329 RGS20 -0.7185355 HIST2H2AA4 -0.5572917 
NCRNA00152 -0.9107011 CCRN4L -0.7080745 TAF4B -0.5557587 
HN1 -0.9074244 LOC389765 -0.7024055 RRAD -0.5535055 
EOMES -0.8777555 TSPYL2 -0.7017301 EGR3 -0.5394191 
CYR61 -0.8712871 LOC650832 -0.6986899 ZNF274 -0.5388789 
KLHL15 -0.862069 DNAJB4 -0.6917293 MED26 -0.5387454 
RNY4 -0.8498074 LRP5L -0.6875 HOXD1 -0.5369979 
EFNB2 -0.8471178 PIM2 -0.6851735 CRISPLD2 -0.5341464 
MKKS -0.8393136 TNF -0.6785714 CSRNP2 -0.5323383 
LOC342933 -0.8298755 ELF3 -0.6749117 ZNF787 -0.529563 
HIST2H2AA3 -0.8286189 MTMR14 -0.6702341 C18orf19 -0.5283019 
LOC100133984 -0.8245955 SLC9A1 -0.6649485 LOC100130445 -0.5270936 
SOCS1 -0.8216833 LPIN1 -0.6618576 RASL11B -0.5241845 
RND3 -0.8206039 NKX3-1 -0.6611741 CASP3 -0.52349 
SMG5 -0.8193384 TNFRSF12A -0.6569536 SNHG1 -0.5233645 
FOXD1 -0.8187919 KLF2 -0.656 LOC100133012 -0.5165239 
HES6 -0.8130406 C10orf67 -0.6532663 VPS37B -0.5160121 
ANKRD1 -0.8015979 HIST1H4H -0.652439 IL11 -0.5118979 
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LOC100129882 -0.8002672 JUNB -0.6521739 ZFP36 -0.5074627 
DDIT3 -0.8 FAM90A1 -0.6514286 NEFM -0.5065711 
IER5 -0.8 SNORD104 -0.6507592 AHSA2 -0.00464756 
TOB1 -0.7979966 SNORD12C -0.6462436 TBC1D8 -0.004175365 
RGS2 -0.7972028 CABYR -0.6414415 SGMS2 -0.002059732 
NR4A1 -0.7876289 CD83 -0.6322581 AMHR2 -0.00180018 
ARGLU1 -0.786141 LOC644250 -0.6293873 IFIT2 0 
TBPL1 -0.7858082 DNAJB1 -0.6271732 IFNB1 0 
VCX3A -0.7857143 C9orf156 -0.6265233 OASL 0 
TIPARP 0 POU2F1 0.6142778 RFX1 0.7610009 
RIC8B 0.003139717 KDM6B 0.6143791 NAT15 0.7698413 
PER2 0.003976143 LOC728640 0.6147186 LOC728014 0.7702265 
SNX11 0.00436205 LOC728153 0.6168675 PLEKHH3 0.771633 
BCMO1 0.005665722 SOCS3 0.6221693 STC1 0.779002 
SLC38A2 0.5045372 ZBTB20 0.6238015 C10orf10 0.7816994 
LOC728888 0.5066667 LOC646626 0.6255924 OAS2 0.7906274 
TXNL4B 0.508612 ITGA5 0.6296296 CFB 0.7958115 
OTUD1 0.5138889 FZD4 0.6314678 IL29 0.8 
LOC90586 0.5156398 IFI16 0.6341463 DMWD 0.8002586 
BTG1 0.5240893 SP110 0.6385405 SESN2 0.8098522 
INTS6 0.5267576 TIGA1 0.6442812 DCP1A 0.818638 
TMEM156 0.5300113 SETX 0.6473029 MBD6 0.8324325 
ALB 0.5357873 RP5-1022P6.2 0.6480938 NR0B1 0.834375 
PRKD2 0.5362079 CRTC2 0.6537998 ELF1 0.8431373 
RN7SK 0.5384616 DHX58 0.656 RGAG1 0.8485264 
MTF2 0.5384616 BEX2 0.6652221 ATXN7L3 0.8492429 
OGFR 0.5397816 CCL5 0.6666667 NKD2 0.8549906 
PUM1 0.5415713 RIPK4 0.6718147 YY1AP1 0.8552486 
ULBP2 0.5420561 GABARAPL1 0.6734694 CBLL1 0.8594164 
NFE2L2 0.5437263 ASAP1 0.677686 BCL2L13 0.8647115 
SIRT2 0.54385 ZNF410 0.6803219 COL7A1 0.8738676 
BCAR1 0.5456608 SHOC2 0.6817102 ISL2 0.8873239 
OAS1 0.5476923 TGIF2 0.6845238 ZFP36L2 0.8896552 
DDIT4 0.5485232 HERC6 0.6915888 OAS3 0.9048086 
MUC5AC 0.5538462 NPIP 0.692422 PLSCR1 0.9128631 
ZNF503 0.5554425 NDRG1 0.6961483 PLEKHA4 0.9411765 
VAMP2 0.5561358 NCALD 0.6985962 STAT2 0.9444033 
XBP1 0.5563093 LOC401317 0.7011494 CXCL1 0.955414 
FBRS 0.557377 EHD4 0.7059713 ARID5B 0.9571328 
SNHG8 0.5654281 PRIC285 0.7114094 STK40 0.9627851 
LMO4 0.5672371 HLA-E 0.7117009 FAM46A 0.989733 
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AKAP13 0.5762712 TICAM1 0.7208672 TRIM21 0.9929078 
TAP1 0.5785536 WHAMM 0.7216495 ARID3B 1.016897 
DEDD2 0.5842531 PVRL2 0.7293128 IRX5 1.021475 
WARS 0.5854859 LOC100131713 0.7366864 EIF4A2 1.026263 
LOC100132247 0.5869565 CNOT2 0.7372073 ULBP1 1.034749 
IL28B 0.5882353 PHACTR4 0.7377279 LOC387763 1.047619 
EFHD1 0.5920537 LOC286512 0.7405356 ERF 1.05864 
GATAD2B 0.5957447 GAS2L3 0.7431124 SOD2 1.150301 
NFIL3 0.5964912 B4GALT5 0.7465438 PTPRH 1.181818 
LOC730316 0.5975976 SNPH 0.7468672 RND1 1.219512 
TNFAIP2 0.6074767 LOC440353 0.7569721 PARP9 1.22449 
SP2 0.609319 SDCBP 0.7571338 SAMD9 1.256281 
C5orf41 0.6122977 MARCH7 0.7586207 PARP12 1.273044 
    MX1 1.376147 
    CH25H 1.659341 
    IRF9 1.740741 
      
 
Table 27. Table of genes positively or negatively regulated by IFN signalling defined 
by their difference in peak induction rank difference from transcriptomic expression 
profiling (weighted rank difference) in WT vs. IFNA/LR KO cells.  
 
Figure 8.1 NFKB signalling gene expression comparison 
 
Figure 8.1: Transcriptome data for NFKBIA and NFKB1 in wild-type A549 cells. 
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Figure 8.2 Partial tryptic digestion of RIG-I  
 
Figure 8.2: Partial tryptic digestion assay of activated RIG-I by Sendai Virus (MOI 5x). 
 
Figure 8.3 Cross-linking of RIG-I and MAVS 
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Figure 8.3: PFA based cross-linking assay. A) Sendai virus infected cells treated with 
1% PFA to cross link oligermised RIG-I was detected on 6% SDS-PAGE gel. B) and 
C) Using RIG-I KO cells reconstituted with RIG-I, oligomerisation was detected by gel 
electrophoresis for RIG-I and MAVS. 
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